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sTELLINGEN
1. The assumption that parents never refuse to donate 
is not a reason to use them as means to an end. 
(this thesis)
2. Not the size of the global donor inventory but the 
diversity and availability of donors are keys to 
success of hematopoietic stem cell transplantation. 
(this thesis)
3. Banking of high quality cord blood units is probably 
the best option to compensate for the lack of 
minority donors in the global inventory. (this thesis)
4. A global registry for any donor’s serious events and 
adverse reactions is the only way to prove safety of 
stem cell donation. (this thesis) 
5. Unrelated donor search is like top sport: the faster, 
the better. (this thesis)
6. Despite the fact that some humans can be 
legitimately sold such as soccer players, we 
disapprove of remuneration for the donation of 
tissues or organs.
7. Donor autonomy, in addition to donor safety, 
should be paramount. (Belinda R. Avalos, Biol Blood 
Marrow Transplant,2011;17:1739-1746)
8. Donor altruism as motivation to donate must not be 
confused with ‘carte blanche’.
9. A donor registry is a means not a goal.
10. When you come away from quilting you are not in 
the same mood (Maggie, in Burt & Atkinson, Journal 
of Public Health Advance Access, 2011;1-6)
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Tissue donation: giving rather than taking
The first attempt to use blood for transfusion purposes, with fatal results for 
both patient and donors involved, was described in the late 15th century, almost 
50 years before the existence and working of the cardiovascular system became 
known1. The way this first donation/transfusion attempt was carried out – involving 
minor donors, remuneration, and lacking informed consent – is in contradiction 
with the modern philosophy of altruistic donation. In the 17th century in France, 
Denys performed transfusions using blood 
collected from sheep and calves with variable 
outcome. It would take until 1901 before Karl 
Landsteiner discovered the major ABO blood 
groups and until 1907 before transfusion 
of human blood became a reality. sir Percy 
Oliver started a transfusion service in 1921 
from his own home. The first official Blood 
Transfusion service, consisting of a panel of 
400 volunteers, was established over less 
than a century ago, in 1926 by the British 
Red Cross2. The first Dutch transfusion service 
was established 4 years later in Rotterdam 
following the model of sir Percy Oliver. The 
use of blood and (other regenerative) tissues 
donated by related and unrelated volunteer 
donors has since then become indispensable 
for standard practice of health care. However, 
frequent transfusion reactions in these early 
days were a trigger for further investigation, 
which lead to an increasing knowledge about 
leukocyte antibodies and human leukocyte antigens (HLA)3,4. It was the start of a 
deeper understanding of the HLA system that would take another half century, and is 
still ongoing today. Although in the 1950’s and 1960’s attempts for transplantation of 
human bone marrow were undertaken, and after the first successful administration in 
1964 of HLA compatible donor platelets5, the importance of HLA in donor selection to 
treat thrombocytic patients became soon clear6,7. This knowledge was subsequently 
applied in the field of kidney transplantation, where retrospective studies showed 
that donations from HLA identical donors had far better clinical outcome than 
mismatched donors8. The first successful bone marrow (BM) transplantations from 
HLA identical sibling donors were undertaken in 1968 in both the United states of 
America (seattle) and Europe (Leiden)9,10, soon followed by studies where identical 
twins acted as donors11,12. Expanding knowledge of the HLA system has led to a 
The first recorded attempt 
of a blood transfusion was 
described by the 15th-century 
chronicler Stefano Infessura. In 
1492, Infessura noted that the 
blood of three boys was given 
to Pope Innocent VIII, who had 
fallen into a coma. Following 
orders from a physician, the 
blood was transferred to the 
pontiff through the mouth, as 
the concept of intravenous 
circulation had not yet been 
discovered. The three young 
blood donors, all ten years old, 
had undertaken this experiment 
after being promised a ducat 
each. Unfortunately, the Pope 
and all three boys died1.
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practice where not only phenotypically matched or partially mismatched family 
members can provide suitable stem cell transplants, but also volunteers are deemed 
appropriate for patients lacking an HLA identical sibling donor13. The use of donor 
derived stem cells for transplantation has now been commonly practiced for almost 
half a century, and is considered as a standard procedure for the treatment of defined 
haematological, immunological and metabolic disorders. Traditionally stem cells 
were harvested from BM through punctures in the sternum and posterior iliac crest14. 
since 1994, recombinant human granulocyte colony stimulating factor (G-CsF) 
mobilized hematopoietic progenitor cells (HPC) collected from allogeneic healthy 
donors have been used as an alternative to BM harvesting15. In The Netherlands, 
G-CsF stimulated HPC collection has been performed in family donors since 1995. 
In 2004 the use of G-CsF in volunteer unrelated Dutch donors was approved by the 
ethical advisory panel of sanquin, the Dutch national blood supply organisation, 
proving at that time most of the potential stem cell donors.
International collaboration for the provision of unrelated donor 
stem cells
since only 30% of patients in need of hematopoietic stem cell transplantation (HsCT) 
have an HLA matched sibling donor, the obvious need for suitable alternative donors 
was soon recognized and addressed. In the late 1970s the first registries for unrelated 
donors were established. With the finding that stem cells from placental blood are 
able to sustain hematopoietic recovery, the first umbilical cord blood banks started 
inventories of cord blood units (CBU)16. International cooperation has resulted in 
the development of a continually increasing worldwide pool of unrelated donors 
and cord blood units, accessible through the participating registries of Bone Marrow 
Donors Worldwide17. One of the first attempts in electronic data interchange of donor 
and recipient information was the establishment of the European Donor secretariat 
(EDs). The European Marrow Donor Information system (EMDIs), a European Union 
supported project to develop a protocol to exchange information between registries 
during the unrelated donor search, was initiated in 1992 and has since then replaced 
EDs. The evolution of the EMDIs protocol is a continuous effort with currently 
involvement of over 30 donor registries. With the development of EMDIs Cord the 
EMDIs community is intensifying the collaboration with cord blood banks, providing 
real time comprehensive CBU data to enhance the unrelated CBU search.
For the mainstream of patients, it is not only the number of available donors but 
the search time span that is the major influencing factor determining the chance of 
reaching transplantation18-22. A Dutch study reported almost one third of patients for 
whom a donor was identified never reach HsCT due to deterioration in the patients’ 
health. This was most likely due to the length of the search process23, usually defined 
as the time between diagnosis and transplantation, and not as the time to identify 
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an acceptable donor. For example, a prolonged time span between diagnosis and 
transplantation in patients of older age are found to reduce leukaemia free survival, 
and increase transplant related mortality20. The unrelated donor search is a dynamic 
process, sometimes complicated by unexpected factors. The deferral of a donor 
just prior to stem cell transplantation is most inconvenient and can consequently 
cause delay of the treatment process and in the worst case death of the patient. 
Anticipation of such situations, and identifying a back-up donor or cord blood unit in 
the initial donor search could save precious time and prevent distress. The expansion 
of the global donor inventory not only in quantity of donors but also in quantity of 
HLA phenotypes and quality of HLA typing, has increased the chance of finding an 
acceptable unrelated donor, although the advantage seems to be in particular for 
patients of north western European descent23.
Donor care and safety: the importance of a standardized system
Despite overlapping aspects in the procedures of BM and PBsC collection, dynamics 
of care management for HPC family donors differ substantially from care for 
unrelated donors. The first reports of successful HsCT only indirectly mentioned the 
consequences of donation for the family donors involved. Despite the importance 
of their contribution, at that time donors seemed to be considered of minor interest 
and no attempts to document immediate effects or follow-up (FU) were reported. 
A possible explanation is that donors, as healthy volunteers, might be considered 
as non-patients by the medical staff, in contrast to the recipients who are the ‘real 
patients’24,25. Over time, the importance of donor care management and donor 
insurance in case of unintended sequelae have become clear, although not initially 
for the family donors. Presently, still almost half of all stem cell transplantations 
worldwide are carried out with donors who are a relative of the recipient26. With the 
introduction of unrelated stem cells as a source for transplantation the first donor 
studies addressing the medical risks of stem cell donation were initiated27-29. 
Voluntary donation of haematopoietic progenitor cells requires as an imperative, 
that informed consent procedures be established for all stages of the donation 
process30. Informed consent is considered a fundamental principle, not primarily with 
the goal to explain medical terms and conditions in every detail, but to provide a 
donor with an overview of the risks or implications of the treatment for his personal 
health and well-being31. The decision to donate tissue or cells is to be made free of 
any coercion and in accordance with international legislation and regulations, but 
it also requires the implementation of a quality system to optimize and maintain a 
certain level of quality and safety for both the donor and the recipient32,33. The attitude 
towards a donor is important for a positive donation experience, and to prevent him/
her of feeling unimportant or even neglected once the tissue is obtained24,25. Clinical 
practice and medical ethical considerations have dramatically improved over time. 
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However, findings from surveys in Europe and the United states indicate that the 
care for the family donor and in particular the informed consent procedure is still 
(more) often performed by medical staff members who are indirectly involved in 
the recipient’s care rather than an independent physician, and as such introduce a 
potential conflict of interest34,35. 
Although research mainly focused on the unrelated donor, Confer & stroncek36 
have suggested that the standard of acceptable risks for family donors should not be 
lower than that of unrelated donors, i.e. protecting the volunteer relative from undue 
risk is no less important than protecting the unrelated donor. The establishment 
of a (global) standardized system for family donor care comparable to unrelated 
volunteer donors is meant to protect and follow-up on donor’s health, without 
limiting a donor’s decision-making autonomy or freedom to choose. Consequently 
if there is an increased health risk for a family donor to donate, while a suitable 
unrelated donor is available, it can be discussed if, despite the unfavourable cost-
benefit ratio, it is ethical to expose the family donor to donation. In daily practice 
however family donors, because of their relationship with the recipient, may be 
accepting a higher than medical deemed tolerable risk or even disregard their own 
health issues. A possible explanation for this behaviour is that for related donors the 
benefits are so much higher37, that they are willing to accept higher potential risk. 
For example, age as donor exclusion criterion is strictly adhered to in the unrelated 
donor setting, in contrast to the family donors, where very young children and elderly 
donors are commonly used. In the Netherlands, the use of minor donors requires 
proxy consent by the parents or legal representatives and legal permission granted 
by an independent family judge of the local court, after a psychological assessment 
of the potential donor.
It is unclear whether, in case the suitability of a related donor is doubtful, the 
costs to perform an unrelated donor search and obtain products are a barrier in the 
decision making process to initiate the search for an unrelated donor. However, it 
was mentioned by Labopin et al. that initial HLA typing restricted to HsCT candidates 
after reaching first remission to reduce costs, introduces a potential delay in reaching 
transplantation38.
Optimal care management for stem cell donors is now well described by 
regulatory authorities39-41, but only recently explicitly addressing the needs for 
family donors. Regulation for unrelated donor care management started in 1994 
with the international collaboration World Marrow Donor Association (WMDA). 
The WMDA is bringing together experts from all over the globe on all aspects of 
HPC donation, including clinical, legal, ethical and regulatory issues42. The WMDA 
standards are addressing all stages in the process of unrelated stem cell donation41. 
Changing international legal and regulatory requirements necessitates a continuous 
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process of revision and re-evaluation of the standards. Additional guidelines and 
recommendations for the safe and ethical use of stem cell donors are regularly 
published. The development of clinical protocols for additional treatment of relapse, 
viral reactivations, and immunotherapy, often require multiple donations of multiple 
stem cell products, demanding a prolonged donor commitment and the potential to 
affect the donor’s health. This is once more a reason to address and review the role 
and follow-up of donors involved.
Follow-up
The need for and importance of long term follow-up of stem cell donors, related 
and unrelated, was first addressed with the introduction of G-CsF in healthy 
individuals43. The Ethics and Clinical Working Groups of the WMDA are committed 
to this area and have, utilising their experience and expertise, actively pursued 
major changes. Follow-up and reporting of adverse events in all donors, conform the 
WMDA serious Events and Adverse Reactions registry, were addressed at workshops 
in Berne (2009), Leiden (2011) and Vienna (2013). The initiative is a joint effort of the 
WMDA and European Group for Blood and Marrow Transplantation (EBMT), acting 
as a subgroup of their Late Effects working party and attended by representatives 
from a number of international organizations and registries concerned with donor 
care. This resulted in the establishment of an EBMT Board Committee on Donor 
Follow-up in 2012; one of the goals of this committee is to set up a regular donor 
follow-up registry for all EBMT Transplant Centres (TCs) and review any new EBMT 
research protocols where stem cells of allogeneic donors are involved. In 2013 the 
EBMT introduced the possibility for systematically collecting adverse event and 
longer follow-up information for family donors as part of their regular data registry. 
Education of the EBMT TCs is planned to reach implementation of regular collection 
and registration of donor follow-up in the EBMT database, with the potential of data 
observation and analysis. 
One of the obstacles in organizing related donor follow-up remains the financial 
aspect. In general, cost for HPC donation (including the treatment and care for the 
donor during the donation process) are paid for by the insurance company or health 
service providers of the recipient. In practice, since there is no further financial 
reimbursement from insurance companies, follow-up of the family donor ends after 
one year. This is in contrast to the follow-up of unrelated donors, who are advised 
and offered a regular follow-up until at least 10 years after donation42. The cost 
for unrelated donor (UD) follow-up is covered in the price of the product. To date, 
the financial cost of long term follow-up of family donors has not been explicitly 
addressed by pertinent legislative authorities and as such no regulations regarding 
this issue have been formulated, but initial coverage of FU in the donation costs 
seems to be the most effective way. 
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Regardless the major differences between family and volunteer donors, 
safeguarding of the donor should be a basic principle in any donor care management. 
Respect for a donors’ health and safety, is the least that should be offered in exchange 
for their devotion, sacrifice or altruism. Without the availability and devotion of 
donors worldwide, the practice of HsCT would not have advanced and become as 
successful as it is today.
Extraordinary donations: parents and children as donors
It can be argued that family donors confronted with a very ill relative for whom 
they might be the only hope for survival, do not have a choice, and in fact relatives 
cannot be considered as voluntary donors44-47. The process of decision making has 
evolved over the years from paternalism (treatment decisions are solely made 
by the physician) to autonomy (the decision is made by the patient/donor or his 
representatives). However, current developments have lead to a situation of so called 
shared decision making: the decision as a result of collaborative approach between 
the physician (expertise) and the patient’s and/or his representatives (perspectives)48. 
society might expect parents to sacrifice everything for their child, but do not offer 
support in the decision making process, where it is often felt there is no choice49. 
External expectations (e.g. expressions by relatives or social desirability) might 
influence a free of bias decision and cause coercion. similarly parents of minor 
donors may be unable to make a rational decision if they give proxy consent for 
one of their healthy children to act as a stem cell donor for their other seriously ill 
child. In this light, the earlier mentioned assumption that family donors are naturally 
motivated to donate, might be a fallacy, since they are, often in a state of shock with 
limited time, forced to make a choice50. Within the donor population, family donors, 
in particular parents and minors, form a special group, and as such they are more 
vulnerable than healthy individuals, as they can either be desperate to take all risks 
or feels in the social context of the family circle obliged to donate. It is therefore the 
ethical and moral duty of the medical professionals to protect family donors and help 
them make a fully informed conscious decision. 
BM donation by young children for the benefit of their sibling in need of stem cell 
transplantation has been practiced for over 40 years. BM donation in early childhood 
is rare, and as such, literature on immediate effects and long-term outcome is scant. 
It is perhaps characteristic for the time, but when asked in 1998, the 37 year old 
woman, who was the first child donor in Europe (in 1968) to recall her experiences, 
she only remembered ‘that is was cold, I was sitting in a big bed and wanted to go 
home’ (personal communication, symposium on the Occasion of 10 Year Europdonor). 
Although BM donation in childhood is legally accepted, guidelines for paediatric 
donor care have been lacking for a long period51. The publication of the Committee 
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on Bioethics of the American Academy of Pediatrics (AAP) is the first step towards 
the development of guidelines for the clinical practice and management of pediatric 
donors. The AAP also emphasized the importance of research in both child donors and 
their recipients as well as the collection of long term follow-up data to gain insight 
in the effects of the use of hematopoietic growth factors in healthy children from 
countries where this is allowed52. Published studies concerning child HPC donors 
are restricted to investigations of immediate and sometimes long term side-effects 
of the use of hematopoietic growth factors53-58 and psychosocial effects in a limited 
number of children59,60. 
Parents can act as a source of stem cells for a selected group of children in 
need of stem cell transplantation who lack an HLA compatible donor. This form of 
transplant has recently become more widely used, although the transplant related 
mortality rate is higher than in transplantations with HLA identical donors61-63. 
New technological developments have led to more encouraging clinical results 
in haploidentical transplantation64. Experiences of parents fulfilling a dual role as 
caregiver and stem cell donor, and their long term follow-up, are however scarcely 
reported. As, for every HPC donor, a reasonable balance between donor commitment 
and risks, and patient’s needs is required65. 
Donor Remuneration
The voluntary nature of blood donation was one of the main principles for sir 
Percy Oliver, when he started the blood transfusion service in the United Kingdom. 
subsequently also donation of stem cells or tissue for the well being of an unknown 
person, are considered acts of altruistic behaviour27-29,45,66,67, and thus performed 
voluntarily, without expectation of receiving any type of reward. With the founding 
of the WMDA the unpaid nature of donation, was included as a cardinal principle68. 
Currently donors of HPC do not receive any reimbursement beyond other than out 
of pocket expenses. This policy is stated in Transplantation Acts and subscribed 
by the World Health Organisation. The A lawsuit filed against the National Organ 
Transplantation Act in 2009 in the UsA, challenging prohibition against remuneration 
of volunteer HPC donors, has re-opened the public debate69. Advocates and opponents 
of donor remuneration, not only in the United states, but internationally in the 
professional field of transplantation, have watched this case closely. The decision 
of the Ninth Circuit Court of Appeals in December 2011, that peripheral blood stem 
cells, but not bone marrow donors, may be paid for the donation, has surprised the 
HsC transplant community. It is the opinion of the WMDA that any change to the 
current laws around donor remuneration would have serious repercussions for both 
patient and donor health. In addition, the international exchange of products, which 
is absolutely critical in stem cell transplant where a ‘unique’ product is required, 
would be gravely threatened.
14
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Conclusion
Allogeneic HsCT has become the standard of care for many otherwise incurable 
diseases. In this process, the availability and suitability of related and unrelated 
volunteer donors are indispensable factors and need to be treated as such. Possible 
improvements in HsCT are continually being investigated in an attempt to cure post 
transplant recurrence of cancer or refractory infections. The development of new 
treatment strategies, such as immunotherapy, often imply additional or subsequent 
donation requests from donors. As a result, not only a prolonged donor commitment 
is required but also the necessity to adjust long term donor care. 
Outline of the thesis
Over the past decades various aspects in the dynamic field of family and unrelated 
donor selection and stem cell donation have not yet been settled. stem cell sources 
have been expanded from bone marrow to the use of mobilized hematopoietic 
progenitor cells and stem cells harvested from umbilical cord blood. The immediate 
effects and long term follow-up of unrelated donors, in particular those exposed to 
growth factors have been structurally undertaken, as demanded by international 
regulation. However, for family donors long term follow-up studies are mainly 
performed in retrospect, and cohorts are often small. The lack of well-documented 
pre-donation conditions for donors demonstrates the need for stricter guidelines 
for care management of family donors. In this thesis various aspects of stem cell 
donation underscoring the need for change are described, and include the following 
studies:
•	 A qualitative study on the experience of parents who have donated stem cells 
to their child
•	 A long term follow-up study in children, who have donated bone marrow 
under the age of 13 years
•	 The immediate side effects and long term follow-up of the first Dutch cohort of 
family donors treated with G-CsF
•	 Donor availability between 2001 and 2012 for Northwest European (NWE) and 
non-NWE patients
15
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Abstract
The World Marrow Donor Association (WMDA) is an international organization 
fostering collaboration in clinical transplantation and promoting the interests of 
unrelated stem cell donors. The WMDA has developed standards for the recruitment, 
counseling, work-up and subsequent donations to protect the interests of donors. 
Although the care of family donors has been carefully considered and managed in 
transplant centers (TCs) internationally over numerous years (and increasingly TCs 
are facing accreditation programs, which address this issue) there is currently a lack 
of standardized guidelines for the management of family donors. The underlying 
principles of family donor care are in many ways identical to those concerning 
unrelated donors, although key ethical considerations differ. Although the WMDA 
is primarily involved in the field of unrelated donors, we believe that it is important 
to collaborate with those involved with family donors, to standardize the care. This 
document hopes to encourage increased collaboration between those caring for 
related and unrelated donors, and build on the extensive work, which has already 
been undertaken in this field to homogenize care. We recognize that there will 
be financial, regulatory and logistic differences in different countries and that the 
manner in which these principles are achieved may vary.
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Introduction
The dynamics of care management for hematopoietic stem cell family donors differ 
substantially from unrelated donor care, although there are overlapping aspects to 
both procedures. A survey carried out by the European Group for Blood and Marrow 
Transplantation (EBMT) Nurses Group/Late Effects working party showed that at 
present there is a lack of recognized standardized guidelines for the management 
of family donors1. The World Marrow Donor Association (WMDA) was established 
to foster international collaboration to facilitate the exchange of high-quality 
hematopoietic stem cells for clinical transplantation world- wide and to promote 
the interests of donors2 In former years, working groups of the WMDA have set up 
guidelines for the recruitment, counseling, work up and informed consent procedures, 
subsequent donations and transport of stem cell products to protect volunteer stem 
cell donors. since the establishment of Bone Marrow Donors Worldwide (BMDW) 
in 1989 is worldwide, over 13 million volunteers have been registered as stem cell 
donors3, of whom over 80,000 have actually donated stem cells for an unrelated 
recipient. A substantial proportion of sCTs are also carried out with stem cells from 
family donors (for example, family members of the patient). In many countries 
transplantation centers (TC) are obliged to conform to an accreditation program 
such as the Joint Accreditation Committee IsCT & EBMT (JACIE) or the Foundation 
for the Accreditation of Cellular Therapy. These factors have led to demands for 
new guidelines for the care management of family donors. JACIE requires written 
criteria for stem cell donation to protect the donors’ safety. Related stem cell 
donation presents substantial ethical challenges, which differ from those associated 
with unrelated donation. Although the WMDA is primarily involved in the care of 
volunteer donors, the Ethics Working Group and the Clinical Working Group of the 
WMDA determined that care for family donors is of critical importance, and as such 
formed a subcommittee to establish recommendations for this particular group of 
donors. In this paper, the different steps in the donor care process will be explained, 
discussed and recommendations for family donor care will be given.
Donor recruitement
Traditionally, the health-care professional of the recipient was also responsible for 
the donor. Although there is no substantiating evidence, it would seem rational that 
from time to time divided loyalties and conflicts of interest could arise, more often to 
the disadvantage of the donor than the recipient. To avoid these potential problems 
and to assure maximal donor protection and integrity of the transplant program, it is 
important that the donor is assessed by a practitioner who is not directly involved in 
the recipient’s care. The practitioner does not necessarily have to be geographically 
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dislocated and may even be in the same hospital. It is important that the practitioner 
has an understanding of donor rights and that they can advocate for the donor. In 
some TCs, this may be achieved by dedicated specialist personnel for donor care 
management, while in others, members of the transplant team may be identified and 
empowered to fulfill the donor advocate role.
As there is a need for information before consent, we recommend donor counseling 
before tissue typing. In this way any obvious reluctance to donate, or any medical 
problems precluding donation, can be identified, which will allow for deferral of 
unwilling or unable donors before establishing a full HLA match. As donors may be 
physically distant from the TC, an assessment and counseling may need to be carried 
out by telephone or email and it is important that good donor information, which 
can supplement such discussions, should be available. Whereas volunteer donors 
decide for themselves whether to join the register or not, family donors do in fact 
not have the anonymous choice whether to become a donor or not. They are directly 
approached with the request for HLA compatibility typing for their relative, often 
at the same time the recipient is identified as a candidate for transplantation. Even 
in the case of donor drives, volunteer donors always have the choice to join or not 
whereas relatives often feel coerced by the knowledge of a relative in need of sCT4. 
It is therefore important to give family donors a fair chance to decide whether or not 
to become a donor. A positive balance has to be found between risks for the donor/
benefit for the recipient, but also benefit for the donor/risks for the patient, both 
physically and emotionally5.
Unrelated donors are provided with independent donor advocacy, confidentiality 
and protection by the stem cell donor registry. It is an important requirement that 
unrelated donors always have a specified independent donor advocate to discuss 
any doubts they have regarding the donation procedure, and that they can make 
a decision to proceed, or not, without coercion. Independent donor assessment is 
equally necessary for family donors and involvement of an independent committee 
or independent counseling (psychologist, donor’s advocate) should be considered. 
The role of this person is to perceive any coercion during the information/predonation 
process and to assist the donor to overcome any barriers to donation. This person 
should have knowledge of the risks and side effects of any type of stem cell donation 
and transplantation outcome to fulfill this role. Despite this it has to be accepted that 
by its nature, the possibility of familial pressures/guilt in the family context will never 
be completely eliminated. The requirement for an independent donor advocate has 
been recognized by some countries/TCs and has been introduced by some centers. 
The optimal donor advocate will have a primary role distinct from the transplant 
team. Alternatively, this could be a member of the transplant team who is identified 
as undertaking this role, is trained in donor rights and who is not involved in the 
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care of that donor’s recipient (that is, will advocate for the donor in an unbiased 
manner). TCs must have policies for dealing with situations wherein a conflict of 
interest between the family donor and others may arise. These should include an 
independent advocate acting in the interests of the family donor. It is recognized 
that, for smaller TCs with limited finances and limited suitable expertise, appointing 
a donor advocate may be challenging. In these situations, adequate procedures to 
document and address potential conflicts of interest are even more important.
Children acting as donors require further consideration. Laws and regulations 
governing minors acting as a donor for a sick sibling, differ from country to country. 
Indeed, in some countries a court of law now has to make the final decision to 
permit a pediatric stem cell donation6 Furthermore, children need a special approach. 
Guidelines for child donor counseling and clearance need to be separately established. 
For children who cannot consent, the need for advocacy to protect their interests is 
essential, especially as a parent who is signing consent may have conflicting feelings 
because of their need to be involved in decisions concerning the welfare of both the 
patient and the donor.
Rarely, adult donors with severe developmental or psychological problems 
rendering them mentally incapable of informed consent are considered as stem cell 
donors for a relative. These can be either donors who have always been mentally 
challenged (for example, Down’s syndrome) or donors who are suffering from a 
psychiatric illness. It is advised to first establish whether the aspirant donor could 
endure the donation procedure (both physically and mentally), before performing 
HLA testing7,8. Again, some countries have decided to enforce the rule of the law 
courts to decide on suitability for donation in case of mentally incapable donors who 
cannot decide for themselves.
Informed consent procedures
Volunteer donors give their (written) informed consent when they sign up for the 
registry. Whenever an unrelated donor registry receives a request for confirmatory 
typing or high-resolution typing, they ask the donor yet again for informed consent, 
according to the WMDA recommendations9. Before asking for informed consent, 
family donors should be informed carefully regarding risks and benefits of and 
alternatives to the donation procedure. Although TCs usually have a preference for 
the source of stem cells for transplantation, volunteer donors are given the choice 
whether to donate BM or stimulated PBsCs. At present, it is unclear to what extent 
family donors have the opportunity to choose between forms of donation. Ideally, we 
recommend that the information procedure should be the same for both family and 
28
Focus on the donor
unrelated donors. Long- and short-term risks of G-CsF administration and of donation 
should be clearly presented and understood by family donors. The TC should ask for 
written informed consent for the donation procedure, including physical examination 
and infectious disease marker testing, administration of G-CsF and apheresis, or BM 
harvesting under general or local anesthesia. Family donors should also be asked 
for written permission for storage and discard of either their DNA or cells for future 
testing or research as well as exchange of donor characteristics with third parties 
(for example, EBMT/CIBMTR/APBMT databases) for research purposes. For minors 
or mentally incapable adults, a proxy consent procedure is in most cases inevitable. 
Depending on the local laws and regulations, confirmation by court might be part of 
the procedure. Although this group of donors could not comprehend the effect of the 
donation procedure, they do have the right to receive information, appropriate to their 
age/mental capability. Procedures should be in place to assess the donor’s capacity 
to consent, compliant with local regulatory frameworks. According to the European 
Union directive on safety of tissues and cells, all of the above is mandatory10.
Donor eligibility
The average age of family donors is different from that of unrelated donors. Elderly 
donors especially are more likely than age restricted unrelated donors to have 
co-morbidities that may complicate or prevent donation. systems should be in 
place to assess potential donors before HLA typing. These should include written 
information on the implications of giving blood for HLA typing, outlining the 
problems of withdrawing after a match has been established. They should include 
an assessment of general health and willingness to donate (possibly by telephone, 
using a health questionnaire11) before HLA typing. In this way, obstacles to donation, 
both psychological and medical, can be identified and addressed before matching, 
thus avoiding finding a fully matched donor who has subsequently to be deferred.
The idea that a substantial health risk to a donor is justified because the donor 
is donating to a relative is questionable and certainly controversial. Therefore, it 
is recommended that a local set of Donor Evaluation Guidelines, similar to those 
operated by an unrelated stem cell donor or blood donor panel, is adopted to inform 
decisions on specific medical conditions, for example, cardiovascular disease. When 
donors do not meet eligibility criteria, a procedure must be in place to assess and 
document decisions. However, divulging pertinent confidential medical information to 
family members must be at the discretion of the potential donor. According to JACIE, 
all results (normal and pathologic) have to be explained to a donor and in case of 
pathologic results the donor has to be informed regarding the consequences, further 
diagnostic tests or treatments. The donor medical examination should be carried out 
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by a physician who is not involved in the recipient’s direct medical care, but who 
is familiar with the possible risks and side effects of a BM harvest or an apheresis 
procedure. This is particularly important in those cases in which family donors place 
pressure on themselves and the medical team to be declared as medically suitable 
when there is doubt. When increased donor risks are identified, procedures should 
be in place to assess these against predicted benefits for the recipient. It is not 
reasonable to expose family donors to increased health risks wherein the recipient’s 
outcome is likely to be poor.
Guidelines for donor physical examination and eligibility should include:
•	 Clinical assessment of general health. 
•	 Assessment of donor’s potential risk factors for blood-borne viral infections 
(such as HIV, Hepatitis B and Hepatitis C) and prion disease (as is mandatory 
according to the European Union directive and JACIE).
•	 Referral for specialist clinical assessment of donors with co-morbidities.
•	 Assessment of risks for pediatric donors.
•	 As far as possible an assurance that the donor understands the implications 
of donation. Donors should know that they have the right to refuse donation 
at any time, but the implications to the recipient should be explained to them.
Adverse events registry
Over the past years, case reports concerning both family and unrelated donors 
have been published for serious adverse events. The WMDA Clinical Working Group 
registers severe events and adverse reactions concerning unrelated donors in the 
severe events and adverse reactions registry. Family donors are probably more at 
risk of developing adverse reactions12. A number of countries have established long-
term follow-up arrangements for family donors, either as a legal requirement or as 
research protocols. The establishment of an international registry of adverse events 
for all donors can be envisaged. A subcommittee of the WMDA and the EBMT Late 
Effects Working Party has been established to specifically address this issue (as well 
as barriers to its success, for example, financial). Only structured registration will give 
more insight into adverse effects of donation, including both short- and long-term 
effects of G-CsF administration in family donors. In addition, current adverse event 
reporting through the severe events and adverse reactions registry only captures 
data on severe adverse events and reactions of unrelated donors. It is recommended 
that in addition to these data, the suggested international registry should, at least for 
an appointed time period, also capture data from any potentially donation-related 
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adverse events (from family as well as unrelated donors), whether severe or not, as 
this is the only way to identify the actual occurrence of risks and side effects for both 
family and unrelated stem cell donors.
Follow-up
The necessity for long-term follow-up in healthy individuals to determine any harm 
(for example, malignancies) from administration of growth factors has been under 
discussion since the first (family) donors were treated with G-CsF13.The need for 
continued donor safety monitoring might be of even more significance in the family 
donor, because they are on average older than unrelated donors and therefore more 
frequently experience adverse events12. As studies have shown cytogenetic variances 
in lymphocytes after the administration of growth factors14,15 more research is needed 
to determine whether cytogenetic analysis should be implemented in structured donor 
follow-up. Currently, a study involving donors in the United Kingdom is addressing 
this issue. Moreover, follow-up of family donors of patients who have died requires 
special consideration of the emotional and psychological needs of the family.
some registries advise follow-up of unrelated donors for at least 10 years 
after G-CsF administration and potentially for life16; however, there is currently no 
scientific evidence to suggest the optimal length of follow-up. The maximum follow-
up for family donors is often short (up to 1 year). It is hoped the data from countries 
where long-term follow-up of family donors are being pursued will help to inform 
us of any benefits to extending this time period. More research in this area is to 
be encouraged. The decision as to who is responsible for the costs incurred by this 
long-term donor follow-up is likely to vary between countries and perhaps between 
different centers within one country. Whatever the local situation this issue must 
be resolved for each transplant program at either local or even national level. The 
WMDA has developed short questionnaires for donor follow-up that can easily be 
accessed and implemented17.
•	 short-term follow-up is defined as follow-up until 1 month after donation. The 
costs may be covered by the patient’s insurance company where relevant. The 
follow-up is likely to consist of a health questionnaire and may include a check 
on blood cell count.
•	 Long-term follow-up is defined as follow-up until 5 or 10 years after donation 
and is internationally recommended to safeguard donor safety15,18 For unrelated 
donors, the registries are responsible for carrying out this follow-up program. 
The responsibility for long-term follow-up of family donors may fall to the TCs, 
but the financial and logistic arrangements, which will be associated with this 
must be carefully considered. This is the only credible way to determine the 
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risks of donation in this population. The follow-up is likely to consist of a short 
health questionnaire (self-reporting) or, when possible, by comparisons and 
evaluations of the donor registry with the national cancer incidence registry or 
death registry. Ideally, the follow-up from unrelated and family donors should 
be standardized and a minimal data set of information to be collected should 
be agreed universally. However, the financial and logistic implications of this 
may differ between different groups, and in different countries, and this must 
be taken into account.
Multiple and subsequent donations
New developments in the treatment of hematological diseases might involve the 
infusion of more than one donor-derived cell product. Donors should be informed 
beforehand whether the recipient is involved in a program that might demand an 
additional donation such as donor lymphocytes. In addition, a subsequent donation 
might be necessary when the transplantation was not successful or in case of 
relapse of the original disease. For unrelated donors, registries have strict rules and 
regulations for second or third donations and how often they allow a donor to be 
administered hematopoietic growth factors. It is recommended to have a similar 
system for family donors. This may include a review of the subsequent donation 
request before assessment of the donor, by a medical advisor or advisory group 
(preferably more than one physician within a TC) to assess the risk/benefit ratio to 
both the donor and recipient. In other words, there should be good clinical evidence 
to support performing an additional donor cell harvest and infusion.
Donors as research subjects
Current protocols are often research based and may involve the donors or donor-
derived products. Besides provision of appropriate study-family information, donors 
should be given the option to discuss their participation with an independent 
person19. For example, the harvest of additional mesenchymal stromal cells from 
BM or natural killer cells from additional aphaeresis can be part of new research 
protocols, demanding subsequent donation procedures. Development of protocols 
to support the treatment of severe infections in neutropenic patients with donor-
derived granulocytes after stimulation with G-CsF and dexamethasone is yet another 
example of cellular product donation. These (frequently family) donors should also 
be offered a similar long-term follow-up program. In a situation, when the donor is 
a research subject, institutional review board approval has to be obtained as is the 
case when recipients are involved in research.
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The involvement of child donors in research protocols (for example, as a healthy 
control) should be carefully considered and requires expert ethical/medico-legal 
consultation. Again, a good balance between risk for the donor/benefit for the 
patient and vice versa has to be priority.
Conclusion and recommendations
A number of challenges face us today. stem cell donor care is well described according 
to the European Union directive for safety of tissues and cells; however, the daily 
practice for family donor care management differs substantially from the treatment 
of unrelated donors. Although the WMDA has concentrated its efforts on volunteer 
unrelated donors, one could argue that similar recommendations and standards 
should be considered for the protection of family donors. This is not a direct activity 
of the WMDA and may be considered by other transplant organizations. The Ethics 
and Clinical Working Group of the WMDA, however, feel they have a responsibility to 
offer its experience and expertize in this area. similarly, the follow-up and reporting 
of adverse events in all donors has been addressed at a recent workshop in Berne. 
This was initiated through a subgroup of the Late Effects Working Party of the EBMT 
and attended by representatives from a number of international organizations and 
registries concerned with donor care. Owing to dissimilar circumstances (the donor 
is either a relative or a stranger) it may be challenging to comply with all these 
recommendations. It is, however, essential to establish protocols for family donor 
care and recognize the donor as an autonomous identity. This will help to observe 
the positive balance between a donor’s commitment and a patient’s needs. The 
following is recommended:
•	 Counseling, including written information covering all aspects of family BM/
PBsC donation should be available for each family member before HLA testing. 
This should cover the option for the donor to choose not to donate.
•	 As a family donor who is physically or emotionally unable or hesitant to donate 
may feel pressure from family members, TCs should establish procedures to 
ensure that donors are appropriately counseled regarding their right to refuse 
typing or donation. The practitioner (for example, independent advocate, 
physician) counseling the donor should have a documented donor advocacy 
role and should not be involved in the recipient’s care. The donor must retain 
the right to divulge or not divulge the content of these discussions to interested 
parties including the patient or family members.
•	 systems should be in place to evaluate clinical risk to the donor against defined 
criteria and to document decisions made.
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•	 systems should be in place both for adverse event reporting and for long-term 
follow-up of related as well as unrelated donors.
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Introduction
During recent decades, the number of allogeneic hematopoietic sCTs (HsCTs) has 
steadily increased by, up to, 10% annually on a global scale1–3. Furthermore, several 
new trends in transplantation have emerged: the introduction of reduced-intensity 
conditioning (RIC) regimens has led to an increase in the number of HsCT performed 
in older patients and those with comorbidities and G-CsF-mobilized PBsC have in 
part replaced BM as the main source of hematopoietic stem cells (HsC) in adult and 
pediatric patients.
These developments are accompanied by a parallel increase in the number of 
donors involved in transplantation and substantial changes in the donation process. 
The rapid expansion of the unrelated donor registries, with more than 19 million HLA 
typed unrelated donors worldwide, has allowed for an increase in unrelated HsCT 
activity, now surpassing the number of related donor transplants in some regions1,3. 
The median age of related donors has increased with the increasing age of the 
recipients, leading to potentially more donors with occult or manifest comorbidities 
at the time of donation. As a consequence of RIC, an increasing number of donors 
becomes involved in multiple donations of therapeutic cells. It is likely that this trend 
will continue for the next decade; it might even increase further with future progress 
in transplant regimens. Furthermore, if the use of stem cells for non-hematopoietic 
indications and/or organ repair is confirmed as a useful therapeutic tool, this may 
accelerate the demand for stem cell donations.
since the beginning of HsCT, donor safety has been recognized by the community 
as an important issue4–7. Today, numerous donor outcome registries exist in different 
countries or in individual institutions but only the World Marrow Donor Association 
(WMDA) collects donor outcome data from unrelated donors on a global level. The 
serious events and adverse reactions (sEAR) and serious product events and adverse 
reactions (sPEAR) are collected centrally.
Very rare events may become apparent when the number of donations increases, 
but only if a large amount of the collected data can be analyzed. such events may 
have detrimental effects on donation, if they become public without the benefit of 
coherent investigation and explanation by the scientific and transplant community.
Hence, the need for collection of donor data has been underlined by the recent 
release of the guiding principles on human cell, tissue and organ transplantation 
by the World Health Organization (WHO) in Resolution WHA63.22, endorsed in 
May 2010. Donor safety and follow-up are specifically expressed as principles with 
data collection and analysis as integral part of any therapy8. This need has not yet 
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Table 1: Differences between related and unrelated donor characteristics
Unrelated donorsa Related donors




Number of donations 
allowed for same donor




Maximal: 1-4 donations, 
median 2 donations48
Unlimited, except for 
center-specific guidelines
Maximal dose of G-CSF per 
day
Usually 10-12µg/kg/d Usually 10-12 µg/kg/d, 
doses up to 20 µg/kg/d 
possible
Maximum volume per 
donation (volume for 
apheresis or volume for BM 
collection)
Often limited depending on 
donor’s body weight/blood 
volume
Unlimited
DLI Number of donations 
variable from one to multiple 
(no limit)48
Unlimited, except for 
center-specific guidelines
New mobilizing agents Used very conservatively, 
usually not recommended 
before first experiences have 
been collected in related 
donors
Used conservatively but 
may be used more liberally 
than in unrelated donors
Donor eligibility criteria ‘Healthy donor’21 most often 
very similar to the eligibility 
criteria for blood donors
Multiple co-morbidities 
might be accepted
Donor motivation Altruistic/volunteer Emotional relationship 
with the recipient or 
family. Mostly very 
willing, but some may 
donate because of familial 
obligation alone
Donor advocacy Yes Might be the same team 
as for the patient49
aLimits might differ depending on individual donor registry’s guidelines.
 
been completely addressed yet by other regulatory bodies like FACT-JACIE (www.
factwebsite.org, www.jacie.org).
Today, large registry studies in unrelated donors9–11 form the basis for the current 
knowledge on the frequent side effects during BM and PBsC donation, which are 
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usually of mild or moderate severity. smaller studies from related donors suggest 
that these frequent side effects occur with the same pattern in related donors12–15.
sporadic case reports and a recent large survey among transplant teams 
demonstrate that the donation procedure can be associated with a small but real risk 
for serious adverse events and reactions (sAE/R)16–19. Current experience suggests 
that risks seem to be higher for related than for unrelated donors with the caveat 
of reporting bias and lack of an adequate amount of prospective follow-up data in 
the related donor setting9–11,18. These rare sAE/R that occur with estimates of about 
1 in 3–5000 for serious and 1 in 10–20000 for lethal events are still incompletely 
understood9–11,16–19. Hence, there is urgent need for better understanding of short-
term sAR and to identify donors at risk. Because of the rarity of the events, progress 
can only be achieved by large international collaborations that include both unrelated 
and related donors. Despite the fact, that related and unrelated donors might differ 
for many basic characteristics (Table 1), the quality of adverse reactions associated 
with stem cell donation is not expected to be different between related and unrelated 
donors forming the rationale for a uniform donor follow-up for all types of donors. 
Generally, donor eligibility criteria for related donors are less strict with only a few 
definite criteria20 and may vary significantly between different centers. In contrast, 
eligibility criteria for unrelated donors are summarized by WMDA recommendations21 
resulting in somewhat more homogenous donor selection criteria. Together with 
the unequal basic characteristics, this may lead to differences in the incidence and/
or severity of adverse events in related vs unrelated donors but large data sets to 
support this hypothesis have first to be set up.
The question of long-term effects of donation is even less understood. Despite 
an intensive discussion on hematological malignancies in donors after exposure 
to growth factors a few years ago, data to assess reliably long-term sAE are still 
lacking22–25. The fact that these issues have already been raised almost 15 years 
ago5 underlines the ongoing urgent need to standardize short- and long-term donor 
follow-up.
Methods
The recently founded Worldwide Network for Blood and Marrow Transplantation 
(WBMT; www.wbmt.org), recognized the need for global cooperation in the field of 
HsCT and defined donor issues as one of its prime tasks. In August 2009, a workshop 
of an international group of representatives involved in related or unrelated HsC 
donation developed a consensus for such a donor follow-up on a global level, taking 
into account that resources for new tasks are limited in most teams. These collected 
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data should form the basis to address donor risks in public discussions to safely 
maintain allogeneic HsCT as an important treatment for many patients in need. 
Hence, two main topics were identified that should be addressed with priority:
•	 Prospective data collection should include all sAE/sAR during the donation 
procedure from all types of donors in the same way, that is, unrelated and 
related donors.
•	 Prospective data collection on potential long-term complications should 
focus on a minimum data set, that is, incidence and type of malignancies and 
autoimmune disorders only, and include all donors as above.
Results
Currently available data and experience have been reviewed in detail to form the 
rationale for this consensus. It has been observed, that most immediate or short-term 
sAR, related to the donation procedure, occur either before (during mobilization, 
induction of anesthesia) or within the first 30 days after donation. Hence, this time 
period needs to be analyzed carefully for all donation procedures. It follows the 
convention for a 30-day post-intervention period, which is currently established 
for other surgical and medical interventions. Beyond this point, follow-up and data 
collection will focus on a few potential late events. While they have been selected 
based on the biologic action of mobilizing agents currently in use, both PBsC and BM 
donors will be followed on long term. The reason to also follow BM donors is twofold: 
some of them may get EPO and/or G-CsF before or after collection of therapeutic 
cells and BM donors who did not get any mobilizing drug may represent the best 
available control group for evaluating late effects in donors. Long-term follow-up will 
be more time consuming for centers. Therefore, we propose an approach that should 
be achievable with a minimum of resources.
For more specific questions, clinical studies are needed with a separate funding 
and predefined donor populations and follow-up.
Immediate/short-term sAR associated with the donation procedure:
sAR, in the context of HsC donation, have been described for both BM and 
PBsC donation4,26, including rare fatal events, mainly of cardiac or cardiovascular 
origin17–19,27. Currently, it is suggested that related donors could be more frequently 
affected, because of less strict donor eligibility criteria in this group. sAR may occur 
during mobilization, before cell collection, during the collection or shortly thereafter. 
Most cases have been reported as case reports or by retrospective studies, hence 
causality is frequently not conclusive and relative risks cannot be estimated. some 
of these sAR, such as thrombotic and cardiovascular events or splenic rupture, might 
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be explained by the biological effects of G-CsF that have recently been reviewed 
in detail26,28 or are associated with an inherent risk of the collection procedure 
used (anesthesia, central venous catheter related complications, anticoagulation 
during apheresis, human error). Preexisting comorbidities of the donors are likely 
to have contributed to other sAR (for example, precipitation of sickle cell crisis or 
inflammatory diseases).
Late sAE/sAR associated with the donation procedure:
Late sAE/sAR are defined as sAE/sAR possibly related to the donation procedure 
with onset more than 30 days after completion of the donation. Chromosomal 
changes and changes in microarrays have been described after G-CsF stimulation 
raising concern on an increased long-term risk for hematological neoplasms29,30. 
These concerns have not been substantiated so far31. Chromosomal changes seem to 
be transient and do not affect CD34+ stem cells. Observational data from unrelated 
donor registries do not show an increased risk for secondary malignancies32, but 
the number of donors followed is still limited, given the large number needed to 
detect an even considerable increased risk for hemato-oncological neoplasms33,34. 
Further- more, epidemiologic studies are required for comparison of neoplastic 
events observed in healthy stem cell donors and representative control populations. 
It is important to realize that G-CsF, PEG-G-CsF and CXCR-4 antagonists recruit 
different cell populations according to global gene and mRNA expression levels34–36. 
Finally, it is possible that biosimilars of G-CsF and EPO will also be applied in healthy 
donors although recent statements from the European Group for Blood and Marrow 
Transplantation (EBMT) and WMDA do not recommend it outside of the context of 
well set up safety studies. This emphasizes the need to include all current mobilizing 
agents as well as any new agents that will be introduced into clinical practice in the 
future in a prospective follow-up.
In related donors, an increased risk for hematological malignancies might be 
expected owing to the same genetic background as the patient and the known 
association between HLA and malignancies37.
The degree of risk increase is difficult to estimate from available data. 
Epidemiological studies in families of patients with hematological neoplasms 
suggest that the risk to develop any malignancy is at least twice that of a normal 
population38. some of these donor characteristics may also apply to unrelated 
donors. so far it is not known how many volunteers joined the unrelated donor 
registries because of close relationships with a patient (that is, being a relative or 
having had close contact during many years, which could also include a common 
exposure to carcinogenic agents) and it is obvious that motivation patterns might 
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differ between different countries depending on different recruitment strategies of 
individual registries. Another issue that complicates the interpretation of long-term 
donor follow-up data is the effect of medical clearance before donation: Donors 
may be healthier than a non-donating age- and gender-adjusted control group as 
they have passed the medical clearance on confirmatory typing and work-up level. 
Furthermore, very little is known about the ‘lifestyle’ or socioeconomic status of 
individuals who register as potential stem cell donors compared with the general 
population. Thus every comparison of donor malignancies with age- and gender-
adjusted incidence ratios of the general population has to consider this potential 
bias. Currently, a prospective study is under way at the German Bone Marrow Donor 
Center (DKMs) that addresses this question by analyzing the incidence of potential 
late sAE in donors who donated compared with registered donors who were not 
asked yet to donate but underwent the same health checks simultaneously (AH 
schmidt, DKMs, personal communication).
short-term application of G-CsF changes lymphocyte subset populations and 
might lead to long-term immunological effects. New onset autoimmune disorders 
have been reported rarely39,40, but a causal relationship with previous G-CsF exposure 
has not been confirmed.
Recommendations for a minimal donor follow-up: 
Practical aspects for donor outcome follow-up are addressed below (Tables 2 and 3).
Definition of donation procedure: The donation procedure is defined as a 
procedure with the intent to collect an adequate number of therapeutic cells, that 
is, HsC, MsC, lymphocytes, natural killer cells or other cells. The donation procedure 
starts with the first injection of a mobilizing agent, the start of anesthesia or the 
start of apheresis (in cases of non-stimulated leukapheresis, for example, for DLI) 
and usually ends with one or multiple collections. However, the accomplishment of a 
collection is not required. Even if the preparative actions (that is, start of injections, 
apheresis or anesthesia) are stopped prematurely (because of donor or recipient 
reasons) the activity fulfils the definition of a donation procedure and the donor 
shall be registered and followed-up.
Data registries: It is proposed that recording of donor outcome data should 
become a part of the already well-established registries of member societies of 
WBMT (that is, Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), 
Asia Pacific Blood and Marrow Transplantation Group (APBMT), Center for Interna- 
tional Blood and Marrow Research (CIBMTR), European Group for Blood and Marrow 
Transplantation (EBMT), Eastern Mediterranean Blood and Marrow Transplantation
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Table 2: Minimal data set to be reported after the end of the donation procedure
Time interval covered: start of donation procedure until day 30 after completion of the 
procedure





Relationship to the recipient (twin / sibling / other family member / unrelated donor)
Collection data
Start date of the procedure
Was the product collection completed? (yes / no)
Number of collections / subsequent donations
Were hematopoietic growth factors used (for example, G-CSF)? (yes / no)b
Were cell binding inhibitors used (for example, plerixafor)? (yes / no)b
Was EPO used? (yes / no)b
Were othe drugs usedfor mobilization? (yes / no)
Product
BM (including collections of MSC)
PBSC
Both (BM and PBSC)
Unstimulated leukapheresis (for example, DLI)
Others
Complications in temporal association with the donation procedure
Report only serious adverse reactions (SAE/R) with International Classification of 
Diseases (ICD)10 coding (a list with a selection of the anticipated most frequent 
events is available in Supplementary Informationc). Report every SAE/R occurring 
within the interval between start of the donation procedure and day 30 after end of 
the donation procedure
a There is no global unique donor identifier yet. Each center/registry defines the unique donor ID by 
its own identifier (in the future, the ongoing WBMT activity towards a unique transplant center and 
patient identifier may also include a unique donor identifier).  
b Mobilizing agents may be used before either PBsC or BM collection and should be reported in any 
circumstances. Neither generic names nor information on dosage will be collected in this data set. 
c supplementary Information accompanies the paper on Bone Marrow Transplantation website (http://
www.nature.com/bmt)
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Group (EMBMT), World Marrow Donor Association (WMDA)). Identical data sets will 
allow combining data for analysis from registries of different societies of WBMT. 
societies and national registries are encouraged to reach agreements on how to 
organize data collection so that double reporting will be avoided.
Data collection: Data from the donation procedure and from long- term follow-
up will be collected. Questions have been designed to be as simple and as few as 
possible, and are based on WHO toxicity criteria and International Classification of 
Diseases (ICD) code where appropriate, as these items are already implemented in 
routine use in many countries, well established and standardized.
For reporting, the current ICD-10 code should be used. The most recent version 
for coding including the possibility for online search can be accessed at www.who.
int/classifications/icd/en/.
Table 3: Minimal data set to be reported for long-term follow-up
Time interval covered: up to 10 years after completion of the last donation process
Time of report: minimal reporting after 1 year, 5 years, and 10 years but annual or 
biannual reporting is recommended
Donor survival status
Date of last follow-up or death
Donor alive? (yes / no)
If no, cause of death: ICD code
Malignancy
Hematologic malignancy? (yes / no / unknown)
If yes, certainty of the diagnosis: confirmed / unconfirmed by medical data
ICD code
Non-hematologic malignancy? (yes / no / unknown)
If yes, certainty of the diagnosis: confirmed / unconfirmed by medical data
ICD code
Autoimmune disease
Autoimmune disease? (yes / no / unknown)  
(a list with a selection of the anticipated most frequent events is available in the 
Supplementary Information)
If yes, certainty of the diagnosis: confirmed / unconfirmed by medical data
ICD code
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Time of data reporting for procedure-related data including donor and collection 
procedure characteristics (Table 2): These data should be reported between day 30 
and day 100 after the procedure is completed. The time interval covered is the period 
from the beginning of the donation procedure until day 30 after the completion 
of the procedure. It is important to note that more rapid initial reporting for sAR 
might be required by authorities or individual societies. Every new attempt to collect 
cells is regarded as a separate donation procedure with the focus on the donation 
procedure, not the type of cells collected, that is, a BM donor undergoing a donation 
procedure for BM-derived HsC or MsC should be registered and followed irrespective 
of the collected cell type. Many cells might be collected without a mobilization 
procedure. For example DLI donation may occur several times, either by whole 
blood donation or after repeated apheresis. Other examples may be natural killer 
cell or DC donations. Whatever the cell type is, the donation will be characterized 
as unstimulated leukapher- esis donation. The time schedule for follow-up is always 
determined by the last donation procedure. Contrary to voluntary unrelated donors, 
an upper limit for the frequency and the total number of therapeutic cell donations 
is frequently missing in related donors. Prolonged persistent lymphopenia has been 
described in donors after repeated collections41, but information on the long-term 
follow-up are very scarce.
Practice of data reporting may be essentially the same as for patient data. 
Precise rules might be defined by the individual member societies of WBMT or legal 
authorities from individual countries.
Definition and reporting of sAR: Common adverse events are well known and will 
not be collected in this dataset (modifications of the current proposal might become 
necessary in the future for selected donor groups if new mobilizing agents become 
regularly used in healthy donors). Reports shall include adverse events defined by 
WHO toxicity grades 3 and 442 or sAR using essentially the same definition as WMDA: 
(1) death, (2) life-threatening events, (3) events requiring in-patient hospitalization 
or prolongation of existing hospitalization owing to WHO grade 3 or 4 toxicity and 
(4) events that result in significant disability/ incapacity43.
In many countries, these events are also required to be reported to the regulatory 
authorities. It is evident that a causal relationship with the donation procedure will 
often be difficult to establish; therefore, all events occurring in temporal relationship 
to the donation procedure and fulfilling either of these definitions shall be reported.
Long-term outcome data – time of data reporting and items: Until otherwise 
required by national regulatory authorities minimal follow-up should be reported 
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after 1, 5 and 10 years but annual or biannual follow-up reports are encouraged.
Reporting will be limited to three items: survival, onset of malignancies and onset 
of autoimmune diseases. These are simple questions that can be asked by written or 
electronic mail, by internet-based survey or by phone.
In the case of a positive reply, the level of evidence should be indicated, that 
is if the diagnosis was confirmed by medical data (that is, a diagnostic procedure 
as a pathology report, serological confirmation in certain autoimmune diseases, 
diagnostic criteria, for example, American Rheumatism Association (ARA) criteria 
fulfilled in rheumatoid arthritis and so on). The exact diagnosis should again be 
coded according to the ICD.
Use of newsletters, short message services, new media and social network 
facilities may help to maintain contact with donors, decrease numbers of donors 
lost to follow-up and ensure adequate data capturing. Many initiatives are already 
in place in different countries. Hence, one aim will be to connect and combine the 
already ongoing efforts. Analysis of donor outcome data may follow the same rules 
as, for example, analysis for late effects in transplant recipients.
Conclusions
Thanks to ongoing progress in transplant techniques and supportive care, allogeneic 
HsCT can be offered as a curative treatment to a steadily increasing number of 
patients. securing the willingness of donors to donate in the future is crucial for 
further development of treatments with allogeneic therapeutic cells. It is obvious 
that this willingness will heavily depend on the safety of current and future donation 
procedures. Many issues on donor safety have been addressed in the recent years 
by different groups. side effects during HsC donation are frequent but only transient 
in the overwhelming majority of related and unrelated donors. However, serious 
adverse events do occur rarely in the context of BM and PBsC donation. A causal 
relationship is not always evident and the true incidence of these events remains 
unknown because of different definitions and observation intervals for sAE/R. Most 
data on donor safety are from unrelated donors who represent a positive selection 
among healthy individuals. Data on related donors are scarce12–15,44–47 and only a 
few prospective trials or registration studies are underway (RDsafe study in the Us 
(cf.: www.cibmtr.org), registries for related donors in Japan, spain, Poland, Nordic 
donor registry and switzerland). Certain donor populations may represent special 
risk groups, like children, elderly donors, haploidentical donors (when higher doses 
of mobilizing agents and/or larger volumes for cell collection by apheresis might 
be used in these donors), donors with multiple donations for HsC and/or other 
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therapeutic cells and need to be studied in more detail.
Theoretical concerns about long-term effects after donation have not been 
verified yet. However, reliable data based on prospective registration and follow-up 
of all kinds of donors are still lacking. Current data sets are too small, follow-up is 
too short and numbers of donors lost to follow-up remain a problem, approaching 
50% even in well-conducted registry studies11 and thus impair the robustness of the 
conclusions drawn.
Data collection and analysis of donor outcome have to become an integral part of 
HsCT, to define incidence and risk factors for sAE/R in short and long term to protect 
donors’ health. The aim of a global standardized data collection is to allow us to 
define risks by large international combined registries.
Donor safety must be included in overall HsCT risk assessment. These issues 
also need to become part of accreditation standards. Reimbursement for donor 
outcome data registration must become part of the transplant coverage by insurance 
companies or national healthcare systems. Joint efforts led by WBMT in collaboration 
with its member societies are needed to achieve this goal. Additional private funding 
might become valuable, depend- ing on national properties.
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Background
Relatives donating peripheral blood stem cells (PBsCs) may be accepted for donation 
on less strict criteria than unrelated donors. We evaluated the occurrence of adverse 
events during procedure and follow-up, with a special focus on donors who would 
have been deferred as unrelated donors.
Study design and methods
All 268 related PBsC donors at our center (1996-2006) were included. Data were 
retrospectively collected from medical reports and standard follow-up. Health 
questionnaires were sent from 2007. Medical outcomes of donors, deferrable or 
eligible according to international criteria for unrelated donation, were compared. 
Results
Forty donors (15%) would have been deferred for unrelated donation. short-term 
adverse events occurred in 2% of procedures. Questionnaires were returned by 162 
(60%) donors on average 7.5 years after donation, bringing total person-years of 
follow-up to 1278 (177 in deferrable donors). Nine malignancies and 14 cardiovascular 
events were reported. The incidence rate of cardiovascular events in eligible donors 
was 6.5 (95% confidence interval [CI], 2.5-12.3) per 1000 person-years compared to 
44.9 (95% CI, 17.4-85.2) in deferrable donors; incidence rates of malignancies were 
4.6 (1.4-9.6) and 24.0 (6.0-53.9) per 1000 person-years, respectively, in eligible and 
deferrable donors. All incidence rates were within the range of age- and sex-matched 
general population. No autoimmune disorders were reported. 
Conclusion
In both the eligible and the deferrable related donors treated with granulocyte-
colony- stimulating factor there are few short-term and long- term problems. The 
occurrence of post-PBsC cardiovascular events and malignant disease in related 
donors appears to be within the range of the general population.
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Introduction
Recombinant human granulocyte-colony-stimulating factor (G-CsF) is increasingly 
used to mobilize peripheral blood stem cells (PBsCs) from healthy donors for 
allogeneic hematopoietic transplantation. In the Netherlands, PBsC collection has 
been performed in related donors since 1995. Counseling, collection, and formal 
follow-up evaluations of unrelated donors conducted since 2004 are performed 
in accordance with national policies that conform to the World Marrow Donor 
Association standards1. Although related donors are screened by independent 
physicians not involved in care of the patient, many of these donors are accepted for 
PBsC donation despite the presence of conditions for which they would be deferred 
if they were unrelated donors.
There is ample information about the short-term effects of the PBsC procedure in 
related and unrelated donors, indicating an acceptable safety profile in comparison 
to marrow donation under general anesthetic2,3. Nevertheless, some serious and 
potentially life-threatening complications have been described in allogeneic PBsC 
donation procedures, including splenic rupture4,5, anaphylaxis, vasculitis, and 
acute lung injury6. Myocardial infarctions7, thromboembolic events, sub-arachnoid 
hemorrhage, and cardiac arrests have been reported in at least 13 cases either during 
G-CsF mobilization or within 30 days after PBsC harvest8,9. Careful donor selection 
and observation might mitigate but not completely abolish these risks.
Potential long-term complications are, however, less well known. There are 
some reports suggesting that administration of G-CsF may enhance malignant 
transformation in patients10-12. some have reported the occurrence of hematologic 
and solid malignancies in healthy donors after donation of G-CsF-mobilized PBsCs. 
Furthermore, there are concerns about the potential development or exacerbation of 
autoimmune or systemic inflammatory diseases3,8.
These considerations regarding possible long-term effects have stimulated 
investigators to report on long-term follow-up of PBsC donors13-15. However, long-
term data concerning this topic in related donors are relatively scarce. Leitner and 
colleagues16 observed a cohort of 171 related donors; de la Rubia and coworkers17 
described findings from a voluntary national registry of donation and follow-up of 
predominantly related donors; Halter and colleagues8 reported international survey 
data from the European Group for Blood and Marrow Transplantation concerning 
both related and unrelated donors. None of these investigators found an increased 
incidence of malignancies; all authors mentioned the higher age of related donors as 
a relevant issue and called for systematic long-term follow-up.
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Here we report follow-up data concerning a Dutch cohort of related donors. 
Because of the apparent difference in acceptance of related donors in comparison 
to unrelated donors, we also separately analyzed the data on the individuals who 
would not have been accepted under international screening criteria for unrelated 
donors.
Materials and methods
study population and PBsC procedure:
The study cohort consisted of all related donors who underwent G-CsF mobilization 
and PBsC harvesting at Leiden University Medical Center from May 1996 to May 
2006; the recipients were all patients at the hospital’s transplantation unit. The study 
was performed as part of a larger study that also comprised a prospectively enrolled 
group of donors and for which ethical approval was obtained from the hospital 
medical ethics committee.
Donor consent and medical clearance were performed by an independent 
physician. subject to careful medical assessment, related donors could be accepted 
without upper age or body weight restrictions and sometimes in the presence of 
conditions which would constitute contraindications for unrelated stem cell donation. 
A short description of the procedures and reference criteria is given in Appendix s1, 
available as supporting information in the online version of this article.
Donors received 10 µg/kg G-CsF (filgrastim, Amgen, Inc., Thousand Oaks, CA) 
once daily. The white blood cell (WBC) count was checked on the fourth morning for 
dose adjustment (halving) to take place if there was an increase above 70 x 109/L. 
The fifth dose was administered at the end of the fourth day. PBsC apheresis (COBE 
spectra, CaridianBCT, Lakewood, CO) was conducted on the fifth and, if necessary, 
sixth or subsequent day after an additional dose of G-CsF. If required, calcium was 
supplemented. standard procedures allowed reinfusion of autologous platelets (PLTs) 
prepared from the stem cell product if there was a postapheresis PLT count below 
50 x 109/L or if it was below 80 x 108/L and a second day of apheresis was needed. 
After completion of the procedure, follow-up visits were scheduled at both 1 month 
and 1 year after collection.
Data collection:
We extracted data from medical records and hospital information systems concerning 
predonation examination, donation, and follow-up visits. Furthermore, we evaluated 
findings of medical screening and noted cases of acceptance where the donor 
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would have been deferred under the criteria for unrelated donors. Mobilization and 
apheresis procedural data were extracted, including data on deviation from standard 
G-CsF schedule, use of a central venous catheter (CVC), the number of apheresis 
sessions, PBsC harvest, and reinfusion of autologous PLTs prepared from the stem 
cell product. We retrieved information on requested target stem cell dose and yield, 
as well as on second requests for hematopoietic stem cells and donor lymphocyte 
collections (donor lymphocyte infusion). Finally, we recorded serious adverse events 
(sAEs) during follow-up.
In November 2007 we sent all donors a standardized health questionnaire by 
post. It comprised 14 yes or no questions about medical diagnosis and treatment 
indicative of health problems since the donation; free-text explanation was to be 
added if there were any “yes” responses. If the information given was not clear, 
one of the investigators (JWO) contacted the donor by telephone or e-mail for 
clarification. When necessary medical details were requested from treating physicians 
with written consent from the donor. If the questionnaire was not returned, several 
attempts were made to check the address and find the donor. In January 2011 we 
accessed the hospital patient database to ascertain whether the recipient was alive 
or retrieve the date of death.
Definitions:
Donor eligibility status was retrospectively assessed according to the Assessment 
Tool at Workup from the National Marrow Donor Program (NMDP, 2009 version, 
Minneapolis, MN)18, which was applied alongside general blood donation criteria. 
Broadly, unrelated donors must have no history of cardiovascular, diabetes, systemic 
autoimmune, eye, or thyroid disease; donation is permitted up to age 60 years and 
a body mass index (BMI) of 40 kg/m2. Donors who would not have been eligible as 
unrelated donors are referred to as “deferrable donors”.
All events requiring unscheduled medical examination or treatment from the 
start of mobilization until the 1-month follow-up were taken into consideration and 
categorized as procedure-related sAEs.
Follow-up period is defined as the period starting 1 month after start of G-CsF to 
the latest contact with the donor. Contacts from 30 up to 100 days were considered 
as early follow-up and contacts from 100 to 730 days as late follow-up.
The study outcomes were as follows:
1. Any malignancy (basal cell carcinoma excluded).
62
Focus on the donor
2. Cardiovascular disease (CVD) after the procedure: a combined outcome of 
medically diagnosed fatal or nonfatal myocardial infarction, newly diagnosed 
coronary disease treated by medication or ischemic vascular disease, cardiac 
intervention or vascular intervention, cerebrovascular event, medically 
diagnosed transient ischemic attack for which treatment was instituted, or 
venous thromboembolism.
3. (systemic) autoimmune disease of any type.
statistical analyses:
Data for all donors are presented, with comment on completeness of information. 
Means, medians, and interquartile ranges (IQRs) were calculated as descriptive 
statistics. For each donor, the number of follow-up years was determined from 
the time of donation to the latest contact date. Annual disease-specific incidence 
rates were calculated as the number of events per 1000 person-years of follow-up, 
including all follow-up years until occurrence of the first event or until the latest 
contact date with donors without events. Confidence intervals (CIs) are given for the 
95% level of statistical significance.
To compare incidence rates in our study group with those in the general 
population, age- and sex-specific incidence rates of CVD and for cancer within 
the Dutch general population were retrieved from the national statistics database 
(http://statline.cbs.nl/statweb/?LA=en) and from the national cancer registry (http://
www.iknl.nl/). Using the number of follow-up years for male and female donors in 
each age band we calculated the numbers of cardiovascular events and malignancies 
which would be expected in the study population if they had the same rate as in 
the general population. The standardized morbidity ratio (sMR) was determined, the 
ratio of observed events to the number expected. (A sMR less than 1 means that 
there were fewer events in the study cohort than expected.) The sMR and 95% CI 




The 268 related donors had a median age of 43 years (range, 14-70 years) at donation; 
the demographic charac- teristics of the cohort are shown in Table 1. Forty donors 
would have been deferred according to NMDP criteria; the reasons are summarized 
in Table 2. Apart from age over 60 years, BMI over 40 kg/m2, and hypertension (>160/ 
95 mmHg), medical contraindications were present in 10 donors: Factor V Leiden and/
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or previous deep venous thrombosis (n=2), coronary atherosclerosis and medication 
or revascularization (n=2; stable), aortic valve stenosis (stable), Parkinson’s disease, 
past treatment for breast cancer (more than 5 years previously), diabetes mellitus 
Type 1 or 2 (n=2), or low concentration monoclonal (M) protein.
Table 1: Donor characteristics and medical history*




Female 115 (43) 18 (45)
Age at donation (years) 42.8 (34.6-51.2) 60.4 (46.9-63.5)
BMI† (kg/m2) 24 (22-28) 27 (24-30)
* Data are reported as number (%) or median (IQR) 
† BMI known for 242 donors
Table 2: Deferral reasons of 40 deferrable donors*
Deferral reasons Number
BMI (> 40 kg/m2) 2
Hypertension (> 160/95 mmHg) 13
Other medical conditions 10
Age > 60 years 21
* More than one reason may apply
All procedural data were complete for 262 donors. Data on both target and yield 
of CD34+ cells were available for 234 donors. A collection of PBsCs that was deemed 
adequate was achieved in all but three donors (1.1%; one female and two male 
donors deferrable for age over 60 years).
The collection was completed in one session in 176 donors (66%): 76% for male 
and 52% for female donors. Most of the remaining donors underwent 2 days of 
apheresis; more than two sessions were needed in five (three males). A CVC was 
used in 22 of 268 (8%, 16 females). Four females out of these 22 donors were 
deferrable (two for hypertension, one for age >60 years, and one for both BMI > 40 
kg/m2 and hypertension).
Follow-up visits are recorded for 230 donors (86%): 207 (77%) for early follow-
up within 100 days and 156 (58%) for late follow-up approximately 1 year after 
collection, some because of subsequent donations. There was no correlation between 
this follow-up attendance and survival of the recipient in the first 6 months after 
transplantation. A total of 122 donors made subsequent donations: 113 donated 
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lymphocytes (donor lymphocyte infusion) on one or more occasions, seven donors 
underwent a second PBsC collection, one donor donated granulocytes, and one donor 
donated marrow because of inadequate PBsC yield. The interval for subsequent 
donations was on average 329 days (IQR, 170-398 days; median, 248 days).
Procedure-related and short-term events:
G-CsF led to changes in hematologic variables as expected. Eighty donors (30%) 
received autologous PLTs (60 donors once and 20 donors twice or more) separated 
from the PBsC product. No transfusion reactions to PLTs or serious biochemical 
changes were recorded. All of the mild elevations of LDH and bilirubin normalized 
within 6 weeks of harvest.
Table 3: Procedure-related sAEs




Excessive tiredness, one night hospitalization after 
PBSC
M, 32 Hypertension
Chest pain; no explanation F, 34
Inpatient opiate pain control; G-CSF stopped on Day 
3 with WBC count of 59.7 x 109/L
M, 39
Inguinal venous thrombosis after CVC F, 45
Persistent pain symptoms at injection site F, 24
Potentially serious dose incidents
Received incorrect G-CSF dose; no excessive increase 
in WBC count
F, 36 Previous DVT
No dose reduction on Day 3 (WBC count was 80 x 
109/L); precollection WBC count of 107 x 109/L
F, 55 Previous DVT
DVT = deep vein thrombosis
Table 3 shows the sAEs, one of which was related to the use of a CVC. In all, five 
donors (2%) required unscheduled medical attention and/or hospitalization during 
the period of G-CsF administration or harvest or during the direct follow-up period. 
We found no correlation between donor’s eligibility status and the occurrence of 
short-term procedure-related sAEs. The table also details two potentially serious 
dosing incidents. A total of eight donors (3%) reported excessive tiredness in relation 
to the procedure, which lasted for longer than 1 week, persisting until 6 weeks post-
donation in three cases.
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Follow-up:
Figure 1 summarizes the response to the follow-up questionnaire. Of the 268 donors, 
162 returned questionnaires giving a response rate of 60%. Responders were more 
likely to be female and older; there was no difference in proportion of responding 
donors according to death or survival of the recipient.
Figure 1: Responses to the follow-up (FU) health questionnaire 
The total number of donor follow-up years was 1278. The median follow-up was 
4.5 years (range, 0-13.6 years; IQR, 0.6-8.4 years). No autoimmune disorders had 
been diagnosed during the follow-up period. Table 4 shows the reported long-term 
morbidity and follow-up outcomes together with the eligibility status of the donors. 
Fourteen (new) cardiovascular events had occurred and nine malignancies were 
diagnosed (excluding two donors who had been treated for basal cell carcinoma). In 
all, four donors are known to have died: one of a cardiovascular event and two from 
lung cancer while a fourth donor is known to have died but the cause is unknown. 
Four donors had a new diagnosis of Type 2 diabetes and two, previously controlled 
on diet alone, had started taking oral antidiabetic agents; one of these six donors 
was in the deferrable group (for age >60 years). A donor who had suffered from 
persistent pain at the G-CsF injection site continued to be affected by fibromyalgia-
like symptoms over 5 years after donation. The donor who had a femoral venous 
15 Abroad (13 lost to FU, 2 known to be “in good health”)
53 No / incorrect address or telephone info or no 
telephone contact
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thrombosis still suffered from functional impairment in the leg and inability to work 
despite adequate anticoagulant treatment and resolution of the thrombus.
Table 4: Follow-up findings in donors
Sex (M/F),  




Problem during follow-up Deferral reason 
(if present)
F, 45 and 24 Persistent symptoms after procedure
Cardiovascular total n = 14; interval median, 3.5 years (range, 6 weeks-10.5 years)
F, 70 5.8 Pacemaker implantation Age
M, 37 3.2 Dissecting aneurysm*
M, 42 4.9 TIA
M, 44 2.4 Myocardial infarction Hypertension
M, 45 6.8 Myocardial infarction Hypertension
M, 47 0.6 DVT
M, 50 3.8 Peripheral vascular disease Other
M, 52 3.7 Myocardial infarction
M, 54 1.4 Angina pectoris diagnosed
M, 55 4.9 Myocardial infarction Hypertension
M, 57 1.5 Coronary revascularization
M, 58 0.5 Vascular dementia
M, 60 10.5 Cardioversion for atrial fibrillation Age
M, 62 0.2 Myocardial infarction Hypertension
Malignancies total n = 9; interval median, 4.2 years (range, 3.0-10.1 years)
F, 16 4.1 Hodgkin’s lymphoma
F, 46 4.2 Breast cancer
F, 51 7.6 Bowel cancer
F, 52 7.5 Lung cancer*
F, 55 8.6 Breast carcinoma in situ
F, 70 3.9 Breast cancer Age
M, 44 10.1 Glioblastoma Hypertension
M, 60 3.1 Rectal cancer Age
M, 66 3.0 Lung cancer* Age
* Deceased; in addition a female donor in the eligible group, aged 56 at donation, is known to have 
died but the date and cause are unknown 
DVT = deep vein thrombosis; TIA = transient ischemic attack
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Table 5 shows the incidence rates of cardiovascular events and of malignancies 
in the study cohort and age- and sex-adjusted rates in the general population. The 
incidence rate of cardiovascular events in deferrable donors was 44.9 per 1000 
person-years (95% CI, 17.4-85.2 per 1000 person-years) in comparison to 6.5 per 
1000 person-years (95% CI, 2.5-12.3 per 1000 person-years) in eligible donors. 
The rates of cardiovascular events and malignancy in deferrable donors were in the 
range of the expected rates on the basis of age- and sex-specific rates in the general 
population; that of cardiovascular events in eligible donors was 0.6 times that of the 
general population (95% CI, 0.2-1.1).
Table 5: Incidence rates (IRs) of cardiovascular events and malignancies in study cohort 














Eligible 7 1080 6.5 (2.5-12.3) 11.5† 0.6 (0.2-1.1)
Deferrable 7 156 44.9 (17.4-85.2) 33.3† 1.3 (0.5-2.6)
Malignancy
Eligible 5 1086 4.6 (1.4-9.6) 3.9‡ 1.2 (0.4-2.5)
Deferrable 4 167 24.0 (6.0-53.9) 10.2‡ 2.4 (0.6-5.3)
* Per 1000 person-years
† Expected rate per 1000 person-years on the basis of age- and sex-specific population figures: 
“Hospital admission for disease of heart orcirculation”
‡ Expected rate per 1000 person-years: incident cancer diagnoses
Discussion
In this cohort of related donors, 15% would have not been accepted according 
to international criteria for unrelated PBsC donation. The likelihood of procedure-
related sAEs was similar in these deferrable donors compared to donors who would 
have qualified as unrelated volunteer donors. The overall incidence of 2% short-
term procedure-related sAEs associated with mobilization and PBsC harvest is 
consistent with figures previously reported in larger series. For instance the Center 
for International Blood and Marrow Transplant Research and European Group for 
Blood and Marrow Transplantation reported 15 (1.1%) donation-related adverse 
events among 1337 allogeneic, mostly related PBsC donors, of which five were 
catheter-related19.
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The use of autologous PLT transfusions was imple- mented in our institution to 
comply with the guidelines, which do not allow stem cell apheresis if the preapheresis 
count is below 80 x 109/L and which require daily monitoring until recovery of PLT 
counts if the postapheresis count is below 50 x 109/L. The procedure and its effect for 
the donor as well as for the stem cell product have been validated in our center. No 
adverse transfusion effects were observed.
In our long-term follow-up, the incidence rate of cardiovascular events in 
deferrable donors was 45 events per 1000 person-years (95% CI, 17-85 events per 
1000 person- years) in comparison to 6.5 per 1000 person-years in eligible donors. 
Rates of malignancy as well as cardiovascular events in both deferrable and eligible 
donors were in the range of age- and sex-adjusted population rates. The point 
estimate of the sMR for malignancy in the deferrable group was 2.4; however, the 
95% CI is very wide and our data cannot exclude an increased incidence up to 5.3-
fold.
A theoretical concern has always been that use of G-CsF might favor the 
development of malignancy which would only become apparent after several 
years’ latency. The overall number of malignancies in our study was relatively high 
compared to other studies. Halter and coworkers8 reported the survey of both related 
and unrelated donors by the European Group for Blood and Marrow Transplantation, 
which included almost 100,000 person-years of follow-up of more than 23,000 
PBsC donors. A total of 12 hematologic malignancies occurred. While the rate of 
hematologic malignancy was higher in PBsC donors (1.2 vs 0.4 in 27,770 former 
marrow donors) this is probably explained by the higher age of related PBsC donors. 
Pulsipher and coworkers15 reported on follow-up findings ranging from 2 days to 
99 months, with a median of 49 months, on 2408 unrelated donors (9% older 
than 50 years at donation) for recipients within the NMDP program; there were 
21 nonhematologic malignancies excluding basal cell carcinoma and one case of 
chronic lymphocytic leukemia. Concerning solid malignancies in former PBsC donors, 
Hölig and coworkers14 reported on 3928 unrelated donors in whom a total of eight 
nonhematologic and four hematologic malignancies occurred. All investigators made 
comparisons with data for the general population and found no indication of any 
increase. Our cohort was approximately 9 years older than the donors reported on 
by Hölig and coworkers who had a median age of 34 years; in our group only two 
malignancies occurred in donors aged below 40 at the time of donation. Although 
our data give no reason for concern that there might be a relevant increase in rate 
of malignancy, our cohort is small with a limited follow-up. More person-years of 
follow-up would be needed to reject the possibility even of an implausibly high 
10-fold increase in rate of malignancies20.
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The occurrence of autoimmune disease has less frequently been evaluated16,21. 
so far, no investigators have found any indication of an increase of autoimmune 
conditions. Even if we consider a worsening of existent Type 2 diabetes mellitus as 
a possible effect of G-CsF, the six cases of new or worsened Type 2 diabetes in our 
cohort are not in excess of what would be expected.
Our study benefits from the fact that it describes results from a single center 
using uniform standard procedures; however, the relatively small group of donors 
remains a limitation. Its retrospective design, in particular the impossibility to trace a 
large number of donors, is a further limitation. This leads to missing data and a risk 
of ascertainment bias. The sMR is calculated using age- and sex-specific population 
rates and the numbers of follow-up years in females and males in each 5-year age 
band. Hence the result is fully adjusted for the fact that responders tended to be 
female and older. However, any conclusions are based on the assumption that 
responders and nonresponders do not differ in their rate of the studied outcomes. 
In the observational setting the validity of this assumption cannot be tested. The 
difficulty of follow-up of related donors beyond a year after G-CsF exposure is 
encountered by other investigators16,22,23. In the Netherlands, the standard schedule 
ends after the 1-year attendance because the recipient’s health insurance only 
reimburses such follow-up to 1 year after donation. In our study this lack of routine 
follow-up was addressed by postal health questionnaires. However, nearly one-fifth 
of donors could not be traced and the overall response of 60% is suboptimal.
A strength of the study is that it additionally captured data on CVD in the years 
after participation in the PBsC procedure. The incidence of late vascular events beyond 
4 weeks has to our knowledge never been systematically recorded. The comparison 
with population data gives no indication of any excess morbidity. However, donors 
should normally constitute a lower-risk population, which is reflected in the incidence 
of CVD in the eligible group.
Importantly, the incidence rate of approximately 45 per 1000 person-years in the 
deferrable donors suggests that the safety margins in this group are smaller. Vascular 
disease is an important reason for deferring donors in view of the short-term risk of 
thrombotic complications. The survey by Halter and coworkers8 describes clustering 
of cardiovascular events in the first weeks after the proce- dure. This was not seen in 
our study population although three cardiovascular events occurred in the 7 months 
after the procedure.
Raised and/or drug-controlled blood pressure and age were the most frequent 
reasons for which the related donors would not have been eligible for unrelated 
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donation. Candidate-related donors, most of them being siblings of cancer patients, 
tend to be older than unrelated donors and age in itself brings increased risks of CVD. 
In our center the donor assessment is performed by a physician who is not involved 
with the treatment of the patient. While this prevents any conflict of loyalties and 
minimizes risk, it is not a strict policy to rigidly defer all donors with one or more 
characteristics, including age, that would have led to deferral of an unrelated donor. 
Our data are consistent with other observations and show that if screening is 
performed as for unrelated donation, a population at lower (cardiovascular) risk will 
be selected. We also found that related donors who do not meet acceptance criteria 
for unrelated donors have a higher incidence of cardiovascular events, indicating 
smaller safety margins. Therefore, these criteria – including age – should in our 
opinion also be taken into consideration in the assessment of related donors. If a 
family member presents factors that would lead to deferral for unrelated donation 
because of potential higher risk of the procedure, it should not be assumed these 
risks may be accepted even if the donor is willing to proceed for the sake of a family 
member.
Overall our results show acceptable risks of the use of G-CsF in these related 
donors concerning most important side effects. The long-term occurrence of CVD and 
of malignancy for both eligible and deferrable donors falls within the range reported 
for the population. However, the small size of the study means that the CIs are wide. 
There is insufficient information to conclude that there are no relevant long-term 
increases of cardiovascular or malignant disease. Late medical events will not be 
systematically captured unless active follow-up extends beyond the first year, not 
only for unrelated but also for related donors. We therefore strongly support efforts 
by the international transplantation community to ensure long-term follow-up for 
unrelated donors and related donors as well22,23.
In conclusion, this study gives no indication of long-term increased risks of CVD 
or of malignancies in related donors who have undergone G-CsF mobilization and 
PBsC apheresis, but cannot exclude this either because of the small size of the cohort.
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since the beginning of hematopoietic stem cell harvesting from volunteer unrelated 
donors, ensuring donor safety has been a necessary goal of all parties involved in the 
process. As donation of BM or PBsCs is not in the interest of the donor’s own physical 
health, donor registries and transplantation centers must take into account both 
medical and ethical aspects involved in the donation procedure. One of the principal 
goals leading to the formation of the World Marrow Donor Association (WMDA) was 
to establish internationally acceptable standards for all aspects of unrelated donor 
care.
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Introduction
The first World Marrow Donor Association (WMDA) recommendations and 
requirements for standardized practice in this regard were published in 19941. This 
paper discusses the current WMDA guidelines for both medical and ethical aspects 
of donor safety. Where possible, each of the issues has been introduced using the 
appropriate WMDA standard (version 1 November 2008). Explanatory remarks and 
key references about the standards are provided. This document deals primarily with 
adult unrelated donors, and aspects specific to mothers donating cord blood units 
can be found in ‘International exchange of cord blood units-the registry aspects’ in 
this series.
Donor recruitment, including education, managing expectations 
and informed consent
WMDA standards
•	 The willingness to become a donor must be the individual choice of each adult 
donor or each maternal donor of a cord blood unit, that is, donations must be 
voluntary. Donors must be willing to donate on behalf of any patient being 
treated in any part of the world.
•	 Donors must not be paid for their donation, but may be reimbursed for 
expenses incurred during the donation process, for example, time lost from 
work or travel to the collection center.
•	 Adult donors and maternal donors of cord blood units must be informed 
regarding their potential role in the donation of hematopoietic stem cells, the 
risks involved in the donation and the tests to be performed on the donor.
•	 signed consent must be obtained initially at the time of recruitment.
Context2,3
Volunteerism is one of the basic principles of becoming an unrelated hematopoietic 
stem cell donor or donating cord blood units for public use. Education given at 
the time of recruitment should not only include appropriate information on the 
registration, counseling and the donation process, but also emphasize the voluntary 
nature of the donation and that the donor has the right to withdraw. Although the 
primary responsibility of the registry is in protecting the donor and ensuring their 
safety, the registry must ensure that the donor is aware of the serious, and potentially 
life-threatening, consequences to the recipient if the donor chooses to withdraw at 
any time, but particularly if this is after the recipient’s pretransplant conditioning has 
commenced. Donors should also be informed that there is a reasonable possibility of 
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multiple or subsequent donation requests. In addition to verbal information, donors 
must be provided with appropriate written information before or at the time of 
recruitment and during the various stages of the search and donation process.
Confidentiality
WMDA standards
•	 To ensure confidentiality, the identity of donors must be protected. Approaches 
to ensure donor confidentiality must be established. The registry must have 
a written policy listing the conditions under which donors and recipients 
might be informed of each other’s identity. These policies must comply with 
governmental laws on disclosure.
•	 Donor and patient identity must remain confidential during the search process, 
so that only appropriate registry personnel can have access to these data.
Context2,4
The fundamental idea of anonymity or confidentiality during the search and 
donation process is to prevent, in every possible way, influencing or coercing the 
donor to undertake something that they either do not understand or do not wish 
to do. Violating the principle of confidentiality during the search process makes it 
practically impossible for the donor to make an unbiased decision. However, many 
registries do allow certain patient information to be given to the donor (for example, 
age, gender, disease of the recipient). Thirty-five percent of the registries allow direct 
donor-recipient meetings after a previously established time period. In the light of 
present therapies (for example, reduced intensity or non-myeloablative conditioning), 
where subsequent donations are more often requested from donors, each registry 
should carefully consider their policies, to ensure the donor has, at all times, the free 
and unbiased ability to choose whether to continue to donate or not.
Donor health assessment and eligibility
WMDA standards
•	 Requirements for donor health affecting the eligibility of donors must be 
established.
•	 Characterization of adult volunteer donors or maternal donors of cord blood 
units for blood group markers, for the presence of infectious diseases and for 
any other markers considered important in transplantation must be performed.
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•	 The medical history of donors selected for specific patients must include 
questions to identify persons at risk of disease transmissible through 
transplantation, according to WMDA recommendations.
•	 The adult volunteer donor must be medically examined to ascertain fitness 
to donate. This examination must be performed by a physician who is not a 
member of a team who has cared for the patient.
Context5,6
The WMDA has developed recommendations about the eligibility criteria and 
evaluation of donor health with a view to ensuring donor safety before, during and 
after the donation; and protecting the recipient from diseases transmissible by the 
graft. In order to avoid accepting ineligible donors onto the registry, the medical 
evaluation of the volunteer before or at recruitment is of critical importance. Once a 
donor is selected for a specific patient, a thorough medical history, examination and 
investigations are required. As the health status of the donor may change over time, 
it is reasonable to ask the donor relevant questions about their health at any time 
that they are contacted for a potential donation.
The eligibility criteria may differ depending on whether the registry is affiliated 
to a blood transfusion service or not. Registries recruiting only among blood donors 
may have stricter health criteria than those recruiting other members of the public. 
Because a blood donor is rarely unique and a specific blood transfusion rarely critical, 
it is possible to implement stricter risk management than would be appropriate for a 
hematopoietic stem cell donor, where an individual may be the only person available 
worldwide who can provide for a curative procedure.
Registries will ask questions to assess the donor’s risk of having a transmissible 
disease (for example, infectious, autoimmune or genetic disorders). Many of these 
questions may be of a sensitive nature (for example, use of non- prescription drugs 
or sexual behavior). Testing for specific infectious disease markers (for example, 
hepatitis or HIV) is mandatory to protect the recipient. Donors must thus be informed 
that in the event of a positive result they will be counseled as to the impact and 
implications of the findings and any consequences that there might be to his/her 
health. In some, but not all, cases the donor may be medically deferred.
Donors may elect to donate stem cells either by BM harvest or G-CsF-mobilized 
PBsC collection. The donor should be fully informed about the pros and cons of 
each method. Although the final choice of route of donation rests with the donor, in 
practice many donors will agree to whichever product is requested by the transplant 
center (TC), if a preference is stated. In certain circumstances, the donor may only 
be permitted to donate by a single route (for example, donors with a history of 
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serious back pain may not be permitted to donate BM). such restrictions must be 
communicated to the TC. Conversely, in some cases the TC will only accept a certain 
product; for example, certain treatment protocols require either BM or PBsC. In such 
cases, the TC may need to search for a different donor. It should be borne in mind 
that in the future additional mobilizing agents and routes of donation could emerge.
The legal and regulatory requirements for donor health assessment in individual 
countries may well be additional to the WMDA recommendations.
Registry responsibility for liability and death (benefits) insurance
WMDA standards
•	 Fully informed and legally valid written consent must be obtained from all 
adult volunteer donors at the time of workup.
•	 The registry must assume responsibility and establish procedures for all 
donor medical expenses including the precollection physical examination, 
the collection proce- dure and all post-collection medical expenses that are 
directly related to the donation. No donor should assume financial liability 
for any portion of the follow- up testing and/or stem cell harvest/procurement 
process. The registry is responsible for all reasonable expenses incurred by the 
donor.
•	 The registry should offer disability and death benefits to all stem cell donors. 
These benefits might be provided through insurance coverage.
Context7,8
Fully informed consent is a central principle of self- determination, however any 
medical intervention carries a certain level of risk. It is critical to reduce the risk to 
the lowest possible level for the individual undergoing the procedure, as well as for 
the persons and institution performing the procedure. A donor should not be asked 
to consent to donate stem cells without adequate insurance or other recognized 
recompense arrangements in place.
Minimum criteria for accessing a donor
WMDA standards
•	 The registry must make their policy for the minimum criteria needed to allow 
a specific donor to be available for a specific patient available to the public.
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•	 This policy might include a minimum level of HLA match, guidelines for 
patient-specific criteria such as specific diseases or disease stages for which 
transplanta- tion is not considered appropriate, the optimal amount of marrow 
aspirated based on the weight of the donor, or requirements for TC credentials.
Context8-11
When a stem cell donation is planned from an unrelated donor, the patient and the 
TC enter into an agreement with the donor and the donor registry with expectations 
on each side. It is important for the WMDA to provide some level of reassurance 
that registries protect their donors’ expectations by ensuring that the donation is 
not futile. Each registry must establish the minimal information required from the TC 
(and must make these criteria known), such as patient demographics (weight, age), 
indication for transplant (including the type and stage of the disease), confirmatory 
HLA typing, TC credentials (for example, accreditation status) and likelihood of a 
request for a subsequent donation. For more detailed information regarding TC 
accreditation processes, please refer to the ‘standards, regulations, and accreditation 
for registries involved in the worldwide exchange of hematopoietic stem cell donors 
and products’ in this issue*.
Registries should review their policies regularly, as the field can advance rapidly in 
some of these areas. In addition, registries should have internal structures to address 
individual requests, which either appear to fall outside or are not addressed by their 
policy. The policy is not intended to be ‘absolute’ and it is expected that registries will 
have a medical director, medical advisory group or committee to act as an arbitrator 
of the decision- making process.
Subsequent donations
WMDA standards
•	 Adult volunteer donors must be fully informed in advance of the original 
donation regarding the possibility of and possible procedures involved with a 
subsequent donation of hematopoietic stem cells or blood products intended 
for therapeutic use for the same patient and the risks involved in the second 
donation.
•	 The registry must have a written policy regarding the process to be followed 
upon a request by a TC for a subsequent donation.
 
*) In 2010 Bone Marrow Transplantation published in a special section a series of White Papers by the World Marrow Donor 
Association (WMDA). The reference for the mentioned paper is by Hurley et al, Bone Marrow Transplantation, 2010;45:819-824
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Context12,13
Unrelated donor stem cell transplant activity is increasing and in 5-10% of cases 
a subsequent donation of stem cells or donor lymphocytes may be requested. It 
is acceptable practice for any TC to request a subsequent donation and it is 
recommended that donors should be counseled about this possibility before their first 
donation. In most PBsC-mobilized donations, the yield of CD34+ cells far exceeds 
the cell dose that TCs regard as optimal and sufficient for transplantation; hence, 
many registries will routinely allow ‘excess’ cells from the original donation to be 
stored in case of future need, in order to decrease the likelihood of a donor needing 
to give a subsequent donation. In this case, the consenting procedure must include 
this option. some registries may have a requirement that the donor be informed if 
the excess cells are used. Registries must have policies that cover such topics as: the 
number of subsequent donation requests which will be accepted, the time period 
between donations (or before a donor is allowed to donate to a different patient), 
the route of donation (for example, number of G-CsF-mobilized PBsC collections 
allowed) and the possibility of donating to a different recipient.
second donations of stem cells have not been shown to be associated with an 
increased risk of donor complications, but the yield of CD34+ cells may be lower in 
some donors. However, because there is a paucity of data regarding the outcome 
of multiple donations, the WMDA is not able at this time to recommend evidence-
based stipulations and therefore broad guidance only can be given. The policies 
within individual registries may differ, and indeed there is a broad diversity in 
practice between registries. It is recommended that all registries have a structure to 
process and consider individual requests that fall outside of their policy (for example, 
medical director or review board). It is important to document such requests and the 
subsequent decisions.
Donors as research subjects
WMDA standards
•	 Consent must be obtained if donor blood or other biological material or 
information is stored and/or used for the purpose of an ethically approved 
research project.
•	 Cells or DNA from donor and recipient should be preserved for research 
purposes by the registry if approved by national legislation in the countries of 
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Context
The current practice of transplantation often includes treatment in the context of a 
clinical trial or components of the procedure that are intended to address research 
questions. This has led to the discussion about whether it is appropriate in all settings 
to ask volunteer donors to donate stem cells and whether they are research subjects 
if they become involved in such protocols. In the majority of transplant protocols 
involving a research question for the patient, the donor is not regarded as a research 
subject. However, it is important to avoid conflicts of interest between donor centers 
and TCs, thus a document addressing this issue, and outlining when the donor is 
or is not considered a research subject, has recently been produced by the WMDA. 
Furthermore, it is quite possible that in the near future, donor registries will receive 




•	 The registry must have policies and procedures for the short-term follow-up 
and care of adult volunteer donors for conditions related to the hematopoietic 
stem cell donation. short term is defined as within the first year following 
donation.
•	 The registry must have policies for the long-term follow-up and care of 
adult volunteer donors for conditions related to the hematopoietic stem cell 
donation. Long term is defined as the time period following the first year after 
donation and extending for at least 4 years.
Context14–20
Volunteer unrelated donors have been donating hemato- poietic stem cells since 
the late 1980s. In the early years, stem cells were harvested, usually under general 
anesthesia, from BM through punctures in the iliac crest. Complications of this 
procedure are rare, and follow-up was usually only short term (with the inference that 
‘short-term follow- up’ is meant to ensure that the donor recovers in a reasonable time 
period from the actual donation). With the advent of administering hematopoietic 
growth factors (G-CsF) to volunteer unrelated donors and the harvesting of PBsC 
through apheresis, further discussions about the need for long-term follow-up (‘late 
effects’) were set in motion. Definitions of short-term and long-term follow-up have 
been a topic of discussion at recent international meetings. The number, frequency 
and method of donor contact following harvest differ among registries and the type 
of stem cell source donated.
84
Focus on the donor
The possibility of long-term effects from G-CsF (in family donors) was raised 
by two publications in 2004 and 2006. The WMDA addressed these concerns as a 
priority and a consensus statement regarding the safety of G-CsF was released. This 
was widely publicized through the WMDA website, international meeting sessions 
and peer-review publications. The WMDA guidance indicated that insufficient 
evidence of long-term effects to donors exists, and therefore halting the donation of 
G-CsF-mobilized PBsC from volunteer donors was not recommended. Ongoing basic 
research and clinical studies are being performed to further investigate any impact 
of G-CsF on the long-term health of donors.
Although serious adverse events (sAEs) (short and long- term) are currently 
collected within WMDA, there is no such registry system for family donors. During 
a donor outcome workshop in Berne (2009) (in collaboration with the European 
society for Blood and Marrow Transplantation, EBMT) a minimal data set of follow-
up information to be collected from all donors (family & unrelated) worldwide was 
agreed. A document describing the data set and providing recommendations for 
implementation is in preparation.
Patient follow-up
WMDA standards
•	 The registry should collect data on the status of the patient post transplant.
Context21
A WMDA survey on patient follow-up practices has shown that registries collect data 
on transplant outcome for several reasons. some registries collect data to inform the 
donor on the outcome of the transplant, if he/she so wishes. In this case, registry 
staff should be trained to counsel donors, in the event that the transplant has not 
succeeded. Other registries prefer not to inform the donor, and collect data for their 
own quality assurance system. A number of registries are collecting data for research 
and statistical analysis purposes. The frequency and duration of patient follow-up 
requests also differs among registries. With the yearly increase of transplantation 
activity, the number of follow-up requests is also growing. Collaboration with 
international organizations, such as the Center for International Blood and Marrow 
Transplant Research (CIBMTR)/EBMT/Asia Pacific Blood and Marrow Transplantation 
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Adverse events following donation
WMDA standards
•	 Donor health issues post-donation potentially affecting the health of a patient 
having received a hematopoietic stem cell donation from that donor must be 
reported to the TC.
•	 Adverse events affecting donors undergoing harvest of hematopoietic stem 
cells and occurring long term as a consequence of the donation must be 
defined, identified, documented, investigated and corrective action taken.
•	 sAEs occurring at the registry or at its associated entities must be brought to 
the attention of the WMDA in a timely manner.
Context22–25
Each registry has a responsibility to provide the best advice and to protect the health 
of the donor, as well as ensuring the integrity of the stem cell product (that is, the 
safety of the patient). To assist registries in this effort, the WMDA developed a 
voluntary system of reporting sAEs in 2001 (Figure 1). All registries who are members 
of the WMDA are encouraged to participate in the scheme. For a registry to achieve 
WMDA accreditation, participation is requested. 
It is the responsibility of the chief medical officer (CMO), or equivalent, of each 
registry to report sAEs in a timely manner to the office of the WMDA. The office 
maintains the central database and informs the chair of the Clinical Working Group 
(CWG). It is the responsibility of the CWG chair to collate the sAEs and to report 
these back to the general membership at the annual meetings. The sAEs are also 
published in the WMDA annual report. Currently reports remain anonymous.
Two registers are in place:
•	 sEAR – serious Events And Adverse Effects Registry. sAE reporting in the donor 
follows clinical trial definitions (that is, any event in the donor that leads to: 
life-threatening disease, death, in-patient hospitalization or considerable 
prolongation of existing hospitalization, persistent or significant disability/
incapacity and the association of the event with the donation are graded 
as definite, probable, possible and unlikely). Examples of such events are 
events related to anesthetic, cardiac, infective or hemostatic complications, 
mechanical injury and (late) malignancies.
•	 sPEAR – serious Product Events and Adverse Effects Registry. This system 
highlights risks to the patient related to the product. Examples include 
impairment of the quality of the graft (for example, clots, damage to the bag, 
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loss of part of product), wrong product infused, severe infusion reactions, 
serious transportation problems, unpredicted transmissible infection risk (for 
example, Hepatitis B), unpredicted transmissible non-infection (for example, 
malignancy) risk. Damage to stem cells due to unsafe transportation is also 
an important consideration, and WMDA recommendations for couriers and 
transport arrangements are in place and should be followed.
Figure 1: Mechanism for reporting serious adverse events to the WMDA (sEAR 
and sPEAR) 
The WMDA is considering making reporting a mandatory requirement for all 
registries. In addition, consideration is being given to entering these events on an 
existing central register (for example, the ProMIse system of EBMT), although the 
legal and regulatory requirements in each country will have to be followed. A key 
consideration is ensuring that sAEs that occur in unrelated donors are communicated 
to physicians involved in the care of related donors. This is achieved through 
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collaboration with other societies, for example, EBMT, APBMT and CIBMTR. An 
unresolved issue exists around how to communicate information about the donor, 
which the TC may uncover, for example, a donor-derived malignancy or cytogenetic 
abnormality. Although many registries will inform the donor, currently there is no 
WMDA standard addressing this issue.
Collaborations
The Clinical and Ethics Working Groups have active collaboration with the following:
•	 European Group for Blood and Marrow Transplantation (EBMT)
•	 The donor subgroup of the Late Effect Working Party References (LEWP) of the 
EBMT
•	 Center for International Blood and Marrow Transplant Research (CIBMTR)
•	 Asia Pacific Blood and Marrow Transplantation (APBMT)
•	 Worldwide Group for Blood and Marrow Transplantation (WBMT)
Conclusions and future directions
One of the missions of the WMDA is to promote the interests of donors. This has been 
achieved by establishing a set of standards against which donor registries can be 
assessed. In addition to the standards, numerous publications of recommendations 
and guidelines for the safe and ethical use of volunteer unrelated donors have been 
published. These are continually being re-evaluated and revised in order to remain 
compliant with changing international legal and regulatory requirements. The WMDA 
works closely with other organizations in the field to attempt to standardize the 
recommendations. The interested reader is referred to the WMDA website for more 
information on the harmonization of international legal and regulatory requirements.
The WMDA addresses issues around donor safety that arise (for example, concerns 
around the long-term safety of G-CsF) and produces consensus statements based on 
the best available evidence and expertise. New standards are being developed which 
encompass these recommendations.
Today, the HsC field faces a number of challenges. As the WMDA has 
concentrated its efforts on volunteer unrelated donors, one could argue that similar 
recommendations and standards should be considered for the protection of family 
donors. This is not a direct activity of the WMDA and may need to be considered by 
other transplant organizations. The WMDA, however, has a responsibility to offer 
its experience and expertise in this area, and the Ethics Working Group and Clinical 
Working Group have recently produced a document addressing this issue. Likewise 
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the follow-up and reporting of adverse events in all donors has been addressed at a 
recent workshop in Bern. This was initiated through a subgroup of the LEWP of the 
EBMT and attended by representatives from a number of international organizations 
and registries concerned with donor care, inclusive of the WMDA.
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Abstract
Hematopoietic stem cell transplantation is an effective therapy for life-threatening 
hematological diseases. Parents may be asked to donate hematopoietic stem cells for 
their child when no compatible related or unrelated donor is available.
Objective: Parents donating G-CsF mobilized peripheral blood stem cells 
simultaneously and uniquely fulfill the dual role of donor and caregiver for their 
ill child. The experiences of both sibling and unrelated stem cell donors have been 
extensively reported but not those of parental donors.
Methods: We therefore undertook a study specifically to investigate the 
experiences and coping strategies of parental stem cell donors. In-depth qualitative 
interviews were conducted with 13 parental donors, which were subsequently 
transcribed and subjected to thematic analysis. In addition, parental coping was 
assessed utilizing the Utrecht Coping List.
Results: Qualitative analyses revealed four main thematic categories describing 
the way parental stem cell donation was experienced, namely ‘Hope and Fear’, ‘Need 
for Information’, ‘Do Anything for your Child’ and ‘Transplant Outcome’ In addition 
parents noted similar difficulties which were unrelated to their specific role as a 
donor, for example they felt socially isolated.
Conclusions: Individual information for the parents needs to address not only 
the transplantation procedure but particularly those aspects related to the donation 
process. We feel there is a need for a protocol specifically designed to support and 
coach parental donors.
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Introduction
Allogeneic hematopoietic stem cell transplantation (HsCT) is a proven treatment 
for selected children suffering from malignant and non-malignant life- threatening 
diseases1. since the first bone marrow transplantations were performed, several 
methods of HsCT have evolved. At present, hematopoietic stem cells are obtained 
from bone marrow, peripheral blood or umbilical cord blood of a healthy donor. 
Donors are matched for human leukocyte antigen (HLA) type, and may be family 
members or unrelated volunteers2. The source of hematopoietic stem cells depends 
on the patient’s disease and the availability of a donor.
The most important factor affecting the outcome of HsCT is the degree of the 
HLA match between donor and recipient1,3. A sibling with the same inherited HLA 
is considered the best donor, but is found in only 30% of all patients requiring 
HsCT4. For patients without a family donor, an unrelated donor might be optional. 
Currently, the HLA characteristics of 14.6 million donors are registered in Bone 
Marrow Donors Worldwide (www.bmdw.org). Despite this, a significant number 
of children requiring urgent HsCT will be left without an HLA matched donor. For 
these children, haploidentical HsCT is a feasible alternative. Haploidentical HsCT 
is a procedure utilizing stem cells from a donor who is one full HLA haplotype 
mismatched with the patient. In a pediatric setting, stem cells are commonly obtained 
from a parent, undergoing G-CsF administration to mobilize peripheral blood stem 
cells, which are then collected by a leukaepheresis procedure. Although technical 
advances have improved outcome1, haploidentical transplantation has a higher risk 
for transplant-related complications and mortality5-7. A delay in immune recovery 
leads to vulnerability to viral reactivations post transplant8. Despite these potential 
disadvantages, haploidentical transplantation is, in specific cases, the only chance 
for cure for patients without an acceptable fully matched donor.
Parents requested to donate stem cells for their own child may feel that they have 
no alternative but to agree. This perception of limited options raises questions about 
the degree to which parents may feel pressured or even compelled to donate. Taylor9 
concluded that a parent has to fulfill dual roles, the role of parent and caregiver of 
a seriously ill child and that of stem cell donor. Conflict of interest in the decision-
making process seems to be implied, but parents’ perception of donating stem cells 
can be equally considered as an extension of parental care.
Although an individual child’s chance of a cure with HsCT may be considered 
poor, parents tend to believe that their child will survive10. Despite this optimism, 
Oppenheim et al.11 found that the main source of parents’ distress was the fear of the 
child’s death, whether imminent or at a later stage. Experiences of stem cell donors, 
both related and unrelated, have been extensively investigated12-16. Although levels 
of parental distress prior to HsCT have been shown to be temporary and unrelated 
96
Focus on the donor
to the type of transplant17-19, the distress in haploidentical parent donors has not 
been specifically studied. This seems an area of particular concern as these donors 
are likely to be more vulnerable, given the fact that their child is seriously ill and they 
have a vested interest in protecting and caring for their child.
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Parents are in the position of fulfilling both caregiver and donor roles. As parental 
perceptions have not been investigated in this context, the central goal of this 
investigation was to investigate experiences of parents who had donated G-CsF 
mobilized peripheral blood stem cells to their child. 
Participants and methods
Twenty-three haploidentical transplantations were performed in 18 children 
between 1997 and 2002 in the pediatric transplant unit of the Leiden University 
Medical Centre. The majority of children were referred for HsCT from other academic 
pediatric units, located throughout the Netherlands. Three children received 
transplants from both their father and mother, and one father donated twice. A 
total of 21 parents donated stem cells to their child. Of these, five parents were 
excluded for various reasons, i.e. living abroad (n=2), not able to understand and 
communicate in Dutch (n=1) or suffering known severe psychiatric disease (n=2). 
sixteen parents were invited to participate, of whom 13 (82%) consented. At the 
time of the interview, six children had died either from infection (n = 1), graft failure 
(n=2) or relapse (n=3). Bereavement was not an exclusion criterion. Characteristics 
of donors and children are summarized in Table 1. The protocol was approved by the 
institutional Medical Ethics Committee. 
For the purpose of this study, a phenomenological approach is appropriate. In-
depth qualitative interviews were conducted with study participants with the goal 
of examining their ‘lived experiences’ in the context of the donation process20. All 
interviews were conducted by the lead research investigator (sMvW), the majority 
in participants’ homes, and audio-recorded, using a minidisk recorder. Participants 
were able to stop the recording at any time. Three parents paused the recording due 
to emotional reactions to the topics being discussed. All interviews opened with an 
invitation for parents to describe their donation-related experiences.
“Mr, Mrs, you have donated stem cells to your child ......... which placed 
you in a special position, you had a dual role: the role of a parent and 
the role of a donor. Could you please tell me what it was like for you to 
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be a parent of a child with a life threatening disease and the donor for 
that child at the same time? From the moment you were confronted with 
being a donor, would you describe your experience, and share as many of 
your thoughts, perceptions and feelings as you can recall”
The parents were allowed to freely describe their experiences in their own words. 
Probes were used to elicit additional information and examples when necessary. 
The interviewer focused particularly on instances of how the experience of donating 
stem cells to their child had influenced parents’ physical, emotional, cognitive and 
social functioning before, during and after the donation process. The length of 
the interviews varied per participant, but was never longer than 120 min (mean 
interview duration 45:28 min, range 28:20–115:54 min). Appointments for follow-
up by telephone approximately 2 weeks later were made immediately after the 
interview. Field notes were made during the research process to obtain information on 
appointments, cancellations. Immediately after each interview, the researcher wrote 
a short impression with observational details concerning environment, weather, 
reception, interview setting and participant during the interview. These specific 
details are relevant and serve as a record of the researcher’s own construction of 
meaning21. Each session ended with debriefing and parents were asked how they felt 
about the interview in order to minimize the risk of related emotional stress. In the 
follow-up call this was repeated. Without exception, all parents were positive about 
their participation in the study.
Interviews were transcribed and analyzed using standard qualitative analytic 
techniques21, the central goal of which was to discover thematic elements that 
emerged as part of the parent interviews. Although we had some ideas about themes 
that might emerge, a grounded approach to the data analysis was used – i.e. themes 
were allowed to emerge as part of the analysis rather than being predetermined. 
The process of qualitative coding focused on identifying statements or phrases that 
seemed particularly essential or revealing about the phenomenon or experience being 
described. In this way, how parents expressed their feelings and the use of language 
were taken into consideration and subsequently utilized in the interpretation of the 
findings20,21. From the initial raw data we documented tentative themes, which were 
later refined and categorized by re-analysis of the data. Finally, four main categories 
were determined. To improve the validity of this analysis, themes identified during 
the qualitative analysis were discussed and confirmed, clarified, or revised with 
parents by telephone. six interviews were categorized by senior transplant nurses, 
instructed in the method, and given the opportunity to listen to (parts) of the 
interviews. Results were compared and any intra observer differences were discussed 
and resolved by consensus, i.e. investigator triangulation22. In an attempt to quantify 
the qualitative findings gathered via the in-depth interviews, participating parents 
were asked to complete the UCL23, which identifies the primary coping strategy of 
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individuals confronting a problem. This self-report questionnaire consists of 47 items 
on a 4 point Likert-scale. The items comprise seven subscales assessing different 
types of coping strategies: (1) Active problem focusing: view the situation from 
different angles and approach problems in a purposeful and confident manner. 
(2) Palliative reaction pattern: look for diversion and occupy oneself with other things 
(like smoking or drinking) so as not to have to think about the problem. (3) Avoidance 
behavior: let the case run its course. (4) social support seeking: share feelings and seek 
comfort from others. (5) Passive reaction pattern: show hopelessness by immersing 
in the problem or the situation (6) Expression of emotions: show annoyance or anger 
or work off the tension. (7) Reassuring thoughts: console oneself with the thought 
that things will get better24. To allow for a structured analysis, the UCL strategies 
were traced back to the reduced classification of Lazarus and Folkman25 as described 
by Heck et al.26  (Table 2).The specific categories developed from the interviews 
were analyzed and logically assigned to the UCL coping strategies. To assess the 
internal consistency of the UCL the Cronbach’s coefficient alpha was calculated for 
all seven subscales. Descriptive analysis was used to compare the results of fathers 
and mothers, as well as parents of surviving and deceased children.
Table 2: Comparison between the theory of Lazarus and Folkman and the scales of the UCL 
(Heck et al., 1989) in correlation to the categories found in the study
Lazarus and Folkman Utrecht coping list Categories in this study
Emotionally directed coping Expression of emotions Hope and Fear; Need for 
Information
Passive reaction pattern 
Rejection
Transplant Outcome
Problem directed coping Active approach Needs for Information
Seeking social support Do Anything for Your 
Child
Palliative reaction pattern Need for Information
Evaluation Reassuring thoughts Transplant Outcome
Results
Analysis of the interviews revealed four main categories (investigator triangulation 
less than 2% adjustment):
•	 Hope and Fear
•	 Need for Information
•	 Do Anything for Your Child
•	 Transplant Outcome
100
Focus on the donor
Each category contained themes that were related to a specific time period in the 
total process of HsCT. These periods were (1) Facing haploidentical transplantation: 
parents are informed that no HLA compatible donor was available and confronted 
with the donation of haploidentical stem cells; (2) Decision making: parents have to 
decide to continue with HsCT and become their child’s donor; (3) Donation process: 
parents are assessed as donor and given medication for the procedure; (4) Reflection: 
parents reflect on the transplantation period and outcome. The attempt to relate 
these categories to coping strategies as determined by Lazarus and Folkman and the 
UCL are summarized in Table 2.
Feelings of Hope and Fear were found throughout the transplantation process. 
The feelings hope for cure, and fear of losing one’s child was often experienced 
simultaneously, leading to turmoil and confusion. Parents reported that on hearing 
that no HLA compatible donor was available, they experienced feelings of despair, 
frustration, powerlessness and sorrow:
“When we first heard that we could not find a compatible donor this was 
a very disappointing situation. We did not know how to go on”
However, the use of reassuring thoughts as a way of coping with the extreme 
stressful situation was also evident. Parents expressed hope gained from the new 
developments in transplantation techniques and the offered opportunity:
“This was a surprise for us... We were told that only a donor with 
compatible bone marrow was acceptable. When we were told about this 
opportunity, we were very happy, and faced it very positively”
This was despite the emotional stress of their role as a donor:
“... at that moment, you are so emotional,y.yes, so overwhelmed that you 
can do something for our child... everything else they tell you goes in one 
ear and out the other” 
The ‘Need for Information’ in relation to all aspects and periods of transplant 
procedure and donation varied, but was reported by all parents. This concerned not 
only the treatment for their child, but also about the donor procedure:
“The information session is more about the patient. They talk to the 
parents about their child. There should also be a specific session for the 
donor”
Parents were uniformly dissatisfied with the donor information, e.g. they 
were unprepared for the bone marrow puncture undertaken during the physical 
examination:
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“I had this talk with the physician and some blood samples were drawn. 
‘You will also have a bone marrow puncture’. What? ‘Didn’t you 
know?’ No, I was really upset and frightened. Nobody told me about it 
before; the nurses didn’t tell me anything’. ‘It would have been better if 
they had put the side effects and long term effects in a folder. What can 
you expect, what is going to happen, how often you get the injections 
etcetera? (...) I still do not know what the long term effects of the growth 
factors are, what it can cause to my bones for instance”
The lack of familiarity with the hospital environment, staff and the isolation 
procedures compounded the difficulties. Parents used the Internet to supplement 
the information, which is a way of problem directed coping. Parents spoke of the 
uncertainty and lack of information about the future. The experimental character of 
the treatment meant the medical staff were not always able to resolve these issues 
for the parents.
“What I can remember, every time, we talked about that period and 
they said: it could have been different. If you hadn’t done it, he might 
have also died. And then what? So..., yes such things, they told us 
such things, mostly. Yes, what I said before, when we left after such a 
meeting, we felt: why did we go there,” ......
Parents would ‘Do anything for their child’ but often had feelings of powerlessness 
or having no choice. The decision-making process was mentioned by all participants. 
All parents were unanimous about their decision to donate although they all felt that 
they simply had no choice.
“...... In fact, we had no choice, it was made very clear. Without 
transplantation he would certainly die”
Two parents mentioned the importance of taking the opinion of their child (7 and 
8 years old) into consideration during the decision-making process.
“I think that it is very important, that we, as parents, despite how 
nayve our children seem to be, do not underestimate them. Children 
who have suffered so much, have heard so much, have seen and felt and 
experienced so much, they are able to make that decision for themselves”
“It was clear for him. He wanted to go there, he wanted to be cured. 
We talked it over with him, I was afraid he was not able to comprehend 
everything, but it was clear for him. And I think he made the right 
choice”
One parent felt guilty for making the decision on behalf of his child who was 
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not capable of doing so. The last category, ‘Transplant Outcome’ is more or less a 
reflection by the parents concerning the whole process.
“I realize now that the whole period in Leiden, was complicated, but also 
gave us a lot of hope”
some parents expressed feelings of helplessness, but equally did not blame any 
individual for the outcome.
“I cannot blame anyone. This is what Life has caused me”
All parents mentioned that maintaining contact with other people was important 
to overcome these feelings. Most of them were able to receive practical support from 
family members, although some found it difficult to discuss their situation with close 
family. Almost half of the parents reported it was important to have contact with a 
‘partner in misfortune’, i.e. someone with a similar experience. Many emphasized the 
necessity to send newsletters to keep family, friends, school and colleagues updated 
about the progress of their child, in order to minimize their social isolation. This 
approach is also an example of seeking social support.
If children had died due to non-engraftment, rejection or post transplant infection 
some parents felt that they had fallen short of being a good donor. They felt the 
transplant outcome reflected on them personally and diminished their self esteem.
“I had these periods in the hospital, if only I could reverse, turn back the 
time. In particular the first time, when my cells were rejected”
Fathers were less likely to place importance on their career and job prospects 
whereas mothers became more critical of other parents concerns such as minor 
illnesses and school achievements. They considered such things to be of less 
importance having confronted a life-threatening illness or even death of their child.
“You have learned to put things into perspective, you are aware the 
relativity of things. In early times I would get really wound up about 
things (...) The death of my son was my greatest lesson for life. How it 
went and also the way I face religion and after life, it has really changed 
me”
Mothers were more likely than fathers to actively try to reduce stress by seeking 
social support and contact.
Parents whose child had died had, as might be expected, a more negative 
reaction to life events. They were more likely to seek reassuring thoughts to maintain 
the balance in their lives..
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“You can’t do anything about it. That’s the way it goes. Parents 
didn’t choose for it, neither has the child, to become ill’. ‘I kept a diary, 
this period, and I can advice it to every parent. It really helped me to 
assimilate this period. There are also pictures in it, it brings back the 
memories”
Parents universally reported that participating in the interviews was a positive 
experience. several expressed relief and gratitude for the opportunity to tell their 
story. None of the parents expressed the need of additional psychosocial care as a 
result of the in-depth interview.
Discussion
Haploidentical G-CsF mobilized peripheral blood stem cell transplantation from a 
parent offers a new option and the hope for cure. The experiences of these parents 
have not been previously investigated. The use of an interviewer independent of the 
transplantation unit may have allowed parents more opportunity to discuss their 
feelings. Although this retrospective information may not be a genuine reflection of 
past experiences, is does however reflect the current view of parents regarding their 
dual role25.
We were able to establish four distinct categories that encompassed the 
experiences of parental donors. The first of these, ‘Hope and Fear’, have been 
reported in previous publications in relation to being a stem cell donor9,16,26 or 
being the parent of a stem cell recipient17,27,28. It is therefore not surprising that this 
category is of similar importance to parental donors, representing both roles. From 
a linguistic point of view, hope and fear are opposites; in practice they seem more 
often to coexist in these parents. The impact of being told that there was no suitable 
bone marrow donor made them confront the possibility of their child’s death. It 
subsequently seemed incomprehensible to many that they would be considered 
an alternative donor. In our experience, parents oscillate between these contrary 
feelings attempting to find an emotional balance. Emotionally directed coping as 
described by Lazarus and Folkman, comparable to the expression of emotions (UCL), 
is reflected in this category. Parents acting as donors become in their own eyes 
the hope for cure. Vossen pointed out the fear, uncertainty and mental suffering of 
parents and patients29. He stated that taking care for these patients is not in the least 
routine, and demands an integrated approach to the delivery of good quality care.
Consenting to HsCT as a life-saving treatment for one’s child places an 
overwhelming burden of responsibility on parents9. Aversa stated that virtually every 
patient has a donor5, but parental donation is not usually discussed during the initial 
information session. A parent as donor is not the first choice. The reported lacks 
of sufficient information often lead to uncertainty and sometimes feelings of guilt. 
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The perception of the information provided may have been distorted because of 
emotional difficulties. Breaking bad news (i.e. no donor was identifiable) seemed 
to make parents numb and less receptive. We were not able to determine to what 
extent these recollections were altered by time, nor were we able to document what 
information had been given to the parents. However as this was uniformly reported 
it would seem likely that the extent of information given was either inadequate 
and/or poorly communicated. Parents’ ‘Need for Information’ under comparable 
circumstances has been reported16,30. Fisher30 reviewed eight studies on the needs 
of parents of chronically ill children. she found that the majority of parents were 
dissatisfied with the information they received. similarly, this has been reported in 
parents of children diagnosed with acute leukemia31. Dermatis and Lesko27 found that 
the strongest predictor of parental level of distress was the quality of the physician/
parent communication. This category highlights both passive and active reaction 
patterns of emotional an problem directed coping strategies. In light of our findings 
we feel that this issue is of paramount importance which needs to be addressed by 
all centers undertaking haploidentical transplantation. As a result of this study we 
have optimized the information, using a standardized checklist and introducing the 
option of haploidentical transplant in an early stage of the consultation.
The third identified category, ‘Do Anything for your Child’, is a proactive 
approach and can be considered as a way of problem-oriented coping. Although 
the chances for a successful outcome were not always hopeful, all parents took the 
offered opportunity, hoping they could thus save their child’s life. This decision was 
not always easily made. Due to circumstances, some parents hardly had time to 
consider the procedure. Decision making as part of the consenting process for both 
the experimental treatment of their child and being a donor themselves suggests a 
possible conflict of interest. High levels of distress may limit the ability of decision 
making. Caregivers need to realize that parents are the ones who must live with 
their decision for the rest of their lives32. The urgency of transplant often reduced the 
opportunities for parents to balance the risks versus benefits. Although no parent was 
reluctant to donate, some admitted being fearful of the procedure. Knibbe33 found 
in parents, who were asked to act a living liver donor for their child, that donation 
was ‘not a matter of choice’, due to the intimate relation with their child. This has 
also been reported by sibling donors34. Having a choice implies more than one option 
and for parents facing donation, not-donating means the certainty of losing their 
child, which is not an acceptable choice. In this respect, Atkins and Patenaude26 
and Christopher16 both highlight donor’s fears, emphasizing the importance of 
discussing the impact of a potential negative outcome on the donor’s life. The 
perceived extension of parental duty must be considered. The willingness of parents 
to Do anything for their child should not be equated as a license to do anything with 
the parents. Counseling parents who are prospective donors may require specific 
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advocacy, as is the norm for unrelated HsCT donors35,36.
The sense of isolation common to many parents whose child is undergoing HsCT 
was a major theme for all participants. The geographical dislocation from their home, 
away from family, resulted in isolation. Their unique situation as donor may have 
contributed to their loneliness. Many parents found it difficult to relate to others 
who had not donated stem cells. This study was not able to distinguish the extent 
to which this problem was related to the experience of parents acting as donors. 
Writing newsletters may have helped them to work through their emotions and in 
some way shielded them from direct confrontation with well-meaning enquiries. As a 
result family, friends, school and colleagues remain updated about the situation. This 
approach is both exemplar for palliative reactive pattern (emotion directed coping) 
and seeking social support (problem oriented coping). Again, like hope and fear, this 
illustrates the dichotomy of feelings.
Eight parents (including the two couples) were bereaved. Coping with this loss 
was seen as an inhuman burden and some parents had continued feelings of guilt 
and/or anger. Irrespective of Transplant outcome the parents’ lives were altered. 
severe depression as experienced by a survivor’s father has been described by van 
Dongen-Melman25, as maintaining the problem and feelings of loss. Losing a child 
can be experienced as a loss of oneself. This has been succinctly described in Louise 
Kaplan’s book ‘No Voice Is Ever Wholly Lost’37, by a father:
“..., if losing a child is losing a piece of your own self, you can still get 
yourself back, maybe not all of yourself, but just enough to bring back 
the spirit of your child. Your child cannot live again. Some part of you 
will never live again. But you can still speak with the spirit of your child 
that was the spirit of you”
Coping strategies can be problem directed (active approach, seeking social 
support or a palliative reaction), emotion directed (express emotions, palliative 
reaction pattern, rejection) or reappraisal (reassuring thoughts)38,39. Each of these 
ways of coping is meant to finally reduce the experienced stress. The transplant 
requires various coping abilities. Wochna10 has found that helping family donors 
to cope during the search is an appropriate method to reduce stress. Rodrigue et 
al.28 advises counseling and appropriate education to minimize parental stress. 
Frequently, the initial information session is the first time parents and transplant 
center staff meet and makes difficult the initiation of strategies aimed at assisting 
parents develop ways to cope with the dual role.
Conclusions and recommendations
The phenomenon of the dual role of parent and stem cell donor was not strongly 
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evident in the qualitative interviews, but parents’ experiences were similar to both 
roles as described in the current literature. As the transplantation was the only 
chance for cure, parents considered the role of being a donor one of relatively 
minor importance. Their decision to consent to the procedure concurred with their 
feelings of having no other choice. Parents regularly experience simultaneously 
feelings of hope and fear which, although linguistically opposites, may be 
experienced simultaneously. Parents’ efforts to balance these feelings is often the 
cause of confusion and additional stress. All coping mechanisms were evident in the 
conducted interviews. Parents were found to adhere to different coping strategies in 
different circumstances. These results show that parents’ coping strategies need to be 
continually evaluated. staff members of the transplant unit need to be aware of and 
respond to these changes accordingly, in order to be able to give appropriate support. 
Individual information for the parents needs to address not only the transplantation 
procedure but particularly those aspects related to the donation process. Based upon 
the findings of this study, we now routinely inform parents on a more frequent basis, 
with both spoken and written information, regarding not only the transplant but also 
their role in the donation procedure. We recommended that all units undertaking 
parental haploidentical stem cell transplantation should aim to develop specific 
guidelines and follow-up program for future parental stem cell donors. To this extent 
the World Marrow Donor Association is active in developing recommendations 
which may assist in the development of such guidelines33. Future studies should be 
conducted ideally in a multi-center setting to accrue sufficient numbers of parents 
and be designed to prospectively follow-up parents’ experiences before, during and 
following donation. A donor subcommittee of the Late Effects Working Party of the 
European group for Blood and Marrow Transplantation is preparing such a study that 
will focus on both long-term follow-up of physical and psychosocial consequences of 
haploidentical G-CsF mobilized peripheral stem cell donation.
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Abstract
The first successful European pediatric allogeneic bone marrow (BM) transplantation 
was performed in Leiden, the Netherlands, in 1968, with a 7-year old female sibling 
donor. since then, more than 300 young children have donated BM in our unit. We first 
retrospectively studied a cohort of 210 donors, younger than 13 years at donation, 
to survey procedures of donor eligibility and reports on immediate effects of BM 
donation. We then performed a long-term follow-up (FU) and health related quality 
of life (HRQoL) study. Despite the occurrence of previous medical conditions, no child 
was declared unfit to donate. We found that iron deficiency anemia or low iron stores 
in BM did not result in treatment or extended FU. Harvest volumes exceeded 15 ml/
kg in 65% of donors, with more than half requiring allogeneic blood transfusions. 
Donors had no structured FU after their first post donation control. In this study 25% 
of donors reported at least one somatic complaint at long term FU. Finally long-
term HRQoL revealed high scores in most sub domains (representing a higher QoL), 
compared to norm groups. These results indicate the need for development of (inter)
national guidelines for pediatric stem cell donor care management.
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Background
In the Leiden University Medical Centre (LUMC), in 1968, the first pediatric stem cell 
donor donated bone marrow (BM) for the benefit of her baby brother. since then in 
over 40 years, more than 300 children have donated BM. Pediatric stem cell donation 
poses an ethical dilemma in that it exposes a healthy child to a potentially harmful 
medical procedure that has no direct clinical benefit. This is counterpoised by the 
positive emotional impact of being able to help a seriously ill sibling1. BM donation 
in early childhood is rare, and as such, literature on immediate effects and long-
term outcome is scant. Although no cumulative registry data is available, statistics 
provided by the CIBMTR show that in the year 2006 over 4000 patients under the 
age of 20 years underwent allogeneic transplant transplantation2,3. Approximately a 
third of these received a graft from a related donor. We would estimate this to equate 
to approximately 3000 pediatric donors recruited annually worldwide. BM donation 
by minors is, according to international legislation, restricted to siblings4. In contrast, 
living solid organ donation is in Europe not permitted under the age of 184,5, although 
in the Netherlands, every person over the age of 12 years is allowed to carry a donor 
codicil. The use of first cousins, although practiced, falls outside EU regulations. 
While in our institution the minimum age for donation is six months, harvests 
elsewhere from younger children have been described6. Even though BM donation is 
a generally accepted and legally permitted, young children are considered incapable 
of giving informed consent7. Informed consent procedures for children involved in 
BM donation have only lately been specifically addressed5,8. In most cases, however, 
parents or legal representative of the prospective donors will give proxy consent for 
BM harvest1, leaving the donor no other choice but to donate9. The recognition that a 
legal representative is required to protect the interest of the young donor (under the 
law), has only recently been adopted10, albeit not universally. Legal representation 
for the benefit of family donors has been suggested, although smaller centers might 
be less able to implement this policy11-13. The lack of formalized (long-term) follow-up 
(FU) programs for (pediatric) donors is making it even harder to study the outcomes 
and impact on health and health related quality of life (HRQoL) in large cohorts. With 
the introduction of the use of hematopoietic growth factors in healthy individuals, 
the call for FU programs has resulted in a recommended system for unrelated stem 
cell donors, carried out by donor registries14. Individual institutions are required to 
develop a (pediatric) donor care program at their own initiative. 
In many countries transplantation centers (TC) are obliged to conform to an 
accreditation program such as the Joint Accreditation Committee IsCT & EBMT (JACIE) 
or the Foundation for the Accreditation of Cellular Therapy (FACT). These factors have 
led to demands for new guidelines for the care management of family donors. The 
current JACIE standards (version 4) require written criteria for stem cell donation 
to protect the donors’ safety, although there is no requirement for structured donor 
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follow-up at the present time15. In the 5th version, which will become actual in 2012, 
the section for donor selection, evaluation and management is extended, demanding 
TC’s to develop a policy, including minor donors. so far, studies into donor experience 
and side effects have been undertaken in adult sibling donors where it was found 
that the physical side effects were outweighed by the reinforcement of donors’ self 
esteem, and increased meaning and worth of life16. A Cochrane literature review 
focused on bone marrow versus peripheral blood stem cell donation in adult donors17. 
since adverse events and complications in adult donors may differ from those in 
children, although the findings are of interest, they are not directly comparable. 
For child donors, literature on the immediate physical effects of donating stem cells 
is scant6,18,19 or limited to the use of hematopoietic growth factors in children20-25. 
Furthermore research has concentrated more on the psychosocial effects in pediatric 
donors9,26-28. To date, no significant long-term FU studies in pediatric donors have 
been performed. We aimed to describe the characteristics of a large retrospective 
cohort of pediatric donors and further to analyze the immediate and long-term 
physical effects, medical outcome and HRQoL associated with the donation of BM 
in early childhood.
Donors & methods
Group I consisted of a retrospective analysis of recorded medical and/or computerized 
laboratory data. All donors aged less than 13 years at the time of donation, who 
donated BM from 1968-2002 (n=210), were eligible for this cross sectional study. 
Blood counts were expected to be performed during initial physical examination (PE), 
pre and post harvest. Datasets were obtained for medical history and examination, BM 
harvest volumes, immediate consequences of donation and erythrocyte transfusion 
history. Donor medical fitness and the immediate effects of the donation process 
were investigated. Bone marrow was harvested from the posterior iliac crests under 
general anesthesia. Red cells were salvaged from the graft and given back to the 
donor (institutional policy). According to our institutional guidelines, a target cell 
dose of 1-2 x 108/kg recipient body weight (BW) infused was aimed for successful 
engraftment. In cases where major ABO incompatibility was documented between 
donor and recipient, a minimum of 500 ml BM harvest was deemed necessary for 
processing. All available BM aspirates (n=145), routinely obtained at the time of 
harvest, were retrospectively analyzed to document hematological findings. A review 
of the original reports (produced by two independent observers) was undertaken by 
a trained pediatric hemato-morphologist, and representative archived material was 
evaluated to confirm the original findings. Furthermore the volume of BM harvested 
in relation to red cell transfusion requirements was investigated. 
Group II consisted of a prospective cohort of childhood donors who were invited 
to complete a self reported questionnaire regarding general health and quality of life. 
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The inclusion criteria were at least 12 years of age at initiation of the study, resident 
in the Netherlands and fluency in the Dutch language. The invitation to participate 
consisted of a letter of explanation (consisting the background and objectives of the 
study) for donors and/or parents (in case the participant was younger than 18 years) 
and a request for informed consent. surviving recipients and non-donor/non-patient 
siblings were invited to act as controls. The rationale to invite the survivors was to 
investigate whether their quality of life would impact the donors’ responses 
A self reporting health consumption questionnaire and validated questionnaires 
to assess HRQoL included Medical Outcomes study short Form-36, the General 
Health Questionnaire, and The Pediatric Quality of Life InventoryTM Version 4.0, 
depending on the age of the participant. Donors > 18 years (n=61) received the 
GHQ-12 and sF-36 questionnaires. The Medical Outcomes study short Form-36 (sF-
36) is a widely used generic health status measure that is available as a validated 
tool in the Dutch language29,30. The sF-36 health survey is composed of 36 questions 
and standardized response choices. The instrument examines eight specific domains: 
physical functioning (PF), role limitations due to physical health problems (RP), bodily 
pain (BP), general health perceptions (GH), vitality (VT), social functioning (sF), role 
limitations due to emotional problems (RE), and general mental health (MH), scoring 
each on a scale of 0-100% (worst to best). Higher scores indicate a higher level of 
functioning or wellbeing. 
The General Health Questionnaire (GHQ-12) has been extensively used as a short 
screening instrument for mental illness in general health care, and is available in the 
Dutch language. The instrument is found to be remarkably robust after widespread 
testing31. The instrument measures changes in normal psychological functioning. 
Items are rated on the standard 0-0-1-1 scale and summed to a total score.
The Pediatric Quality of Life InventoryTM Version 4.0 (PedsQL) is a modular 
instrument for measuring HRQOL in children and adolescents ages 2-18 years. The 
instrument consisting of four core scales (physical, emotional, social and school) was 
found to be valid and reliable32. All of the above, except for the physical functioning 
scale are summarized in the psychosocial health summery score. A five-point Likert 
scale is utilized and scores are linearly transformed to a 0-100 scale. The PedsQLTM 
4.0 is applicable for healthy school and community populations, as well as pediatric 
populations with acute and chronic health conditions. 
Where available, results were compared to Dutch norm groups (as provided with 
validated instruments) or information from the Dutch Central Bureau of statistics 
(CBs)33.
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This study was approved by the scientific Committee of the Willem Alexander 
Children’s Hospital and the Committee for Medical Ethics of the LUMC in the 
Netherlands.
statistical analysis
Descriptive analysis (e.g. histograms with normality curve, box plots), reported as 
percentages, mean values and standard deviations, was performed to examine 
whether the study groups were normally distributed. Analysis was performed using 
sPss and Ms Excel, to examine associations between the study groups. In addition 
patterns of association among variables were estimated based on variables’ level 
of measurement. These included visual representation and statistical measures of 
association/difference (e.g. Chi-square, Fischer’s exact test, paired T-test and analysis 
of variance (ANOVA)) to address the level of specificity. Differences and correlations 
were regarded as statistically significant if p<0.05.
Results
Group I - general
For 13 from the 210 eligible donors, no data was available, resulting in 197 donors 
(94%) eligible for further analysis. Two children included in the study were extended 
family donors (i.e. non-sibling relatives). They were cousins of the recipients and 
were HLA matched due to the presence of a frequently occurring haplotype in non 
consanguineous families. Donor characteristics of this group are summarized in Table 
1.
Donor eligibility
All donors were evaluated as medically fit to donate by a qualified pediatrician, who 
until the early 1990’s was a member of the pediatric transplant team, also involved 
in the care of the recipient. Thirteen donors in group I (7%) had a previous medical 
history; seven children had persistent problems at the time of physical examination 
(PE) prior to donation (Table 2), which warranted additional considerations. None 
were deemed unfit to donate. Only one child underwent physical evaluation prior to 
HLA typing.
Peri donation events
Of the seven donors with persistent problems at time of donation, four had 
documented severe adverse events during or immediately after harvest. Donor 
027 was moderately difficult to intubate (Cormack and Lehane gr II: vocal cords 
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only partly visible) in light of an enlarged epiglottis, which was not documented 
at screening. Donor 071, a child with severe cardiac abnormalities, developed 
significant tachycardia during anesthetic, which responded to medical intervention. 




Donor characteristics at donation at donation at study
Age in yrs. (median; range)
Male 6.4 (0.6-12.0) 6.4 (0.6-11.1) 22.2 (12.8-39.4)
Female 7.7 (0.6-12.3) 7.1 (0.8-12.3) 23.9 (14.2-47.8)
Gender
Male 113 (53%) 36 (45%)
Female 97 (47%) 44 (55%)
Recipient outcome
1 year after donation 75% alive 78% alive
At time of study 60% alive 61% alive
Donor is (%)
Twin sibling 4.3 3.6
Younger sister 21.0 25.3
Younger brother 24.3 22.7
Older sister 23.3 30.8
Older brother 26.2 16.4




Malignancy 139 (66%) 57 (72%)
Immune deficiency 15 (7%) 3 (4%)
BM failure 36 (17%) 13 (16%)
Hemoglobinopathy 12 (6%) 4 (5%)
Other 8 (4%) 2 (3%)
Birth order (%)  FU donors recipients
Oldest child 33 36
Middle child 29 25
Youngest child 30 39
Only child (after bereavement) 8 n.a.
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Table 2: Characteristics of donors with a pre-donation medical history
Gender 
(UPN)






M (012) Fontan procedure for 
hypoplastic heart; congenital 
asplenia*
8.4 yr 686 ml Rulide 
prophylaxes; BMI 
18
F (091) Spastic tetraparesis due to 
perinatal asphyxia; suspicion 
for neurofibromatosis
7.7 yr 152 ml; Respiratory 
problems, one night 
ICU
Non responder
F Blalock shunt for congenital 
transposition great arteries*
0.6 yr No documentation Non responder, 
recipient died
F (071) Congenital heart condition, not 
other specified*
4.4 yr 681 ml; Tachycardia 
(Hb 6.4g/dl)
Stent placement;  
BMI 17
M Premature born (34 weeks) 0.7 yr 131 ml Non responder
M Premature born (34 weeks) 8.9 yr 514 ml Non responder, 
recipient died
F Premature born (34 weeks); 
repeated febrile convulsions; 
pyelonephritis
6.5 yr 378 ml Non responder
F Premature born (36 weeks) 8.2 yr 748 ml; 2nd dx after 4 
weeks for other sib
Non responder, 1st 
recipient died
F Premature born (31 weeks); 
hypothyroidism*
1.7 yr 199 ml Atopy; GE 
problems n.o.s.
M (027) Non syndromal developmental 
delay*




M (081) Failure to thrive* 0.7 yr 125 ml; Hypoxic, 50 
ml FFP
Healthy
M Heart murmur; testicular 
atrophy (suspicion adrogenital 
syndrom)
3.7 yr 396 ml Non responder, 
recipient died
M At 7 weeks: sleep apnea (6 
months monitored)
5.6 yr 488 ml Non responder
* indicates that the medical condition warranted consideration at time of donor physical examination. 
UPN of donors refer to the text
Donor 091, a child with a severe tetraplegic handicap had post extubation 
breathing difficulties, leading to an overnight observation in the pediatric intensive 
care ward. Finally donor 081, a child of 7 months old with failure to thrive, weighing 
8.3 kg, having undergone a harvest of 15 ml/kg bodyweight developed hemodynamic 
instability requiring volume replacement therapy with plasma. In spite of these 
operative complications, only one donor received donor FU. 
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Twelve of 210 (5.7%) donors donated sequentially: two donated to different 
recipients, the remainder donated for the same recipient due to either poor 
engraftment, rejection of the graft or relapse of the original disease. Median time 
between donations was 6.8 months (range 1-170 months). One child, who donated 
twice in four weeks for two recipients, was not re-assessed, but had laboratory 
results prior to the second donation; the other donors who donated more than once 
were all re-assessed for their second donation. 
Three donors were diagnosed with minor infections pre-donation (sinusitis, otitis 
media) and treated with antibiotics; no FU was recorded.
Laboratory results
Laboratory results were available for 147/197 (74%) of donors. Both pre- and 
immediate post-harvest (within 24 hours) full blood counts were documented for 
126 donors; nineteen donors had only pre harvest values documented. Older donors 
had a lower Hemoglobin (Hb) level pre donation than younger donors, possibly due 
to the harvest of an autologous unit. Despite transfusions, Hb levels after donation 
compared to pre donation, were reduced in 89% (n=113/147), with a median loss 
of 2.5 g/dl (sD 0,46; range 0.3-5.2; median Hb 10.5 g/dl; p=0.0001). In 28 donors 
a post donation Hb level lower than 9.7 g/dl (median 8.9 g/dl; range 6.6-9.5) was 
documented (p=0.0001). No medical intervention or laboratory FU was documented. 
These results are summarized in Table 3.
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Bone marrow analysis
BM reports from 145 donors were available. seventy percent (n=106) bone marrow 
aspirates were representative for histological examination. Iron stores were 
determined by supra vital staining with potassium ferricyanide (Perls). Absence 
(n=16) or reduced (n=54) iron stores were evident, mostly in children with normal 
Hb levels. Age distribution analysis revealed that infants and pre pubertal children 
were more likely to have reduced BM iron stores. No further investigation into the 
iron status of the donors post harvest were undertaken and/or documented. Low 
iron stores of donors were not related to the transplant indication of the siblings (i.e. 
B-thalassemia, sAA). Four donors had decreased or absent megakaryocytes, but had 
normal peripheral platelet counts and morphology. Other documented abnormalities 
included white cell aberrations in 6%, mainly undiagnosed hypereosinophilia, 
lymphocytosis and five cases of mild leucopenia, none of which were actively 
pursued.
Harvest characteristics
Harvest volume data was available for 109 of all donations, including three second 
donations. Harvest volumes ranged between 6-47 ml/kg donor body weight (BW) 
(corrected for age, mean 18 ml34, or 8-62% (mean 24%) of the estimated total 
circulating whole blood volume. In 65% (n=66) of donations the volume harvested 
exceeded 15 ml/kg donor BW, with 34 of these children donating more than 20 
ml/kg. Donors with an older recipient (n=49) were more likely to donate a larger 
volume. In donors with a younger recipient (n=47), 21 donated more than 15 ml/kg, 
with six donating more than 20 ml/kg (see Figure 1). Transfusion data were available 
for 160 donors. Overall 94 donors (52.5%) received a blood transfusion, of which 
74 were allogeneic. In children whose harvested volume exceeded 15 ml/kg donor 
BW, 71% (47/66) required blood transfusion (40 allogeneic, and 7 autologous stored 
units), compared to only 35% (14/40) donors when the volume was restricted to 15 
ml/kg or less donor BW (p<0.0005). In total 25 children older than 10 yrs received 
their autologous red cells, harvested at the time of initial physical examination. 
In 77 cases complete data regarding cell yield infused and total volume harvested 
were available. A poor cell yield in the graft (defined as <1.0 × 108 per kg/recipient 
BW infused) was documented in only 10 cases, in all of whom greater than 15 ml/
kg donor BW was harvested. None of these patients had documented graft failure, 
with eight long term survivors and two children having died from a relapse of their 
leukemia. A cell yield of ≥3.0 × 108 per kg/recipient BW was seen in 34 harvests; 
twenty of these donors donated more than 15 ml/kg donor BW. A major blood group 
incompatibility between donor and recipient requiring red cell depletion was evident 
in 18 couples, only six of whom were in the group of large volume harvests.
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Figure 1: Harvest volumes often exceed 15 ml/kg (range 6-47 ml (mean 18 ml) donor BW, 
particularly in donors with an older recipient.
short-term FU
Only 24 donors had documented FU information, within 100 days post donation, 
including hematological control. Only one donor (m, aged 7.9 yrs; Hb 9.0 g/dl, 1 week 
post donation) had a second FU 8 months after donation, due to persistent epistaxis. 
His Hb was 10.6 g/dl and platelet count 263 × 109/L at that time. With regards to 
the amount of donors that underwent large volume harvest and received allogeneic 
blood transfusions, no further FU with respect to the development of neither red cell 
antibodies nor transmissible diseases was performed. Reasons for not undertaking 
further evaluation for the remaining donors were not recorded.
six donors had iron deficiency anemia pre-harvest, retrospectively diagnosed 
by characteristic red cell morphology in the presence of a hypochromic microcytic 
anemia in the absence of hemoglobinopathy. Intervention with iron suppletion 
was not documented. Full medical details were available for five of these donors. 
Four boys and one girl, aged between 3.1–11.4 years, who subsequently donated 
between 12 to 25 ml/kg body weight BM. Only three donors had their Hb levels 
controlled at six weeks FU, and in two donors persistent anemia was documented in 
the laboratory report. No data on long-term sequelae was available.
self reported health questionnaire (group II); Long term FU
One hundred and ninety of the 197 group I donors were at least 12 years of age at the 
initiation of the study, and were thus eligible to participate. seventeen of these were 
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referrals from abroad, with no known present address. The remaining 173 donors 
were invited by mail, to participate in a long-term FU study. Twenty-eight invitations 
were undeliverable, leaving 145 questionnaires that were presumed as received 
(Figure 2). seventy-nine of 145 donors (54%) responded to the questionnaire, and 
were equally distributed throughout the study period when analyzed by five year 
intervals. Of 92 surviving transplanted siblings, 44 (48%) responded to the invitation 
to participate. since the recruitment of non-donor / non-patient siblings did not 
result in sufficient numbers for comparative analysis (n=10), these results were not 
further analyzed.
Figure 2: Inclusion and response; excluded donors: 17 donors were living abroad; 6 donors 
had not reached the age of 12 years at time of the study. One donor had died; 28 donors 
were untraceable. Thirteen files were no longer available.
At time of the study in total 85 of all recipients had died (35%). All surviving 
recipients (n=79), who were at least 12 years old, were invited to participate in the 
study. The total number of FU years was 1340.
Informed consent was received from 79 donors, including four of the donors 
with a medical condition at the time of donation. At time of the study 91% (71/79) 
of the donors considered themselves overall healthy. However, 25% (20/79) had 
developed medical complaints since the BM donation. One donor (donor 071) with 
congenital heart abnormalities mentioned stent placement at age of 16 years; donor 
012 reported the prophylactic use of antibiotics due to his congenital asplenia and 
heart abnormality. seven donors mentioned regular upper airway infections, and 
seven donors reported problems related to asthma of allergies. Furthermore three 
donors reported having developed autoimmune diseases (rheumatoid arthritis, 
hypothyroidism and Crohn’s disease) since donation. Many other donors reported 
1   Death recorded
13 No les available
6   Too young
17   Living abroad
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non-autoimmune joint problems such as bone fractures and contusions or hospital 
admissions due to (minor) surgery. Two donors suffered from epilepsy and two others 
were anemic; none of these donors had a medical history at time of donation. Two 
donors required medical intervention for severe psychological problems, five suffered 
from long lasting fatigue. One donor reported persisting back pain since the second 
time she donated to her sibling. six donors reported more than one health issue. The 
majority of the donors had a healthy body mass index both at time of donation and 
FU, although 33% of the donors were underweight at time of donation, compared to 
13% of healthy Dutch children.
Health related Quality of Life (HRQOL): PedsQL, GHQ-12 and sF-36
PedsQLTM 4.0
Donors 12-18 year (n=18) were asked to complete the PedsQL. No significant 
differences were found between mean scores of child donors and the norm group 
of healthy school children. However, when taking into account the survival of the 
recipient, donors with a living recipient (n=13) scored significantly better on the 
“physical health” domain, than did donors of whom the recipient was deceased 
(n=5, T-test, p= 0.025). In contrast no significant correlation could be found between 
the sum scores of the donors and those of their recipients (n=16), suggesting that 
the health status of the recipient does not influence HRQoL of the donor.
General Health Questionnaire, GHQ-12
The mean total score of the adult donor group did not differ significantly from 
the healthy adult Dutch population. socio-demographic and donation-related 
characteristics, such as marital status, education, gender and recipient survival was 
not associated with the mean total score or the percentage of psychopathology in 
the donor group.
Medical Outcome study short Form 36, sF-36
All donors had significantly higher (=better) raw scores in the sub domains “physical 
functioning” (p=0.000), “role physical” (p=0.000), “bodily pain” (p=0.000), “general 
health” (p=0.000), “social functioning” (p=0.000) and “mental health” (p=0.0034) 
compared to the general healthy Dutch adult norm group. The difference on the “role 
emotional” scale was close to significance (p=0.054). since all of the sub domains, 
included in the “physical component summary score”, differed significantly from the 
norm group, it was not surprising for this score to be significantly different as well 
(p=0.000). When comparing male to female donors, male donors scored significantly 
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better on the sub domains “vitality” (p=0.018) and “mental health” (p=0.030). They 
also scored significantly better on the “mental health summary score” (p=0.013). 
Donors with a living recipient scored significantly better on the “role emotional” 
sub domain, compared to those with a deceased recipient (p=0.032). No mean 
differences were found according to education or marital status. There was a 
significant positive relationship between the “vitality” of the donor and the “vitality” 
of their recipient (p=0.030). A significant positive correlation was also found between 
“bodily pain” of the recipient and “mental health” of the donor (p=0.038), “general 
health” of the recipient and “mental health” of the donor (p=0.028) and “mental 
health” of the recipient and “bodily pain” of the donor (p=0.037). All of the other 
sub domains did not show any significant correlations (see Figure 3).
Figure 3: Figure 3: sF-36 subscale means of donors compared to the norm group 
GH = general health; VT = vitality; RE = role emotional; MH = mental health; 
BP = bodily pain; RP = role physical; sF = social functioning; PF = physical functioning. 
*** significance at the <0.001 level; ** significance at the <0.05 level; * not significance
Discussion
This is the first study addressing the immediate effects and long-term somatic 
and HRQoL outcome of BM donation in a large pediatric cohort. The Leiden unit 
performed the first European pediatric sibling BM transplant over four decades ago. 
As such the unit has considerable expertise and experience in the management 
not only of pediatric patients, but also of child donors. We anticipated that our 
results may be influenced depending upon the year of donation, since the study 
spanned a considerable period of time. Over this period clinical practice and ethical 
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considerations have changed. We were able to retrieve a substantial amount of 
information from archived medical files and the hospital computerized information 
system, which similarly was not compromised by year of donation, allowing us to 
confidently report our long term follow-up findings. This is particularly important, 
as to date no other published data is available for such a comprehensive study 
on pediatric donors. Recently the Pediatric Diseases Working Party of the EBMT, 
reported the early side effects of childhood stem cell donation35, in a prospective 
study. This study differs from our report as all age groups were included and both 
bone marrow and peripheral blood stem cell donation and FU was only 1 year 
post donation. However, their observations confirm our findings that large volume 
harvests are associated with significant reduction in hemoglobin levels and the need 
for allogeneic transfusion. Also children ages less than 4 years were more likely to 
experience events. Furthermore, in the Us the RDsafe study, which is ongoing, is 
collecting extensive clinical and psychosocial information from a sample of 100 
pediatric stem cell donors.
Donor Eligibility
During the study period the major accepted criteria for donor eligibility were being a 
sibling and an HLA match. The lack of well defined criteria for pediatric donors may 
well explain the fact that donors were declared fit to donate despite a concurrent 
medical condition. Although partly explained by the early years of transplantation 
included in our study, our analysis and recent publications show that the care for 
related donors is still, even in large transplant centers, in development12,13, compared 
to unrelated donors. Our study shows there is a wide variance in the management 
of pediatric donors, suggesting that donor eligibility criteria specifically designed 
for children would be helpful for pediatric transplant physicians. Potential donors 
with co-morbidity might place an additional burden on parental consent, which may 
disadvantage the welfare of the donor1.
Laboratory results and donation procedure
The retrospective nature of our study did not permit us to investigate if donors 
were or were not routinely evaluated. This in part may be explained by the fact 
that laboratory results predating computer datasets (i.e. before 1995) were less 
available. Interestingly the unit policy of routine morphological BM examination of 
sibling donors at the time of harvest, allowed for a comprehensive review of BM, 
especially in relation to iron stores, irrespective of year of donation. Literature on the 
composition of healthy infant BM is scarce and concerns cellularity and classification 
of normal cells, without special attention for iron stores36,37. The fact that two-thirds 
of the reviewed BM smears showed reduced or absent iron stores, suggests that FU 
regarding hematological recovery, pertinent to iron status and where applicable oral 
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iron suppletion in young pediatric donors is necessary. This should include serological 
assessment of iron stores. In our study, the relationship between BM iron stores 
and serological parameters could not be assessed, as the latter was not routinely 
undertaken. It is not clear whether autologous red cell collection affected iron 
stores. The importance of maintaining normal iron stores is relevant in the pediatric 
age group, as iron deficiency has been associated with delayed neuro-cognitive 
development and poor school function38, especially in early school age.
Harvesting procedure
In this study harvest volumes often exceeded 20 ml/kg (which is the standard in 
(un)related adult donation, equivalent to approximately 20% of total circulating 
volume)19,39,40. Although only approximately 10% could be explained by major ABO 
incompatibility and/or poor cell yield, we were unable to determine the reason for 
large volume harvests, especially in the donors donating to younger siblings included 
in this study. The large volumes harvested frequently resulted in a, unnecessary high 
cell dose for the related setting. since 2007 our department has limited the harvest 
volumes to 15ml/kg donor body weight. An analysis of 43 donations undertaken 
since implementation showed full engraftment in 41 recipients (100% donor), stable 
mixed chimerism in 1 child with homozygous ß-thalassemia (transfusion independent) 
and 1 late rejection in a child transplanted for homozygous ß-thalassemia. Our data 
suggest that limiting the harvest volume does not impede successful cell yields 
sufficient for engraftment for the vast majority of children. Recent analysis (data 
not provided) in our department, shows that in the past 5 years, we have limited 
our collection volumes for child donor to this standard, without compromising the 
graft. Erythrocytes from the graft were re-infused in all donors to reduce post harvest 
anemia. Pertinently, in more than half of all donors in our study, when harvest volumes 
exceeded 15 ml/kg, allogeneic blood transfusion was necessary to compensate for 
the blood loss, with the additional risks involved41,42.
Long-term FU & Health Related Quality of Life (HRQoL)
Although this study is based upon a self-reported questionnaire, this is the first 
attempt at documenting the donor’s perception of HRQoL following childhood 
donation. since there is no comparable data available, the response rate was 
compared published data from prospective studies (involving both related and 
unrelated donors). An overall response of 38% of all donors in the study period 
responded to the questionnaire, however, considering that only 145 invitations were 
presumed delivered, this figure rose to 54%. Participation in our study was equally 
distributed throughout the study period. In comparison, Hoelig et al.43 reported a five 
year post donation FU response of only 42% in unrelated donors. The experience in 
Austria with related donors was even lower, with a response of less than 10%, ten 
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years post donation (personal communication A. Rosenmayr). As in all retrospective 
studies of a self reporting nature, the results could be influenced by the non-response 
bias44. The recollection of the donation and the period following may have been 
influenced by the lapse of time or the recipient’s death. More than half of donors 
with medical problems at time of the donation responded to the questionnaire (4 
out 7, see Table 2). Although continuing medical problems were reported, none 
were directly related to the donation procedure. The reporting of non-specific clinical 
problems, such as recurrent upper airway infections and joint problems are difficult 
to interpret, and most likely do not reflect a long term consequence of BM donation 
in early childhood. However, as the participants felt them sufficiently relevant to 
report, we included them for completion. The study was not designed to verify self 
reported medical conditions. With this study an attempt has been made to disclose 
aspects of pediatric donor care., 
On average 16 years post donation, adolescents and adults function remarkably 
well, both physically and mentally. Higher raw scores on the sF-36 as observed in 
our study have also been reported in living kidney donors45-48. It is unlikely that this 
phenomenon is directly related to the donation procedure. However, it has to be 
mentioned that the age range of the comparative sF-36 Dutch adult norm group 
(mean 43.1 yr) is higher than those of the adult donors (mean 23.9 yr) in our study, 
which may explain the observed differences. Male donors scoring better than female 
donors on “vitality” and “mental health” sub domains of the sF-36 questionnaire, 
is consistent with the findings of published data30,49. Our findings that donors whose 
recipient was alive, compared to donors who were bereaved, scored significantly 
better on the “role emotional” sub domain. This is similar to findings among living 
kidney donors50, but contrary to findings of bereaved related donors in the UsA16. 
One explanation of our findings may be that the impact of bereavement at a young 
age may cause difficulties in adaptation and emotional development in adulthood7. 
In children, donors of living recipients scored better on the “physical health” 
domain than did donors of a deceased recipient. The occurrence of physical problems 
in children has been shown to predict internalizing problems such as depression 
and anxiety and externalizing problems, such as aggressive or acting-out behavior 
at a later age51. Our study suggests that these problems may persist into adulthood 
in selected cases of child donors. Encouragingly only two donors reported severe 
psychological difficulties. 
Although the donation procedure involves no physical therapeutic benefit for 
the donor, the psychological benefit of being able to help a sick family member is 
evident9,16. This might justify a limited amount of risk for a healthy child who is due 
to age limitations not able to give informed consent1,25,52.
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We were unable to address the issue of informed consent at the time of donation 
as the study was limited by its retrospective nature. However, consent in the pediatric 
population remains an important issue to be addressed in future studies. To what 
extent pediatric BM donation is still a voluntary act, is questionable. MacLeod et 
al.9 reported that two-thirds of sibling donors had ‘deliberate no choice’, while the 
remainder felt ‘forced’ or coerced to participate. Contrary to the adult (un)related 
donor practice, informed consent is rarely requested from young children. Young 
children have a right to be informed4,53 before committing them to undergo invasive 
procedures, especially when the intervention is not to their direct medical benefit. 
Careful consideration should be given at all times to weigh the balance of risks and 
benefits to the donor54.
Conclusions and recommendations
BM donation in early childhood does not lead to significant physical or 
psychosocial impairment at a later stage in the majority of donors. However, the lack 
of accepted guidelines for child donor care management leads to inconsistencies 
in the procedures, even in a single centre. Our study highlights the importance of 
independent medical assessment of child donors, especially in children with pre 
existing medical conditions to avoid peri-donation events. The limitation of the 
maximum harvested volume to 15 ml/kg donor body weight prevents young children 
being exposed to allogeneic blood products. Our study would suggest this would not 
be detrimental in terms of poor cell yields, to the recipients. 
Low iron stores were frequently detected in our study population, suggesting that 
hematological follow-up pertinent to iron status is desirable and where necessary 
oral iron suppletion should be prescribed. 
Although this study has shown that BM donation in early childhood does not 
negatively affect a donor’s life on long-term, it is important to weigh the risks and 
benefits and thus safeguard the interests of the child donor.
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Summary
The importance of identifying a back-up donor, once a primary suitable unrelated stem 
cell donor has been found, is often underestimated. Transplant centres erroneously 
count on the unrelated volunteer donors to be willing, available and medically fit 
for actual donation. According to our data, which includes 502 unrelated donor 
work-up procedures performed for 425 Dutch patients between 1987 and 2002, 
one of 11 work-ups ended in the primary requested donor failing to donate. Of all 
donor-related cancellations (n = 46), 78% of the procedures were deferred due to 
medical reasons and 22% due to nonmedical reasons. Most of the donors deferred 
for medical reasons were female (P = 0.005). In 50% of the cases for which a back-
up donor was already identified, the patients were transplanted with a delay of less 
then 2 weeks; when no back-up donor was available, the median delay increased to 
18 weeks. We strongly encourage implementing a search for at least one back-up 
donor in the primary search. Identifying a back-up donor can save precious time and 
complicated logistic rescheduling.
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Approximately one in three patients in need of stem cell transplantation has a 
suitable related donor1. The remaining patients depend on allogeneic transplantation 
with stem cells from an unrelated but human leucocyte antigen (HLA) compatible 
donor, as this has proven to be a suitable alternative2. Europdonor has facilitated 
unrelated stem cell donor searches for Dutch patients since 1987. Improving 
qualities of international services like Bone Marrow Donors Worldwide (BMDW) has 
shortened the search period over recent years. The experience of facing deferral of 
the chosen donor, just prior to the transplantation procedure, has led to a search 
policy in which we try to identify two donors for each patient. The best donor is 
chosen, the second best donor is released as a back-up donor. studies performed 
on the availability of unrelated donors during confirmatory HLA typing stage have 
shown the relationship between psychological factors concerning volunteer history, 
recruitment and donation and the level of attrition3,4. Deferral of a chosen donor 
prior to harvest is less than optimal; without an identified back-up donor, a new 
search has to be performed which is time consuming and can lead to necessary extra 
treatment courses and hospital admissions for the patient. Until now no data has 
been available on the advantage of identifying a back-up donor in the first search 
for a patient. It is our policy to identify a stem cell donor and back-up donor for each 
patient whenever possible. We addressed the question whether a back-up donor 
saves precious time and analysed the different reasons for not completing a donor 
work-up procedure, with special attention given to the donors’ deferral.
Materials and methods
The analysis concerned the 502 work-up procedures following unrelated donor 
searches for 425 Dutch patients facilitated by the Europdonor Foundation in the 
Netherlands, from 1987 to 2002. Patients originated from the following transplant 
centres: the Leiden University Medical Centre (n=204, 71 adults/133 children), 
Erasmus Medical Centre/Daniel Rotterdam (n=108) and the University Medical 
Centre Utrecht (n=113, 84 adults/29 children). statistical analysis was performed in 
sPss11 using Chi-squared test and Mann–Whitney U test.
Our search criteria include HLA match grade, CMV status, donor gender, donor 
age and ABO blood group system1. Confirmatory HLA typing and additional 
immunogenetic tests, such as Mixed Lymphocyte Culture (MLC) and Cytotoxic 
Lymphocyte Precursor test (CTLp), are performed with potential donors and the best-
matched donor is requested for work-up. A work-up procedure involves the formal 
request for physical examination and preparation of a donor for stem cell harvest. 
The transplant centre can express the preference for bone marrow or stimulated 
peripheral blood stem cells with the decision being driven largely by the patient 
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condition and disease stage, or current transplant protocol. It depends on the 
policy of the donor registry and the willingness of the donor to determine if this 
request can and will be fulfilled. The transplant centre determines a tentative date 
for transplantation. The donor centre contacts the chosen donor for counselling and 
physical examination, and arranges the definitive date for the stem cell harvest. At 
the time of the work-up request of the best-matched donor, the second best donor is 
selected to be the back-up donor in case the first donor fails to donate. This donor is 
released with the remaining donors, informing the donor registry that he/she is the 
back-up donor. The determination to release this back-up donor to the worldwide 
donor pool is based on the policies of each individual donor registry; ranging from 
immediate release to a temporary removal from the donor pool to await the outcome 
of the primary donor’s evaluation and consent.
Results
Between 1987 and 2002, 502 work-up procedures with unrelated stem cell donors 
for 425 Dutch patients were initiated. Overall, 120 work-up procedures were 
cancelled. In total, 359 first transplantations, 21 second transplantations and two-
third transplantations were performed. In 36 of the first transplantations and 11 
of the second transplantations, a back-up donor was asked to donate stem cells. 
The reason to request the back-up donor at the time of second transplantation was 
deferral of the first donor in one case and preference of the transplant centre in the 
other cases. In total, 492 donors were involved, 265 males, 218 females; in nine 
cases, the donors’ gender was not reported.
Cancellations
In 15% (74/502), the work-up procedure was cancelled due to patient-related 
reasons, primarily because the patient was no longer eligible for transplantation. In 
9% (46/502), the donor was deferred. Table 1 shows the grounds for donor deferral. 
They were either personal (n=10, five male and five female donors) or medical (n=36, 
11 male and 25 female donors). The proportion of female donors in the latter group 
is higher than in the group of all requested donors (P=0.020). Reasons for donors’ 
medical deferral were in a number of cases specified by the donor centre, although 
they have no obligation to do so. Female donors have an increased rate of deferral 
for medical reasons compared to male donors (P=0.005). In this study, pregnancy 
is considered a medical reason for unavailability, with regards to international 
regulations for donor eligibility.
Back-up donor
Confrontation with donor deferral during the work-up stage has led to our current 
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policy of attempting to identify a donor and a back-up donor for each patient. 
Overall, in 63% (305/502) of all examined work-up procedures, a potential back-up 
donor was identified in the initial donor search. The number of patients for whom 
a back-up donor was identified has improved during the past years. In the first few 
years (1987–1989), a back-up donor was found for only 28% of the patients. In the 
last 3 years (1999–2001), a back-up donor was identified for 66% of all patients. 
Currently, 81% of our unrelated donor searches result in the identification of a back-
up donor (Table 2). In these cases, all other donors tested had too many mismatches 
to be acceptable.
Table 1: Reasons for donor cancellation at the time of work-up
Reasons for cancellation Specifications Male Female
Nonmedical, n = 10a 5 5
Unavailable 2
No longer interested 2 4
Unspecified 1 1













a Female donors are deferred more often, due to medical reasons: Chi-squared test: P = 0.005.
In 46 of all cases, the best donor was deferred after the formal request for physical 
examination and preparation for stem cell harvest. For 10 patients, an unrelated stem 
cell donor search had to be reopened. In 36 of the 46 cancelled work-up procedures, 
a back-up donor had previously been identified. In 35 of these cases, the back-up 
donor was requested to donate stem cells. A total of 29 patients were transplanted 
with this back-up donor, mostly without major delay. For one patient, stem cell 
transplantation was no longer an option. Five of the requested back-up donors were 
not eligible for stem cell donation due to medical reasons.
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Table 2: Improvement of back-up donor identification over time
Period in time Number of patients with a back-up donor/total 
number of work-ups (%)
1987 – 1989 6/21 (29%)
1999 – 2001 121/183 (66%)
2002 – 2004a 214/265 (81%)
a The work-up procedures until 30 June 2004 are included: Chi-squared test: P = 2.10–7
Table 3: The advantage in time of an initially identified back-up donor (the delay is defined 







Best donor available 
(n=371)
0 0-155 87%
Best donor deferred: 7 1-100 63%
back-up donor available (n=36)
Best donor deferred: 129 40-555 60
no back-up donor available (n=10)
The absence of a back-up donor can cause delay or even cancellation of the 
preferred therapy. The regular time delay in a work-up procedure is defined as the 
difference in days between the tentative date for transplantation at the time of the 
work-up request and the final transplantation date. The transplant centre proposes 
the tentative date for transplantation; depending on the availability of both the 
donor and the collection centre, the final date for collection will be determined in 
consultation with the transplant centre. The median delay of patients transplanted 
with the best donor is 0 days (range 0–155). Over 85% of the first transplantations 
took place within a period of less then 14 days from the tentative date.
To investigate the delay caused by the deferral of a donor during the work-up 
procedure, we determined the difference in the first tentative harvest date and final 
harvest date. In 29 patients transplanted with a back-up donor, a median delay of 7 
days (range 1–100 days) occurred.
In 10 cancelled work-up procedures, no back-up donor had been identified and 
a new unrelated donor search had to be started. six patients were transplanted 
with a median delay of 129 days (range 40–555 days). The other four patients were 
no longer eligible for transplantation. An overview of the advantage in time of an 
initially identified back-up donor is given in Table 3.
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A successful unrelated donor search does not guarantee the availability of the 
identified donor for stem cell harvest. During the initial search, HLA typing and 
additional laboratory tests are performed. The best donor is chosen and requested 
for stem cell donation; the second best or the so-called back-up donor is released. 
It is our experience that more patients are now referred to us for an urgent search, 
with an initial proposed time frame for transplanta- tion within 6–12 weeks. This is 
likely a result of our success in being able to locate donors at very short notice5,6, and 
changes in current transplantation practice. A variation between 0 and 14 days in the 
proposed and final harvest date is considered acceptable. The policy to structurally 
identify a back-up donor was introduced in 1994 in our search process. since then, 
the total number of identified back-up donors for Dutch patients has tripled over 
the years. This could be attributed to the increasing number of registered donors 
worldwide7, in combination with our evidence-based search strategy.
In 46 cases, the donor centre cancelled the work-up procedure. The reasons for 
donor cancellation were divided into medical and nonmedical reasons. A significant 
number of female donors were deferred due to medical reasons (P=0.005). The 
preference for the selection of male donors for stem cell transplantation was 
discussed before in relationship to transplant-related mortality, relapse incidence 
and graft versus host disease8–11. On the basis of our findings and facts as described 
in the literature, the transplant centres prefer male to female donors if possible.
The reasons for a medical cancellation are not always specified, although a donor 
centre is free to give information to the transplant centre on this point. In a number 
of cases, the medical reason was specified. Obesity is a major reason for donor 
deferral at donor work-up stage; a donor with serious obesity should be deferred at 
least at the time of confirmatory HLA typing request, but more favourably at the time 
of recruitment for the unrelated donor registry. Donor registries should give more 
attention to this point.
There was no difference in donor gender in the nonmedical reasons. Being 
unavailable at the time of the work-up request or personal withdrawal were the main 
reasons. Extensive education and information of the donor might reduce this number 
of cancellations. In terms of volunteer history, it was found that stem cell donors who 
are also blood donors are less likely to drop out3. Generally, the transplant centre is 
not informed about the blood donor status of unrelated stem cell donors; therefore, 
we could not confirm this finding.
To determine the benefit of identifying a back-up donor in the initial search, the 
degree of delay in a normal work-up procedure has been established. A delay can be 
brought about by either donor-related or patient-related reasons. We showed that a 
delay caused by donor deferral could be minimised by identifying a back-up donor. The 
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benefit of identifying a back-up donor not only results in more patients proceeding 
to transplantation but also decreases the cost of overall treatment. This might be of 
substantial importance; the necessity for second unrelated donor search not only 
incurs search costs but also costs of extra treatment and hospital admission for the 
patient. Another aspect is the time that is needed to perform a second unrelated 
donor search. A number of patients will be at risk of relapse or deterioration of their 
disease, and will therefore no longer be eligible for stem cell transplantation if there 
is an untimely delay to transplantation due to donor deferral. It is yet unknown 
how the search procedure affects the mental state of health of the patient. It is 
recommended that future searches investigate the experiences of patients who are 
enrolled in an unrelated stem cell donor search, especially when arrangements for 
transplantation have been made (eg patient’s conditioning regimen is started) and 
the transplantation is deferred due to a donor cancellation and no back-up donor is 
available.
Conclusion and recommendations
Donor deferral, in particular during the work-up procedure, is never welcome and can 
cause a serious delay. It is strongly advised that donor registries ask for basic medical 
information (including height and weight) at the time of recruitment, and certainly 
at the time of confirmatory HLA typing request, to prevent unwanted surprises. Our 
search strategy, including the search for a back-up donor, prevents unnecessary loss 
of precious time for both patient and transplant centre. With the knowledge of almost 
10% donor cancellations during the work-up procedure, identifying a back-up donor 
should be a standard element in the search process. It is therefore strongly advised 
that transplant centres identify a back-up donor in the initial search and inform the 
donor centre about the back-up donor status at the time a donor is released. On 
the basis of these results, transplant physicians are now better able to inform the 
patient concerning the possible obstacles in the unrelated search and donor work-
up procedure. The information should include a discussion of the likelihood that the 
identified suitable donor may not precede to actual donation.
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Abstract
Between 2001 and 2012 the global inventory of unrelated donors (UD) for 
haematopoietic stem cells increased from 7 to 21 million and the number of available 
cord blood units (CBU) increased to over 500,000. We addressed the question 
whether this expansion has resulted in a higher percentage of transplants for 
patients in need of UD or CBU transplantation. UD and CBU searches were evaluated 
for 3124 patients in the Netherlands in two cohorts (2001-2006, n=995, 2007-
2012, n=2129), comparing results for patients of north western European (NWE) 
and non-north western European (non-NWE) origin. Endpoints were donor found 
and transplantation reached. Despite the substantial growth of the global donor 
inventory, the median number of potential volunteer stem cell donors per patient 
(n=7) for non-NWE patients has not improved over time, while for NWE patients 
the median number of potential donors increased from 42 to 71. For the period 
before and after 2007 an UD/CBU was identified for 91% and 95% of NWE patients 
respectively. For non-NWE patients these figures were 65 and 82% respectively 
(p<0.0001), due to more non-NWE patients for whom a suitable CBU could be 
identified. However, the degree of donor-recipient matching was significantly lower 
as compared to NWE patients (p<0.0006). Additionally, a significant reduction of 
the time needed to identify a UD/CBU was apparent. As a result, the percentage of 
patients actually reaching their intended transplant increased from 76% to 82% for 
NWE patients and from 53% to 69% (p=0.0003) for non-NWE patients. Collectively, 
our results show that the increase of the global inventory of UD/CBU has resulted 
in more transplants for patients lacking a family donor. However, the quality and 
quantity of potential haematopoietic stem cell grafts for patients with a non-NWE 
descent is still inferior, indicating an urgent need for those patients.
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Introduction
Allogeneic haematopoietic stem cell transplantation (alloHsCT) is an important part 
of treatment in many haemato-oncological diseases. For patients lacking a matched 
related donor, an unrelated donor (UD) or cord blood unit (CBU) may provide a valuable 
alternative. Alternative donors can be identified through registries of volunteer 
unrelated donors or public cord blood banks. In the past decade, improvements in 
the identification and availability of UD and UCB have been achieved. Bone Marrow 
Donors Worldwide (BMDW), the file of registered unrelated donors, has almost 
tripled (from 7.4 million donors in 2001 to over 21 million in December 2012), while 
the inventory of unrelated cord blood units CBU grew from 87,000 in 2001 to over 
500,0001. An increased knowledge of the HLA system and availability of several 
search related-software tools2-5, may facilitate and speed up the efficiency of the 
search process6-8. Also, the simultaneous search for a back-up donor has been shown 
to minimize the delay if a donor is unexpectedly not fit or unavailable to donate9. 
With these recent improvements, we set out to address the question whether a higher 
percentage of patients in need of an UD/CBU may actually reach transplantation 
nowadays and also whether the time needed to identify an UD/CBU has decreased. 
The questions were addressed in a large cohort of 3365 consecutive unrelated donor 
searches performed between 2001-2012 in The Netherlands, including searches for 
2772 Dutch patients from north-western European (NWE) descent and 352 non-
north-western European (non-NWE) patients.
Patients & Methods
The patients and donor searches
Europdonor Foundation, the Dutch stem cell donor registry coordinates the 
unrelated donor searches (UDs) in the Netherlands, serving a population of 16.8 
million inhabitants. The number of Transplant Centres is eight adult centres and 
two paediatric HsCT units in 2012, and the number of new searches is currently 
500 annually. All UD and CBU searches performed from 2001 until 2012 for the 
patients of all Dutch HsCT centres were included (n=3365, figure 1), and divided 
into two periods: Cohort I, 2001-2006 (n=1093) and Cohort II, 2007-2012 
(n=2272), each cohort was split according to NWE and non-NWE descent. Patients 
were assigned to NWE or non-NWE background, based upon a self identified 
descent10. Descendants from the Netherlands, Germany, Belgium, Luxemburg, 
Great Britain, Ireland, and scandinavia were considered NWE. The non-NWE 
group consisted of patients with genetic ancestry in Northern Africa (n=51), sub-
saharan Africa (n=22), Turkey (n=87), Asia (n=54), Eastern Europe (n=4), Hispanic 
(n=9), or mixed (n=125). Data were collected from the Europdonor national 
search database and patients’ files in the search units in Leiden and Nijmegen. 
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searches for combined donor/CBU and CBU-only and searches for NWE and non-
NWE patients were analyzed separately. 
Diagnoses were described in broad groups (Table 1); haemoglobinopathies, 
immunodeficiency- and metabolic disorders were subscribed to inborn errors (IE). 
Malignancies that could not be described to main groups were assigned to Other 
Malignant Diseases (OMD) and acquired non malignant diseases in Other Non 
Malignant Diseases (ONMD).
Patients with unknown ethnic background (n=35, of which n=14 reached 
transplantation) were excluded. Patients for whom a search was cancelled very 
shortly after initiation and for whom no donor was yet identified were excluded for 
the ‘Donor Found’ (DF) analysis (Cohort I, n=75; Cohort II, n=131). The remaining 
evaluable search cases (n=3124) originated from the following Transplant Centres 
(TC): Academic Medical Centre Amsterdam (n=131), Erasmus Medical Centre 
Rotterdam (n=479), Free University Medical Centre Amsterdam(n=216), Leiden 
University Medical Centre (n=831, of which 312 paediatric patients), Maastricht 
University Medical Centre (n=141), University Medical Centre Groningen (n=74), 
University Medical Centre Nijmegen (n=391, of which 80 paediatric patients), 
University Medical Centre Utrecht (n=861, of which 241 paediatric patients).
For the analysis of ‘Reaching Transplantation’ we excluded n=288 patients for 
whom a donor was found but transplantation was cancelled due to reasons not 
related to the search process (Cohort I, n=89, Cohort II, n=199), see figure 1. Reasons 
include: never reached remission/refractory disease (n=100), alternative therapy 
chosen (e.g. ATG for sAA or randomized for non-sCT arm in study, n=88), autologous 
HsCT (n=5), (extended) family donor available (n=23), indication changed / good 
clinical condition (n=27) and patient withdrawal (n=45). This left n=2836 searches 
for the analysis (n=788 NWE and n=118 non-NWE patients in Cohort I and n=1720 
NWE and n=210 non-NWE patients in Cohort II). 
search strategies
The basis for the current protocol for UD/CBU search was previously described11,12 
and adjusted to new insights and better quality of the donor pool. Each new search, 
irrespective for UD or CBU, started with estimation of the likelihood of finding an 
acceptable donor, taking into consideration the match-grade or stem cell source 
preferences of a centre. These results are communicated with the centre and where 
it is unlikely to find an acceptable donor, search strategies or treatment options are 
adjusted to avoid unnecessary delay. 
The search profile for UD is based upon confirmed HLA-typing of the patient 
(HLA-A, -B, -C, -DRB1, -DQB1 high resolution), including a review of family typing, 
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haplotype frequencies, allele frequencies, HLA-B/C-associations, and HLA-DRB1/
DQB1 associations. Ethnic background and results of BMDW regular match (mismatch 
runs if applicable) are taken into consideration. Where appropriate, advice for a 
concurrent donor search within the extended family search is given12. A 10/10 or 9/10 
HLA matched donor was usually preferred, however, in some transplant protocols 
(e.g. reduced intensity regiment [RIC]), mismatched donors are not acceptable. 
search profile for CBU is based on HLA-A, -B (serological (split) level) and -DRB1 at 
high resolution and the minimum total nucleated cell count (TNC) based upon body 
weight of the patient and according to local protocols is applied13. If no 6/6 or single 
mismatched units with sufficient TNC are identified, a run for two mismatches is 
performed, for both single and double cord searches.
In the selection of donors for verification typing, non-HLA factors (age, gender, 
ABO, CMV status, previous donation) are considered. Verification typing of prospective 
UD’s is performed for HLA-A, -B, -C, -DRB1, -DQB1 high resolution by the centre; for 
the selection of a CBU the minimum HLA typing requirements are HLA-A and -B 
on serological split level and HLA-DRB1 on high resolution level, usually performed 
upon request by the cord blood bank. In this study, a number of patients/donors 
were not typed for HLA-C, due to local policies. Match-grade for these pairs (n=71 in 
Cohort I and n=129 in Cohort II) were considered ‘unknown’.
Definitions
Donor found: a donor/CBU meeting the valid HLA matching criteria of the centre 
at that time. Match-grade UD: for UD all five high resolution typed loci HLA-A, B, 
C, DRB1, DQB1, were taken into consideration. A single mismatch on one of these 
loci is considered 9/10. Match-grade CBU: Only three loci (HLA-A, -B  at the (split) 
serological level, -DRB1 at high resolution) and TNC are both taken into consideration. 
Generally a ≥ 4/6 match according to local protocols is applied13. Length of search: 
the minimal interval in days from start search to identify an acceptable donor or 
CBU. No donor found: if a search was cancelled after the median necessary time 
for a search in that particular year, the search remained included in the No donor 
found-group. 
Statistical analysis
statistical analysis was performed using R version 2.15.1 (Copyright 2012, the R 
Foundation for statistical Computing). For measure of associations and differences 
we used Chi square test, Fisher’s Exact test (two tailed) and Wilcoxon rank sum test. 
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For measure of correlation we used Pearson’s product-moment. A p-value of 0.05 or 
less was considered significant.
Results
Baseline characteristics of NWE (n=2772) and non-NWE (n=352) patients are 
presented in Table 1. The distribution of NWE and non-NWE patients did not 
significantly differ over time between both cohorts (13% non-NWE in cohort I, 
and 11% non-NWE in cohort II). The median age of patients increased significantly 
over time, mainly due to more elderly NWE patients. Non-NWE patients remained 
significantly younger than NWE patients in both periods (p<0.0001). Indications for 
transplantation changed over time. The proportion of patients with CML and inborn 
errors (IE) decreased while the proportion (elderly) NWE patients with acute myeloid 
leukaemia (AML) and plasma cell malignancies (PCD) significantly increased (Table 
1). The distribution of ethnic backgrounds of non-NWE patients in cohorts I and II 
was similar. Characteristics of the search process are reported in Table 2. The median 
number of potential donors increased from 42 to 71 only for NWE patients (p=0.004) 
and remained at seven for non-NWE patients. A preferred CBU-only search was 
significantly more often performed for non-NWE patients (p<0.0001, Table 3).
Donor found
significantly more UD/CBU were found in the second Cohort (p<0.0001) for both 
NWE and non-NWE patients (Table 2). In Cohort I, an UD/CBU was identified for 
91% of NWE patients and 65% of non-NWE patients. In Cohort II, an UD or CBU 
was identified for 95% of NWE and 82% of non-NWE patients. Cord blood as an 
alternative stem cell source was needed more frequently for non-NWE patients in 
both cohorts (p<0.0001), although better matched (6/6) units were more often found 
for NWE patients (p<0.002, supplemental data). The amount of identified CBU’s for 
non-NWE almost doubled over time (18%-33%).
Grade of HLA matching and non-HLA donor-recipient matching aspects
Major differences in match-grade were observed between NWE and non-NWE 
patients. For non-NWE patients in Cohort II compared to Cohort I, less 10/10 HLA 
matched or 9/10 HLA matched donors were identified. For at least 91% of NWE 
patients in Cohort I and 88% in Cohort II a ≥ 9/10 donor was found, compared to 
64% of non-NWE patients in Cohort I and 58% non-NWE patients in Cohort II (Table 
2). 
Other characteristics that may affect transplant outcome, such as donor-recipient 
gender disparity reduced over time for NWE patients but not for non-NWE patients 
in cohort II. CMV mismatches between the pairs decreased significantly for NWE 
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patients but not for non-NWE patients. The median time to identify a donor for a 
combined donor/CBU search in NWE patients in Cohort I was 43 days and in Cohort 
II 34 days and also considerably improved in Cohort II for non-NWE patients (median 
of 56 and 36 days in Cohort I and II respectively, Table 3).
A CBU-only search was performed upon request of the centres for 18 patients of 
Cohort I (2%) and 123 patients of Cohort II (6%). Preferred CBU-only searches were 
in both cohorts significantly more often performed for non-NWE patients. A preferred 
CBU search despite a fully matched UD available was less often performed for non-
NWE patients (one and two patients in cohort I and II respectively). For NWE patients 
this occurred for five and 17 patients in cohort I and II, respectively. 
For the group of 288 excluded patients (see patients and methods), searches 
were not longer (median 42 days and 35 days respectively). For n=127/995 patients 
(13%) in Cohort I and n=136/2124 (6%) patients in Cohort II, no acceptable UD/CBU 
was identified. The median search time was longer in comparison to the donor found 
group (p<0.0001, data not shown) 
Reaching transplantation
Despite a successful donor search, procedures were cancelled by the TC for 89 
patients in Cohort I and 199 patients in Cohort II, because the patient clinically 
deteriorated or died (see Table 2). There was no correlation between length of search 
and whether or not a transplant was actually performed. The percentage of patients 
being transplanted increased significantly over time with NWE patients more often 
reaching their intended transplantation. In total 76% (n=599/788) NWE and 53% 
(n=62/118) non-NWE eligible patients in Cohort I and 82% (n=1417/1720) NWE and 
69% (n=144/210) non-NWE eligible patients in Cohort II reached transplantation. 
The increase for non-NWE patients from 53 to 69% was statistically significant 
(p<0.0003). Overall NWE patients were transplanted with better matched donors 
(figure 2), and CBU as stem cell source was significantly more frequent in non-NWE 
patients. 
Back-up donor
In Cohort I, 70 patients (9.3% of NWE and 5.5% of non-NWE patients) and in Cohort 
II 170 patients (9.8% of NWE and 7.8% of non-NWE patients) received stem cells 
from a back-up donor (n=234) or a back-up cord blood unit (n=6). Apart from the 
chosen donor being deferred or no longer available during work up, in both cohorts 
in four cases the TC decided to switch to the back-up donor, because the identified 
donor was only able or willing to donate bone marrow, where PBsC was preferred. 
In one case the donor did not show up on day of aphaeresis. In 10 cases (Cohort I 
n=3, Cohort II=7) a new search for a back-up donor had to be initiated, causing an 
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median delay of 15 days (range 0-412 days) to transplantation, compared to median 
9 days range 1-181 days) if a back-up donor was available. In 27 cases the match-
grade of the requested back-up donor was lower than the originally identified donor.
Discussion
In the last decade, significant investments14 have been made to increase the worldwide 
haematopoietic stem cell donor pool and to improve the quality of donor HLA typing. 
However, there is still concern about the availability of alternative donors, especially 
for patients of non-European descent15. We addressed the question whether the 
expansion of the global donor inventory has resulted in a higher percentage of 
transplants for patients in need of an unrelated donor or cord blood transplantation 
and which patients benefitted in particular. Overall we observed a higher percentage 
of transplants in both NWE and non-NWE patients, for whom a search was started in 
the period 2007-2012, when compared to the search period before 2006. However, 
despite the significant increase of volunteer UD, non-NWE patients showed only little 
benefit and 30% of transplants in this group was performed with CBU, compared 
to 10% in NWE patients. Although overall more donors were found, the probability 
to identify a 10/10 matched donor for non-NWE patients has not improved, while a 
significant advantage for NWE patients (Table 3) has become apparent. 
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Figure 2: Match-grade donor in NWE and non-NWE patients reaching 
transplantation (match-grade unknown for n=52 in NWE 2001-2006, n=84 in NWE 
2007-2012, and n=5 in non-
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model showing the likelihood of finding a well matched UD or CBU for patients 
of different ethnic background in the UsA15. Donor availability, inconsistent typing 
results and donor medical eligibility were taken into account. The model is based 
on donor and cord blood data in their registry (approximately 50% of the global 
inventory), and showing the likelihood of identifying an UD/CBU for both white 
Europeans and African-American patients, which is over 95%. Using 100% of the 
global inventory1, we found for 95% of NWE patients and only 81% of non-NWE 
patients an acceptable UD/CBU with a match-grade of at least 7/8. The difference 
may be explained by the clinical nature of our study, implying that we searched for 
actual patients. The assumption of Gragert et al that the donor population represents 
a true reflection of the patient population is possibly overestimate the probability of 
finding an acceptable UD/CBU in particular for non-NWE patients. Furthermore, a 
mismatched donor or CBU is not always an acceptable alternative. Despite availability 
of mismatched UD or CBU the outcome of the UDs would be No Donor Found. All 
patients for whom no donor was found in our study had one or more rare alleles 
or uncommon HLA-B-C/DRB1-DQB1 associations or a combination of these, often 
originating from a mixed racial background. Currently, for a Dutch NWE patient a 
median number of 71 potentially matched donors are listed, often allowing selection 
for characteristics such as donor age, gender and CMV status, factors that may 
improve transplant outcome. In contrast, we found that the number of potentially 
2001-2006 p 2007-2012 p
NWE NNWE NWE NNWE
Age (median, yrs)* 38.5 13.8 p<0.0001 51.5 19.9 p<0.0001
Diagnosis (%)**
AML 23.8 20.2 n.s. 33.9 21.5 p<0.0001
PCD 5.9 0.8 p=0.02 9.3 3.5 p=0.002
IE & ONMD 8.8 32.3 p<0.0001 5.1 27.6 p<0.0001
Median donors in BMDW 
(n)*
42 7 p<0.003 71 7 p<0.0006
CBU only search (%)** 1 7.3 p<0.0001 4.4 41 p<0.0001
CT samples received (%)* 63 53 p=0.05 65 49 p<0.0001
Length of search (days) 43 56 p=0.01 34 36 p=0.02
Donor/CBU found (%)*** 90.5 64.5 p<0.0001 95.1 81.2 p<0.0001
10/10 (%) 64.2 28.8 p<0.0001 68.8 25.6 p<0.0001
9/10 (%) 26.9 35 p<0.02 19.4 32.8 n.s.
CB as stem cell source (%) 4.7 27.6 p<0.0001 10.1 39.8 p<0.0001
Table 3: Major differences between results for NWE and non-NWE patients in two periods.  
*Wilcoxon rank sum test, **Fisher’s Exact test,***Chi square test.
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matched donors for our non-NWE patients remained low: a median number of seven 
UD per patient. These results confirm that non-NWE patients still lag behind because 
of limited registered, available and suitable non-NWE donors within the national and 
international registries16-20 and are more likely to be transplanted with less optimal 
HLA matched donors or CBUs17,21.
Length of search and reaching transplantation
A significant shorter search time for both NWE and non-NWE patients was observed 
in more recent years, which appeared to be associated with a reduction of cancelled 
procedures. Cancellation, due to clinical deterioration of the patient after an UD/CBU 
was identified, was approximately 30% in the period 1991-200011, but only 10% in the 
years after 2007. It emphasizes the importance of time, in particular in adult patients 
with high risk leukaemia22-24. Future development of HLA next generation sequencing 
techniques are expected to enhance the quality of the global UD inventory25,26 even 
more. In combination with provision of additional donor characteristics, it allows 
TC’s to request stem cell donors that are completely typed on high resolution and 
fulfil additional criteria, thereby minimizing the length of search virtually to one day, 
and facilitating transplantation within a month from UDs initiation. such a combined 
request for verification typing and stem cell donation is occurring more frequently in 
recent years. Further potential saving of time may be achieved in the period between 
donor identification and transplantation. Early recipient HLA typing27, estimation of 
the likelihood to identify a donor and efficient search protocols allow for optimum 
time planning, thus reducing the time to transplantation to a minimum7,8,28-31.
Cord blood as stem cell source for non-NWE patients.
An increasing percentage of actual transplantations was observed for non-NWE 
patients in the most recent period, which appeared due to a higher number of 
CBU transplants. Cord blood is currently increasingly applied in patients with very 
poor risk acute leukaemia, needing an immediate transplant after having obtained 
remission, or children with IE, other than haemoglobinopathies12,32. CBU’s are almost 
instantly available and requires less-stringent HLA matching criteria, but on the other 
hand is associated with a higher rate of graft failure and retarded haematopoietic 
recovery33,34 Recent studies have suggested better outcome following unrelated CBU 
using grafts with higher cell numbers, or double CBU grafts, and/or better matched 
grafts35-39. Although the probability of finding an CBU with at least a 4/6 match 
increased over time for non-NWE patients, the degree of matching in non-NWE 
patients appeared still significantly less than in NWE patients in our study, indicating 
that non-NWE patients continue to receive suboptimal donor grafts. In concordance 
with Gragert et al15, our findings in successive cohorts of non-NWE patients strongly 
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underpin the urge to expand the global inventory, but especially focusing on donors 
and grafts from ethnic minorities.
Conclusion
Collectively, we conclude from this large retrospective study that the increase of 
the global inventory and the major efforts and investments to improve the search-
process have resulted in a strong benefit for NWE patients. However, the probability 
to identify a well matched UD for non-NWE patients has not increased in time 
and non-NWE patients more often rely on CBU as an alternative stem cell source. 
In addition, the match-grade for both UD and CBU is less optimal for non-NWE 
patients. Finally, we observed that improved efficiency of the donor search time is 
associated with overall more NWE and non-NWE patients reaching their intended 
transplantation.
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Focus on the donor
Abstract
Hematopoietic stem cell transplantation is a curative procedure for life-threatening 
hematologic diseases. Donation of hematopoietic stem cells (HsCs) from an 
unrelated donor, frequently residing in another country, may be the only option 
for 70% of those in need of unrelated hematopoietic stem cell transplantation. To 
maximize the opportunity to find the best available donor, individual donor registries 
collaborate internationally. To provide homogeneity of practice among registries, the 
World Marrow Donor Association (WMDA) sets standards against which registries 
are accredited and provides guidance and regulations about unrelated donor safety 
and care. A basic tenet of the donor registries is that unrelated HsC donation is an 
altruistic act; nonpayment of donors is entrenched in the WMDA standards and in 
international practice. In the United states, the prohibition against remuneration of 
donors has recently been challenged. Here,  we describe the reasons that the WMDA 
continues to believe that HsC donors should not be paid because of ethical concerns 
raised by remuneration, potential to damage the public will to act altruistically, the 
potential for coercion and exploitation of donors, increased risk to patients, harm 
to local transplantation programs and international stem cell exchange, and the 
possibility of benefiting some patients while disadvantaging others.
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Background
Hematopoietic stem cell transplantation (HsCT) has been in use since the 1960s and 
is a proven cure for patients with hematologic and metabolic disorders and immune 
deficiencies. A necessity for performing HsCT is that the donor and the recipient 
have identical or close to identical human leukocyte antigen (HLA) phenotypes. The 
first allogeneic HsCTs were performed with HLA matched related donors only. There 
is a 25% chance that 2 siblings inherit the same HLA phenotypes, and ~30%-35% 
of patients will have an HLA identical sibling or closely matched family donor. For 
patients requiring an allograft who do not have a related donor, an HLA matched 
unrelated donor or cord blood unit has been an option for 4 decades.
The single most important donor factor in determining transplantation outcome is 
the degree of HLA matching between patient and donor1,2. The HLA system displays 
extreme polymorphism, such that for many patients, there may be few if any other 
persons who will match their unique HLA type. To assist patients in finding a potential 
unrelated donor, registries of HLA typed volunteer donors were first established in 
the early 1970s. It was soon realized that the opportunity for finding a matched 
donor would be significantly enhanced by creating a mechanism for searching donor 
registries in other countries. This was achieved by the formation of Bone Marrow 
Donors Worldwide in 1988. Bone Marrow Donors Worldwide provides a centralized 
database containing information on the HLA phenotypes of virtually all unrelated 
donors (adult and umbilical cord blood, a source also rich in hematopoietic stem 
cells [HsCs]), allowing the entire international inventory to be searched in one single 
location.
Currently, there are more than 14.9 million registered unrelated donors 
internationally, in 64 stem cell donor registries from 44 countries and in 44 
organizations of cord blood banks from 26 countries3. In 2008, more than 11,500 
patients worldwide received an HsC transplant from an unrelated donor. Greater 
than 44% of those patients used a donor or cord blood unit from another country4, 
emphasizing the benefit of international cooperation in all aspects related to the 
procurement, transport, and use of these stem cell products.
Despite the number of adult donors already registered and the growing numbers 
of publicly stored cord blood units worldwide, many patients in need of an HsCT 
still cannot find an acceptable HLA matched donor because they have a rare HLA 
phenotype. The inability to find an HLA match for specific patients has led to the 
development of strategies to enhance the registries by increasing both the number 
and diversity of the donors listed5,6.
Remuneration of donors is sometimes proposed as a means of incentive so more 
persons join and donate HsCs. In this context, the issue of remuneration of HsC donors 
has been raised in a lawsuit filed in the United states District Court in October 20097. 
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In that case, the plaintiffs sought to overturn the prohibition against remuneration 
for marrow donors found in the National Organ Transplant Act8, arguing that the 
prohibition limited access to persons who might donate if they were remunerated.
The question of remuneration of donors is also currently being openly debated 
in the context of solid-organ donation. For example, the concern about international 
trafficking of organs and organ donors has recently led the World Health Organization 
(WHO) to issue a declaration opposing the international exchange of organs9. In 
2008, in the United states, legislation was prepared that gave states the right to 
provide remuneration of organ donors as a means to address the organ shortage10. 
Although this legislation was ultimately not introduced, it is reasonable to expect 
that developments in the organ donation arena will have implications for donors of 
HsCs as well.
The WHO first formally considered the issue of remuneration for organ, tissue, 
and blood donation in 1991, taking the position that the human body and its parts 
should not be subject to commercial transactions11. This was reaffirmed by the WHO 
in 2008 through the restatement of a set of Guiding Principles12. The European Union 
has also taken a position against remuneration in the donation of human tissue and 
cells13. Many countries and other jurisdictions have taken similar positions14,15.
The World Marrow Donor Association (WMDA) was established to develop 
international guidelines and policies to ensure unrelated donor and stem cell product 
safety and to encourage proactive international collaboration toward harmonizing 
regulatory standards16. The WMDA has consistently maintained a policy against 
remuneration of donors17,18. This position is based on the general consensus of its 
member organizations that a truly volunteer donor-based system would be the most 
effective and safe way to develop donor registries. studies have shown that, although 
donors express several motivations when asked19, altruism, the selfless regard or 
concern for the wellbeing of others, is the fundamental principle behind donation20.
In light of the current debate about remuneration, the WMDA formed a task 
force to review the question and to develop a policy statement in this matter for its 
consideration and adoption. Here, we discuss why volunteer persons who provide 
HsCs to unrelated recipients should not be paid for their humanitarian act.
Common terms
Hematopoietic stem cells (HsCs) mean hematopoietic stem cells derived from bone 
marrow and peripheral blood unless stated otherwise.
Reimbursement means payments for out-of-pocket expenses incurred by the donor, 
replacement of lost wages or time off, or payment for medical expenses incurred by 
or on behalf of the donor related to the donation.
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Remuneration means payment of something of value to a donor or other party in 
exchange for HsCs over and above reimbursement for out-of-pocket expenses.
Ethical considerations
The question of remuneration for donation raises certain ethical concerns. The 
essential act at issue is the decision by an unrelated person to undergo a medical 
procedure for the benefit of someone else. A significant body of work has developed 
around the ethical issues involved in such an exchange, especially in the context of 
solid-organ donation21 and use of donors as research subjects22.
Three ethical principles in particular are often the focus of inquiry. The first is the 
principle of dignity, which is that the transfer of part of a human body is distinct from 
that of a product or service and requires unique considerations so as not to devalue 
human life through commercialization of organ, tissue, and blood. The second 
principle is that the donor should not be subject to unnecessary or unreasonable 
harm. Finally, any system of distribution should be fundamentally fair. In particular, 
no segment within society should benefit at the expense of another segment or 
permit coercion of any kind in the process of acquiring HsCs.
Dignity
The concept of dignity is premised on the view that the human body should be 
treated as having intrinsic value apart from the potential economic value that might 
be placed on organs, tissue, or blood by someone in need. This notion is founded 
in both religious and philosophical considerations. Many religions hold that the 
body is a sacred gift from a higher being and a person has the duty to protect or 
conserve that gift23. Any harm to the body is a violation of that duty, except in the 
case of protecting the person from further harm24. From a philosophical perspective, 
reference is often made to the teaching of Immanuel Kant whose formulation that 
society should “treat humanity ... always as an end and not as a means only”* is 
often cited as the basis to conclude that the payment for body parts is a misuse of 
a human being because it views the provider as a source of supply for the person in 
need and not a distinct human being25. By considering only the economic value of 
a donated organ, tissue, or blood, the potential exists that markets for body parts 
will be created. In such a setting, the sale of a body part is seen as devaluing human 
life by implying that a person’s worth is based on the material value of the body 
rather than as a rational human being. Donation without remuneration is generally 
permitted in the religious setting as an act of charity benefiting a fellow human, 
whereas in the philosophical setting the nonremunerated donation is seen as an 
*) I. Kant, Werke, hrsg. von W. Weischedel; Band IV, Grundlegung zur Metaphysik der sitten, s. 61. Darmstadt: Wissenschaftliche 
Buchgesellschaft; 2005. “Handle so, dass du die Menschheit, sowohl in deiner Person, als in der Person eines jeden andern, 
jederzeit zugleich als zweck, niemals bloss als Mittel brauchest”.
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altruistic act for the benefit or another rather than as a commodification of one 
human for the befit of the other.
The concept of dignity must be balanced with the person’s right to make decisions 
about his or her own body, reasonably free from the control of society. However, 
although recognizing that the person has the right to make decisions about his or 
her own body within a wide spectrum of behavior, society has an interest in avoiding 
behavior that has certain social consequences that include undermining widely and 
deeply held views about the value of life26. The overriding concern is that the person 
be valued as a distinct human being.
In the context of dignity, a further argument for remuneration is often advanced 
as it relates to access to health care for economically disadvantaged populations 
in which minority ethnic groups tend to be overrepresented In the case of organ 
donation, denying compensation on the basis of human dignity may deny access to 
those minority populations that would benefit from donation from persons within the 
same ethnicity. If that group would respond to compensation, the argument goes, 
the harm is offset by the benefit to people in the same ethnic group27. This has some 
resonance in regard to unrelated donor HsCT because patients will probably find a 
donor within their own ethnic group, and registries struggle to find donors within 
their minority populations. To sustain this view, it must be argued that the economic 
value derived from the sale of body parts is more important than upholding the 
concept of personal and societal dignity of human beings. But this is precisely the 
trade-off that undermines the value that society puts on the human being. It may 
also lead to the further commodification of the person or disadvantaged group by 
opening up the potential of remuneration for other body parts, further undermining 
the value of the person or population28.
Harm to donor
As noted earlier, the act of donation is to submit to a medical procedure for which the 
person will not derive any direct benefit. Thus, any harm that might result will not be 
offset by a benefit to the person undergoing the procedure, except for the sense of 
satisfaction derived from an altruistic act. Therefore, care must be taken to minimize 
the potential of harm and to fully disclose any risk to the donor so as to ensure that 
the decision to donate is made freely and willingly. The decision to take the risk 
inherent in the procedure must be made without any undue influence or pressure29.
There is a general agreement that donor registries should have donor safety as 
their first priority18,30-32. Any medical or psychosocial condition that increases the risk 
to donor has to be thoroughly investigated, resulting either in deferral or approval 
for donation.
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Guidelines for donor risk assessment and deferral are used in conjunction with 
an individual medical and psychosocial assessment of donor eligibility to make sure 
that a donor is not asked to take unacceptable risk33. If the risk is known to the 
donor, remuneration has the potential of creating a calculation in which the short-
term economic benefit is overvalued compared with the risk being taken by the 
remunerated donor34. The potential for remuneration may also cause the prospective 
donor to withhold personal health information for fear of being disqualified from 
donation, preventing an accurate risk assessment and disclosure of risks specific to 
that donor. As a related matter, the promise of remuneration raises the question of 
whether the decision to donate is really voluntary when the donor is under some 
duress due to significant personal economic concerns.
Harm to the donor could occur when the cost to the donor in lost wages, medical 
bills associated with the donation, or incurring other out-of-pocket expenses 
would adversely affect the donor. It is widely recognized that the donors should be 
reimbursed for these types of expenses and are not considered remuneration for 
purposes of this discussion.
Fairness
Fairness is the concern that the burden of donation not fall on a particular group 
or class, especially when the benefit accrues to a different group or class. Concern 
about exploitation of populations underlies both the WHO Guiding Principles and the 
Declaration of Istanbul9. When payment is used as an inducement to provide organs 
or tissue, it is argued that a wealthier population will exploit poorer populations that 
will be more susceptible to the perceived short-term gain from the exchange while 
overlooking the long-term risks and psychosocial implications as discussed further in 
“Limited benefit of remuneration to donors”.
Exploitation of patients is another concern, especially in the HsCT setting. The 
donor is in the potentially unique situation of being the only possible donor who 
matches the HLA of the patient, providing significant leverage over the patient; that 
is, the donor would have the ability to name the price, and market principles would 
not apply. The donor would have the ability to name his or her price. Patients undergo 
a preconditioning regimen in the days leading up to the HsCT, which eradicates or 
suppresses their own hematopoietic system and makes them totally dependent on 
the cells from the donor to generate a new donor-derived hematopoietic system. The 
administration of a commercialized donation system while the patient’s life hangs in 
the balance could seriously jeopardize the patient.
Evidence of the exploitative potential of a remuneration-based system has been 
seen in other settings. For example, in the United states a potential related donor 
sought compensation for a commitment to donate35. At the time when called to 
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donate, the potential donor extracted further payment. Tragically, the potential 
donor ultimately refused to donate. Regardless of the final outcome in this case the 
situation shows the potential vulnerability of a recipient if the basis of the exchange 
is financial and not altruistic.
Finally, it has been asked that because personnel and institutions involved in 
HsC donations are paid for their services, why not the donors36? This question, 
however, does not seem relevant, because donors are already reimbursed for their 
out-of-pocket expenses and compensated for income-loss while away from work for 
donation reasons. The donors therefore continue to earn their salary like all others 
involved in the donation, but they earn it despite their absence from work.
Other considerations
safety of patients
Remuneration has the potential of interfering with this process of risk assessment to 
the detriment of the patient. In a system that uses remuneration, some persons could 
find the monetary remuneration so significant that they might hide relevant medical 
or psychosocial information or both37,38.
A process that might induce a potential donor to be less forthcoming in response 
to the screening questionnaire may result in a patient being placed at risk for the 
transmission of diseases from the donor. Additional screening and testing may 
reduce, but cannot eliminate, the possibility of harm to the patient.
Although there may be times when the potential of the transmission of disease 
is outweighed by the benefit to the patient, that decision must be made with the full 
knowledge of all potential risks to the patient so that a truly informed decision can 
be made. The prospect of remuneration may cause the donor to provide information 
late in the process to increase the chance of being selected to donate. Anything 
that interferes with full disclosure of that potential risk early in the process may 
needlessly put a patient at risk.
In a similar context, the question of safety to patients in blood donation has 
resulted in the development of the interna- tional consensus that blood donation be 
voluntary and uncompen- sated to protect the patient, as most recently evidenced 
in the Melbourne Declaration39 of the WHO, which called on “all governments to 
achieve 100% voluntary nonremunerated donations by 2020 as the cornerstone of 
their blood policies”40.
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Limited benefit of remuneration to donors
The effect of financial incentives on HsC donor life circumstances is probably minimal 
and transient. Evidence from the Iranian system of paying unrelated donors for 
kidneys led a past president of Organ Procurement Transplantation Network in the 
United states to state that “The experience in Iran and elsewhere suggests that the 
poor remain poor following a ... sale and then with one less kidney”41.
Not only are the financial incentives offered for HsCs unlikely to change the 
donors’ life circumstances, but donors in these circumstances are also unlikely to 
accrue the known lasting psychosocial benefits of HsC donation. There is ample 
evidence that unremunerated unrelated HsC donors experience enhanced well-being 
from altruistic donation and incorporate the donation experience into their self-
concept. One of the first large investigations of 849 unrelated bone marrow donors 
found that many donors felt that by donating bone marrow, they were actualizing a 
central trait in their identity having to do with willingness to help others42. Many of 
these donors believed that the centrality of this helpfulness trait made them distinct 
from others and more willing to assist. Donors often identified the source of this 
focus on helping as stemming from a strong emphasis on generosity and altruism 
within their family of origin.
A second investigation with a similar group of 493 unrelated bone marrow 
donors found that high proportions of donors reported (1) that they felt like better 
persons for having donated (71%), (2) that marrow donation made them feel more 
worthwhile (67%), (3) that donating marrow was a high point in their lives that 
made everything seem more meaningful (75%), and (4) being proud of having 
donated (96%)43. These extremely positive feelings about donation are directly 
linked to donors’ willingness to engage in future altruistic acts, including donation, 
and to recommend donation to others. More than 90% of donors in this and other 
investigations report that they would be willing to donate again if they were asked, 
and if given the opportunity, they would strongly encourage others to donate. In fact, 
these self-benefits of the marrow donation process were in many cases greater than 
those observed for living related kidney donors. This is because, unlike in the case of 
living related donation, the unrelated donor is under no obligation to the recipient 
and does not stand to tangibly gain from their donation. Thus, these donors are often 
viewed as exceptional and as having gone above and beyond the call of duty by 
family, friends, and coworkers43.
Evidence suggests that a further potential benefit of the altruistic motivations 
that lead to unremunerated donation and the positive feelings resulting from the 
donation itself is that donors may come to view themselves as “medical donors,” a 
self-image that may increase their willingness to engage in other forms of medical 
donation (eg, blood donation, cadaver organ donation19). This will probably be lost 
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in a system that offers remuneration. Finally, it is a general experience that stem cell 
donors frequently are willing to accept considerable discomfort without complaining, 
probably because the act of donation has been so meaningful and valuable for the 
donor. Perhaps this kind of attitude also can promote a speedy recovery.
Effect on existing registries
Commercialization of donors through remuneration may also create a disincentive 
for those who are altruistically motivated from joining or continuing to participate 
on the registry. This behavior has been observed in the blood donation setting44. 
similarly, it has been observed that the expectation of rewards can undermine the 
intrinsic value derived from the behavior, reducing interest in participating45, or 
reduce motivation to continue with participation once the reward is received46. In the 
latter case, sometimes referred to as “the overjustification effect” a reward paid for 
the initial donation may result in less motivation to provide a second donation, which 
is needed in some of the transplantation cases. It is not clear what effect offering 
payment for HsC donation would have on the overall numbers of persons willing 
to provide HsCs. However, the motivations for willingness to provide HsCs would 
be altered, and a significant reduction in the number of donors willing to donate is 
highly probable for 2 reasons. First, the very nature of stem cell donor registries (only 
a small fraction of registered donors will ever donate, and there can be years or even 
decades between registration as stem cell donor and donation) makes it difficult to 
motivate persons to register through financial rewards for donation. second, the 
positive psychosocial effects of donation as described earlier have been successfully 
used by many donor centers and registries as part of their recruitment strategies. 
In a setting with donor remuneration, these strategies could not be used anymore. 
Thus, the offer of remuneration could adversely affect both the willingness of those 
already on the registry to continue as well as the recruitment of new persons to the 
registries.
Effect on international exchange
The current system of international exchange is based on the willingness of all 
participating registries to adhere to a common set of standards and guidelines. These 
standards are informed by a common set of ethical, legal, and practical concerns. 
Remuneration also raises the concern that the donor who is paid may believe 
he or she has a lingering economic right if the unit is not used for the intended 
purpose. WMDA addresses this concern indirectly by requiring that a donation not 
be cryopreserved as a matter of practice. In the rare instances when a product is 
saved and not used for the intended patient, the uncertainty created by the potential 
of other uses when the product was sold for a specific use would be unacceptable. 
Variation in country ownership laws would create further uncertainty in international 
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exchange. If the WMDA were to adopt a standard that allows for use of a remunerated 
donor, those countries that prohibit remuneration or have standards that do not 
permit remuneration for safety or other reasons would need to screen out donors 
from countries that permit remuneration. This could create a 2-tiered system of 
registries and would complicate the current system of international exchange. The 
effect would be to reduce the potential pool of donors for patients in some countries 
and undermine the cooperation among the registries.
Recommendation
The price assigned to the value of human donation is literally the value of life, which 
cannot be expressed in monetary terms. Donor remuneration raises difficult ethical 
issues, has the potential to damage the public will to act altruistically, and may 
involve coercion and exploitation of donors. It may also place patients at increased 
risk, negatively affect local transplantation programs and international stem cell 
exchange, and may benefit some patients while disadvantaging others. These concerns 
have resulted in several national and regional registries as well as legislative and 
regulatory bodies worldwide to oppose remuneration for the donation of HsCs as 
well as organ and blood. The WMDA, therefore, concludes that remuneration for HsC 
donors is undesirable and may be deleterious to the international transplantation 
community of both patients and donors.
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This thesis focuses on the experience of stem cell donation by unrelated and related 
donors (minors and adults), aspects of donor care management, and the process 
of the unrelated donor search. The theme linking these topics is providing patients 
in need of HsCT with the best stem cell product without impairing the safety of 
the donor. In this chapter the results of our findings are summarized and put into 
perspective with regards to current practice and future developments.
Summary
since the first successful allogeneic hematopoietic stem cell transplantations 
(HsCT) were performed in 1968, the number of disorders potentially curable with 
donor derived blood stem cells, has substantially increased, namely hematological 
malignancies, immunodeficiencies, inborn errors and metabolic diseases. Originally 
stem cells were harvested from bone marrow, but the availability of recombinant 
human granulocyte colony stimulating factor (G-CsF) enabled collection of stem cells 
from peripheral blood (PBsC). Furthermore, banked umbilical cord blood has become 
an important resource of stem cells. 
Although HsCT has become a standard of care procedure, the practice is dynamic 
with continuous efforts to develop less toxic conditioning regiments and to reduce 
severe Graft versus Host Disease (GVHD). Furthermore ongoing studies are seeking 
new therapeutic options to harness donor immunity by use of their mononuclear 
cells (MNC) to combat relapse of malignant diseases and uncontrollable (viral) 
infections. These evolvements can directly affect the burden for the donor. Care for 
anonymous stem cell donors is well organized by unrelated donor registries, based 
upon the standards of the World Marrow Donor Association (WMDA). However, these 
regulations do not apply to the related donor. The Ethics and Clinical Working Group 
of the WMDA shared their expertise in donor care management with the European 
Group for Blood and Marrow Transplantation (EBMT) in 2010, on the principles and 
recommendations of donor recruitment, counseling, follow-up and adverse events 
registration (chapter 2). It was a first attempt to raise awareness for related donor care. 
The main challenge is that the donor and recipient are relatives, placing the potential 
donor at risk for coercion. Health care professionals involved in counseling and care 
of related donors should find the optimal balance between donor’s commitment and 
patients’ needs.  The establishment of protocols concerning counseling, evaluation 
of donor’s health, reporting adverse events and offering long term follow-up for 
related donors was also the subject of the first Donor Outcome Workshop in 2009, 
initiated by the Late Effects Working Party of the EBMT. The goal of this Workshop 
was to seek consensus for global standardized donor data collection on immediate 
side effects and long term follow-up (chapter 3). such a large international cohort of 
donor data would allow for defining the risks of hematopoietic stem cell donation in 
other than unrelated volunteer donors. With the scarce available literature (usually 
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case observations or retrospective descriptive analyses) and the lack of randomized 
controlled trials, it is often impossible to determine a causal relationship in reported 
incidents. Theoretical concerns about long term effects of the administration of G-CsF 
in healthy individuals or the influence of multiple donations have not been addressed 
in prospective studies because, among other reasons, it is difficult to find funding to 
cover the overall cost of long term donor follow-up. We performed a retrospective 
study on a cohort of 268 donors who donated G-CsF mobilized stem cells in the 
period 1996-2006 to a relative in the Leiden University Medical Centre. The study 
focused on donor eligibility criteria and cardio vascular and malignancy events at 
follow-up (chapter 4). since strict criteria for donor health were not yet established 
in the early days of PBsC donation, we used criteria of the Dutch unrelated donor 
registry and National Marrow Donor Program to establish in retrospect whether 
donors were deferrable or eligible, and found that 15% of donors (n=40) would have 
been deferred for donation to an unrelated individual stranger. short-term adverse 
events did not differ in incidence reported in cohorts of unrelated donations. At long 
term follow-up, nine malignancies and 14 cardiovascular incidents were reported. 
These incidences were within the range of the age-and sex-matched general Dutch 
population, suggesting that there is no additional long term risk for cardio vascular 
diseases or malignancies in family donors. However, the incidence of vascular 
complications were substantially, albeit non-significantly, lower in NMDP eligible 
donors, questioning the validity of the general population as control group, despite 
correction for age and gender.
The need for registration of serious Events and Adverse Reactions (sEAR) became 
apparent with the introduction of G-CsF administration to healthy volunteers. 
Besides sEARs the WMDA also addressed issues regarding patient safety, (chapter 
5). A registry for serious Products Events and Adverse Reactions [s(P)EAR] was 
established. s(P)EAR not only highlights risks to the patient related to the product, 
but also damage to the stem cells due to unsafe transportation. submitted s(P)EAR’s 
can, depending on severity, be reported to the donor registry and transplant society 
(involved in the care of related donors) in a Rapid Alert. Although registration of 
s(P)EAR is only mandatory for WMDA accredited registries, all donor registries are 
invited to (anonymously) submit any s(P)EAR. 
In pediatric HsCT, when no acceptable donor or cord blood unit can be identified, 
the use of a parent being haplo-identical to the patient is not uncommon (chapter 
6). Parents who donate to their child fulfill a dual role, as caregiver and donor, and 
their experiences were not yet reported. From in-depth qualitative interviews with 
13 parents, four main themes revealed, ‘Hope and Fear’, ‘Need for Information’, ‘Do 
Anything for Your Child’ and ‘Transplant Outcome’. These themes were present in 
all stages of the process (decision making; donation process; reflection). Their role 
as a donor was for most parents of minor importance, and the fact that they felt 
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they had no choice but to donate was a recurrent element in interviews. A proposal 
for a multicentre European study for long term follow-up of parental donors was 
approved by the EBMT working parties on Late Effects and Pediatric Diseases.
Not only parents can donate to their children, children can act as donors to 
provide bone marrow to a sibling as of very young age. We undertook a retrospective 
study to investigate a cohort of 210 donors who donated before the age of 13 years 
in the Leiden University Medical Centre between 1968 and 2002 (chapter 7). Donors, 
on average 16 years post donation, were invited to participate in a long-term follow-
up and health related quality of life study. Although medical problems were reported, 
none were clearly related to the donation procedure. Two donors mentioned severe 
psychological difficulties. Bone marrow donation in early childhood does not lead to 
significant physical or psychosocial impairment in the majority of donors. However, 
clear eligibility criteria and guidelines for donor care management were lacking. 
Obvious, independent medical assessment is required for counseling of pediatric 
donors and, in case of a preexisting medical condition, additional advice should 
be requested from a specialist to determine if the risk of general anesthesia and 
bone marrow donation is acceptable. Despite the presence of medical conditions 
questioning harm of donation, none of the children were deemed unfit to donate, 
while no documentation on follow-up of these children could be found. A review of 
(n=107) bone marrow reports and aspirates revealed low (46%) or absent (15%) iron 
stores, without clear documentation of iron suppletion after bone marrow donation. 
In 62% of the children, the collection of bone marrow exceeded 15 ml/kg donor 
body weight and more than half of these received allogeneic blood transfusions. 
Post-transfusion screening for red cell alloantibody formation was not performed. 
The results of the study underscore the need for international guidelines for care 
management of the pediatric stem cell donor.
The search for an unrelated donor requires, besides expertise of human leukocyte 
antigens (HLA), also familiarity with international rules and regulations for stem 
cell donation. Delay during the donor search is undesired, especially during the 
work up procedure and should be prevented. Approximately 10% of the donors are 
deferred or is not available when asked to donate stem cells. Identification of a 
back-up donor during the initial search is an effective way to avoid loss of precious 
time and inconvenience for all parties involved. However, physicians should always 
inform their patients that a donor might be deferred after counseling. Based upon 
reasons for deferral at work up, donor centres are advised to perform an eligibility 
health check when a donor is requested to provide samples for verification typing, in 
particular when there are reasons to doubt that the donor may be declared suitable, 
such as severe obesity or a wish for pregnancy (chapter 8).
Over time, searching for an unrelated donor or cord blood unit has become more 
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complicated. The still ongoing unraveling of the HLA system, adding thousands of new 
alleles and cumulative potential combinations for phenotypes requires continuous 
adaptation and training of search coordinators. Besides, clinical developments have 
resulted in the use of double cord blood units for transplantation, necessitating a 
different way of matching (chapter 9). Prolonged time between donor search and 
transplantation negatively influences the outcome. Despite efficient activities to 
reduce the length of search to a minimum, search time to identify a match will be 
longer when no donors are available. For patients with a north western European 
(NWE) background, the number of potential donors in the worldwide inventory Bone 
Marrow Donors Worldwide (BMDW) has increased in the paste decade to a median 
of 70 available matched donors, whereas for patients from a non-NWE descent, the 
number of potential donors remains fixed to a median of 7 donors. Moreover non-
NWE donors were more often unavailable at time of verification typing. The fact that 
a remarkable amount of non-NWE patients reach transplantation is because donors 
/ cord blood units with a lesser match-grade are accepted. 
similar as in other health care areas increasing attention for quality aspects and 
enhanced interest in the rules, regulations and ethical aspects of stem cell donation 
have recently come to light, attracting the attention of professionals and the public 
(chapter 10). The remuneration of stem cell donors was the target of a lawsuit 
filed in 2009 against the National Organ Transplantation Act in the UsA. Plaintiffs 
disputed that the legislation forbidding remuneration of stem cell donors would 
deter potential donors from registration as a donor and thus decrease the chances 
of finding a match for a patient. Through intense international collaboration patients 
can receive a stem cell product, often collected from a donor in another country or 
continent. One of the basic principles that donors are not to be paid for their act 
is documented in the standards of the WMDA. Thus (parts of) the human body has 
no economic value, and should be treated with the dignity it deserves. At the time 
of the lawsuit, a taskforce of the WMDA extensively argued the case why stem cell 
donation should remain voluntarily and non-remunerated. stem cell donation is an 
act of humanity and impossible to value in monetary terms, and is literally a gift 
of life. The introduction of payment is not only a potential risk for coercion and 
exploitation of donors, but can also potentially harm transplantation programs and 
the international exchange of stem cell products.
General discussion and future perspectives
The use of allogeneic hematopoietic progenitor cells has become a treatment 
option of choice for patients with defined congenital or acquired disorders of the 
hematopoietic system1. Apart from a growing list of indications, the development of 
non-myeloablative conditioning regiments has cleared the way to HsCT as a potential 
cure for an increasing amount of (mainly elderly) patients. As a result, the median 
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age of sibling donors has increased and due to current stricter adherence to eligibility 
criteria they are more often declared not suitable for donation and more often an 
unrelated donor or cord blood unit is needed. Currently, in over 50% of all allogeneic 
HsCTs the graft is provided through a donor registry2 and it was estimated that in 
2013 daily 33 unrelated stem cell products were crossing an international border3. 
In the past decade (2004-2013) the number of UD increased with an average of 
10.1% per year; the average having only increased slightly in the last three years 
due to the inclusion of Brazilian and Chinese donors. The global CBU inventory has 
grown on average with 14.6% per year4,5. Despite a significant increase of the HsCT 
activity worldwide6, it is assumed that the therapy is still underused as curative 
treatment, due to various clinical and non-clinical reasons7. Considering these facts, 
it is pertinent to investigate what is further required to ensure maximal utilization of 
this potentially curative modality of treatment.
The optimal donor pool: young, male, diverse and available
The preferences of transplant centres (TCs) for the ‘ideal donor’ are subject to 
change. stem cells of older donors as compared to younger donors were reported 
to have adverse impact on overall survival in patients with certain hematological 
malignancies8,9, and it has even been suggested that a younger UD rather than an 
older sibling is preferable10. With time and evaluation, opinions have also varied 
as to the preference for a sex matched donor, in particular for a male recipient11,12. 
A recent analysis of a large cohort in adult male patients transplanted for acute 
leukemia showed no difference in leukemia free survival, but a higher risk for acute 
GvHD when receiving donor stem cells from a male unrelated donor leading to the 
conclusion that a female sibling is preferable13. In light of the fact that a sufficient cell 
dose is of major importance for transplant outcome, an observation that is consistent 
over time14,15, and since male donors provide quantitatively better grafts in terms 
of cells harvested based on body weight16, the commonplace preference for male 
donors may be explained. However, also in male donors, increasing donor age is still 
associated with a modest negative effect on stem cell mobilization17.
In their annual report 2012/2013 the Canadian registry OneMatch mentions that 
three quarters of stem cell donations are derived from male donors younger than 
36 years18. This trend is also seen in the Netherlands where currently 70% of donors 
requested for verification typing are male. Not only has the worldwide unrelated 
donor pool increased significantly over time, so has the average age of the registered 
donors. As a direct consequence donors are more often deferred for medical reasons 
and thus less useful19. Globally, 19% of the registered donors are male and younger 
than 36 years and only 10.5% of all donors are younger than 26 years3. Considering 
age and gender, the current global inventory would not meet the criteria for the 
optimal donor pool, challenging donor registries to be creative and find cost-
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effective solutions. Lowering the age for recruitment has been recently introduced 
in the United Kingdom (16 years) and in Canada (17 years). The Canadian registry 
focuses their recruitment on male donors, younger than 35 years20. Recruitment 
of younger UD as of 16 years of age might be beneficial, however, due to local 
legislation, may not be feasible in each country. When focusing on younger donors, 
registries need to adjust their established operating procedures as was reflected by 
representatives of the Canadian and British registries during the WMDA Fall meeting 
in 2013. The lack of ‘life-experience’, for instance with informed consent procedures 
and doctor’s appointments require age appropriate counseling methods21,22. Also, the 
administration of G-CsF to minors might not be authorized in all countries. In the 
Netherlands for example, there is no consensus about the administration of G-CsF 
to healthy minors.
Despite the steady increase of UD/CBU in Bone Marrow Donors Worldwide 
(BMDW), the mainstream of the UD/CBU is being registered in the north western 
European (NWE) and north American registries23,24. As such, this might be the 
limiting factor of access to transplantation for patients with a non-NWE background 
seeking a matched donor. strategies aiming to increase the HLA diversity of the 
donor pool could be successful in overcoming the present limitations, supplemental 
to ethnic minority donor recruitment efforts25. Apart from recruitment, strategies 
aimed at retaining donors listed on the registry are becoming frequently more 
necessary. since the reasons for donor unavailability were first investigated26, the 
amount of donors in the UsA not being available when they are contacted has 
increased to almost half of their donor pool27,28, and this number is increasing29. 
It has been shown that commitment is lower in ambivalent donors30. When asked 
almost immediately after registration, 35% of newly recruited donors stated that 
they have doubts if they would proceed to donation31. Characteristics like gender, 
duration of registration, and ethnic background are not only indicators for attrition, 
but also have a cumulative effect, negatively affecting chances for patients32. Part 
of the solution to help more patients reach HsCT might be working towards an 
optimal global donor pool. Recruitment among blood donors guarantees a higher 
probability of willingness and suitability for stem cell donation. However, level 
of commitment in new (non-blood donor) prospective donors is also identifiable; 
specifically ambivalence in potential donors is strongly associated with attrition and 
this and other parameters could be used to modify recruitment strategies31. Although 
the chance of Dutch non-NWE patients to reach HsCT has increased over time to 
approximately 70%, their options to identify an acceptable UD within almost 25 
million listed UD are dramatically lower both in quantity and quality, than for NWE 
patients and have not improved over time (this thesis). The underrepresentation of 
non-NWE donors in the pool is lowering the likelihood for non-NWE patients to 
find and receive an optimal matched graft25,27,31-36. Gragert et al. recently reported 
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a theoretical model, based upon population genetics, estimating the likelihood of 
finding a well matched UD or CBU for white European patients and for patients with 
other ethnic backgrounds in the Us37. The model was based upon the donor and cord 
blood inventory of the National Marrow Donor Program (NMDP), which represents 
approximately 50% of all registrations worldwide, and taking availability and 
medical eligibility into account. They claimed a likelihood of over 95% for identifying 
an unrelated donor or cord blood unit for white Europeans and African-American 
patients. In our retrospective analysis, we were able to identify an acceptable stem 
cell source for 81% of non-NWE patients. The assumption of Gragert et al. that the 
donor population represents a true reflection of the patient population37 possibly 
overestimates the probability of finding an acceptable UD/CBU in particular for non-
NWE patients. Besides, a mismatched donor or cord blood are not always acceptable 
alternatives depending on the specific transplant protocol. Patients for whom no 
acceptable donor was identified in our study often originated from a mixed racial 
background. Donors with mixed genetic ancestry are probably least represented in 
the worldwide donor inventory. The importance of a donor’s availability, especially 
in young male donors (since they are most likely to be requested) and ethnic 
minority groups is essential to explain during recruitment31,32. It is necessary to revise 
recruitment strategies to prevent newly recruited donors from dropping out at any 
time during the verification typing and pre-donation process. Most donor registries 
have focused on the volume of their donor pool, but there is an urgent need to 
address the issue of donor attrition, since avoiding waste of money and efforts in 
this direction of recruitment can no longer be ignored29,38. The startling fact that 
over 10% of registry donors is even unable to be located at time of a blood sample 
request, could be addressed in an awareness campaign (through social media, flyers 
or newsletters). Donor registries are unable to function as trackers and delays in the 
search could have serious consequences for patients, and these can be prevented.
S, M, L, XL – donor registries
Currently there are a few ultra-large registries (with over 1 million registered donors) 
and a majority of small (<20,000 donors) and medium-sized registries (<100,000 
donors)39. Taking into consideration that the majority of products (>80%) is annually 
provided through five of the larger registries, of which two XL registries (responsible 
for 67% of all products)3, the vulnerability of countries with s and M registries is 
evident. They have become dependent on stem cell products donated by foreign 
donors. It is unclear why the majority of requests is sent to the XL registries, since 
donors with ‘common HLA phenotypes’ are most likely present in their own national 
registries. It could be argued that national registries should be able to provide a 
certain percentage of stem cell products for their national patients. As a result of 
these developments and the economic crisis, s and M registries are facing difficult 
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times and for new registries in emerging countries it is almost impossible to start 
up  without sufficient financiel support. Determining the optimal size and mix of the 
global donor inventory involves difficult decisions balancing competing objectives 
and requirements27. However, the need for new registries, in particular in emerging 
countries, is obvious since they add unique HLA phenotypes to the global donor 
inventory. Where in recent years approximately one in fifteen donors provided a new 
phenotype, the contribution of new registries such as the Brazilian registry added to 
BMDW in 2011, resulted for that year one in ten donors adding a new phenotype40. 
In virtually all countries CB inventories have a much higher relative contribution 
of new HLA phenotypes to BMDW than the donors. It was stated in the BMDW 
annual report 2012 that CB banks are thus more successful in recruiting units from 
minority groups40. A certain amount of these new phenotypes might originate from 
unique mixed ethnic backgrounds. This is extremely important for a number of those 
patients who would otherwise not have access to HsCT by lack of an acceptable 
(cord blood) donor. Yearly stem cells of less than 0.1% of all registered donors and 
approximately 0.8% of CBU are actually used for transplantation3,41. Completeness 
of HLA typing has a strong impact on donation probabilities42, since donors who are 
types on high resolution are more likely to be requested. A possible explanation for 
the use of CBU being approximately tenfold higher than the proportion of available 
adult donors being utilized might be the phenotypic diversity and potential faster 
availability of CBU. The promising advantage of cord blood as a stem cell source for 
non-NWE patients underlines the importance of banking of high quality cord blood 
units for allogeneic transplantation, and in doing so compensating for the lack of 
minority donors in the donor pool43. With the overall relatively small proportion of 
stem cell donors actually donating yearly, it is important to critically consider this 
before adding ‘more of the same HLA’ to the global donor pool. The introduction 
of next generation sequencing (NGs) will reduce the cost, while resolution of HLA 
typing is higher and determination of further parameters (blood group, CMV, KIR, 
etc.) easily possible, thus adding higher quality donors to the global donor pool. A 
Group of European Medium sized Registries44 are attempting to seek joined solutions 
for the challenges.
Reaching HSCT – clinical and non-clinical factors 
In 2001 it was reported that overall only one third of eligible patients reached HsCT45. 
Over a decade later the WMDA Annual Report demonstrates that 45% of patients 
for whom an unrelated donor search is initiated reach HsCT2. This is most likely a 
subset of all eligible patients. A recent prospective study reported that an unrelated 
donor search for only 51% of patients without a family donor was initiated, without 
a clear explanation as to the reasons for the remaining patients being deferred46. 
Reasons for not reaching transplantation are various; HsCT might be offered too 
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late during therapy7,46 with clinical deterioration, in particular for intermediate/high-
risk leukemia patients, as probably the main disturbing factor47, and the period to 
identify a donor could (and in some cases needs) to be decreased48. The major non-
clinical factor determining restraint of transplant is undoubtedly the lack of donors 
for non-NWE patients. We have proven for our Dutch patients that efficiency of the 
search process can affect feasibility of reaching transplantation to 70%, by reducing 
the amount of searches cancelled due to clinical deterioration of the patient to 
approximately 10%. To perform a search as efficient as possible donor registries 
have developed tools and methods to shorten the UD/CBU search49-53. sharing such 
awareness and insights between donor registries and transplant centres might play 
a key role in improving transplantation figures.
Safeguarding donors: the global approach
safety of stem cell donors considers mainly the suitability of the donor undergoing 
the procedure. Whether the donor is an infant or an adult, an anonymous person 
or a family member, their well-being and interests must always be kept in mind 
as a duty of care. Treating a healthy donor with an agent that is not of in his 
physical benefit demands responsibility from health professionals, and an approach 
where the safety of the donor comes first54. With the introduction of Granulocyte 
Colony stimulating Factors (G-CsF) in healthy volunteer individuals, the issue of (in 
particular) long-term safety has been addressed. In a recent study the short-term 
and long-term serious Adverse Events (sAE) of both bone marrow and peripheral 
blood stem cell donation were analysed55. It was remarkable that the risk of short- 
term sAE was threefold higher in bone marrow donors. From the more long-term 
follow-up data it was confirmed that unrelated donors do not have an increased risk 
to develop a malignancy, auto-immune disease or thrombosis within three months 
after donation55. The WMDA have adjusted their statement with regards to the use 
of G-CsF in healthy volunteers56, however, although these comparisons have been 
stratified for age and gender with the general population, other confounders were 
generally not corrected for. It is also not known whether this statement equally 
applies for the related donor population, since the overall health in the unrelated 
donor population is probably better than in the related donor group or even the 
general population. For patients, older age no longer seems to be a absolute contra-
indication for HsCT, but as previously mentioned, older patients have older siblings, 
and although age is not per se an indication for performance status47, co-morbidities, 
and thus reasons to declare a person unsuitable for donation, are more often seen 
in elderly donors (this thesis). It is known that co-morbidities in related donors (RD) 
are more often accepted since ‘related donors are willing to take a greater risk’57. 
The medical profession assumed for a long time that family members are naturally 
motivated by the prospect of saving the life of a loved one58. It would subscribe the 
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altruistic character and the principle of beneficence referred to as an aspect of human 
nature, that motivates to act in the interest of others59. From this perspective it could 
be justified by the thought of Kant, that if a family donor really chooses to donate 
out of affection, his act would lack moral worth, because it would not be based on 
an obligation59. However, it is unclear whether the above mentioned assumption of 
traditional altruistic thinking would make a relative feeling obliged to donate or deter 
him from free decision making60. In extenso – could this imply violation of the basis 
ethic principle of autonomy, ascribing the right to choose and act freely? Violating or 
ignoring a person’s autonomy is to treat that person merely as a means to an end, 
that is, in accordance with other requirements without regard to that person’s own 
interests59. In that light, the assumption could be an expression of the utilitarian 
view, that is, if the chance of the transplantation success is likely greater than the 
probability of the family donor to experience any harm, it is the donor’s obligation 
to donate59. The situation where the donor has not yet reached the age of adulthood 
or is not able to assent or to give informed consent, is even more complicated. If 
proxy consent for donation is given by a parent or a legal representative, this might 
implicate that the donor is used as means to an end, which would be contradictory 
with the principles of Kant’s second formulation of the categorical imperative: the 
action is considered unacceptable, because the individual’s physical integrity is 
ignored and his dignity diminished by locating his value in a donation activity61. The 
American Academy of Pediatrics (AAP)has addressed ethical concerns in a policy 
and defined criteria that allow for the use of pediatric donors62. Although the AAP 
has advised to have a system in place where (legal or ethical) approval is required 
prior to donation, it was argued that this might not sufficiently protect the interests 
of the pediatric donor and modification of the policy with more emphasis for the 
donor’s rights, competence, and consent was proposed63. Harvesting stem cells is a 
medical procedure that potentially imposes risks and violates the bodily integrity of 
the donor. The argument of ‘best interest’ remains questionable, since the outcome 
of the HsCT, and thus the potential benefit for the donor can not be predicted. The 
debate on quality of life versus medical emancipation became public with the novel 
‘My sister’s Keeper’65, where a 13 year old girl lived with the knowledge that she 
was conceived to rescue her sister, suffering from leukemia. she literally became 
the ‘altruist by proxy-donor’66, seeking for legal medical emancipation after multiple 
donations, and prior to donating her kidney. The novel made clear that abstaining the 
right of decision-making leaves the basic principle of autonomy worthless, even in 
minors65. Apart from the AAP policy, strict regulations or guidelines for practice with 
respect to the suitability, treatment, and follow-up of minor donors are still lacking. 
Even small policy changes could be beneficial for minor donors. For example, limiting 
the volume of bone marrow to be harvested from young donors could prevent them 
from requiring blood transfusions. Furthermore, HsCT outcome in children with high-
risk leukemia has improved over time, regardless of donor source67. Also, during the 
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decision-making process, the search for an alternative donor (if time allows for) 
should be considered. 
Internationally there now is a leading opinion that the suitability of the stem 
cell donor is of importance for all parties involved68. This was acknowledged by the 
transplant society with the establishment of the EBMT Donor Outcome Committee in 
2012. Furthermore the FACT/JACIE standards version 569 explicitly addresses donor 
care issues. since then initiatives to develop and implement more strict guidelines for 
related donor care have been reported70,71. Awareness for the interests of the related 
donors was raised through international collaboration. The World Health Organization 
(WHO) has addressed the need for protecting the health and welfare of living donors 
including appropriate long-term follow-up72. Interestingly, a comparable discussion 
is being held in the field of living kidney donors, where governmental support is 
considered essential to set up a national system for life-long donor follow-up73,74. 
The Worldwide Network for Blood and Marrow Transplantation (WBMT), a non-
governmental organisation focusing on collaboration between existing international 
societies was established to promote excellence in stem cell transplantation and 
donation75. Through several successive Donor Outcome Workshops consensus 
was sought for suitability donor outcome data and lately the need of in particular 
pediatric and elderly donors were specifically addressed, with the aim of providing 
written consensus guidelines (Vienna 2013). The development of a European Union 
funded Master in Donor Health Care (a Dutch initiative) is also underscoring that 
care for the donor of organs, tissues, and cells is taken seriously.
With regards to serious (product) events and adverse reactions (s(P)EAR), the 
WMDA has developed a reporting system, adding to the high quality standards of 
donor care management76. One of the major advantages of the WMDA s(P)EAR 
system is the possibility to send out a ‘Rapid Alert’ to communicate in a timely 
matter with the donor registries and transplant community, whenever appropriate. 
For the related donors no such system is yet in place. There is a strong justification for 
bringing the related donor care in line with those for unrelated donors, especially in 
addressing adverse events in this group77. The establishment of a reporting system to 
cover adverse events of all living donors globally would be a major achievement and 
there is a substantial need to further investigate and develop this global challenge.
Future considerations – estimating the need for unrelated donors
The dynamic field of HsCT is continuously subject to changes. New drug developments 
and stem cell treatment protocols are rapidly following each other and being 
explored. Besides HLA matched related and unrelated UD and CB the use of targeted 
(autologous) immune cells for cancer treatment is under investigation. The extent 
of involvement and the final role of allogeneic donors in the future is thus unclear 
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and this directly affect the activities of all donor registries. Chronic myeloid leukemia 
(CML) was less than two decades ago only curable by HsCT and patients are now 
successfully treated with tyrosine kinase inhibitors78. similar developments are on 
their way for chronic lymphocytic leukemia79. If results of autologous tumor targeted 
T-cell therapy80 can be confirmed in larger randomized controlled trials this may 
ultimately lead to a decrease of the proportion of HsCTs. 
Another development is the renewed interest in transplantation with related 
haploidentical donors, followed by a high dose Cyclophosphamide given early after 
HsCT to reduce the incidence of Graft versus Host disease and graft rejection, resulting 
for leukemia in at least comparable outcome as with HLA identical or matched 
unrelated donors81. In 2013, 40% of the patients in Italy received a haploidentical 
graft; Bacigalupo82 mentioned a 10% reduction of the financial cost in his transplant 
centre while increasing the number of transplantations performed by 20%.
Regional differences in use of allogeneic donors are large, and associated with 
national income, thus widening the gap between more or less affluent countries3,83. 
As an additional effect of the economic crisis, TCs need to investigate ways to cut 
the costs of HsCT, without depriving the standard of quality care84, and keeping 
the treatment accessible85. Although in-hospital patient days are the main part of 
expenditure, cost of unrelated donor selection and stem cell products, in particular 
the cost of (double) cord blood, are also subject to discussion84,86,87. The cost 
effectiveness of HsCT with the several available stem cell sources (including haplo 
identical stem cells) is under investigation88. A concern that was expressed is that 
in countries where a fixed-rate system for reimbursement is negotiated with health 
insurance companies, transplantation with double cord might become prohibitive. It 
was suggested to look into ways to keep the use of cord blood both profitable and 
affordable87. The current discussion is focused on the pricing of stem cell products in 
general, and of cord blood in particular. A ‘one-price-policy’ or a price based upon 
the TNC of a unit (smaller units – lower prices) would positively affect patients 
(money is no longer an argument not to choose the best match). There is evidence 
that increasing the ethnic diversity of cord blood inventories lead to more patients 
reaching HsCT (this thesis) demonstrating cord blood banks the need to develop 
policies to increase ethnic diversity89. Raising public awareness is important to reach 
the goal of covering HLA diversity even within a country90. The likelihood of CBUs to 
be used over time is besides HLA, directly related to the total nucleated cell count 
(TNC)91. Units with higher TNC are more likely to be selected for transplantation91. 
It is known that non-NWE units often contain less TNC, probably related to shorter 
labor time but their contribution to the diversity should be considered89. Other 
policies to make units better serviceable are the provision of maternal HLA typing, 
since a beneficial effect of non-inherited maternal antigens (NIMA) and inherited 
paternal antigens (IPA) of a cord blood have shown a positive impact on engraftment 
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and relapse risk and a reduced graft versus host disease92,93. Also, the efficacy of 
matching cord blood on high resolution HLA-A, -B, -C and -DRB1 was recently shown 
to be associated with lowest non-relapse mortality after transplantation with cord 
blood for acute leukemia and myelo-dysplastic syndrome94, indicating that complete 
high resolution typing of new cord blood units is important.
Donors and (future) research
Over the past decades motivations, experiences, and perspectives of being a stem 
cell donor and donating stem cells, have been studied95. Recently the introduction 
of new mobilizing agents and the use of bio-similars have created a need for donors 
to remain subject of prospective studies96,97. Donor retention, recruitment strategies, 
and safety of stem cell donation in particular by the related donors of all ages remain 
subject of interest for future research. The Leiden University Medical Centre is one 
of the oldest HsCT centres in Europe, and the basis of Europdonor Foundation, the 
Dutch National stem Cell Donor Registry, providing the opportunity to perform 
long-time follow-up studies in unrelated and related, pediatric, and adult donors. 
such long-term effects of stem cell donation include also cognitive, emotional, 
and psychosocial factors. Course of Life questionnaires completed by our pediatric 
donor cohort will undergo final analysis in the near future, allowing more insights 
into the transition into adulthood after bone marrow donation in early childhood. 
Furthermore, we will report on pain management investigated in a prospective 
cohort of related and unrelated donors. The relation between stress and mobilization 
and the sense of Coherence are further subjects to be analysed in above mentioned 
donor cohorts. All donors included in our studies gave informed consent and the 
study was approved by the Ethical Review Board of the Leiden University Medical 
Centre. However, situations can occur where donors indirectly become a research 
subject (i.e. the donation is part of an experimental or research protocol). By donating 
stem cells, donors have proven to be altruistic and thus most likely would agree with 
their involvement in clinical research98. The WMDA requires additional approval for 
donation by a donor registry and informed consent of the donor99, which might cause 
a delay in transplantation. The procedures associated with experimental therapy (not 
considered standard of clinical care) also increased clinicians’ awareness to the fact 
that donors are individuals with legitimate rights100,101. It remains challenging to 
harmonize the interests of all parties involved102, in particular if multiple or prolonged 
donations are involved in the protocol. It is important to address the acceptability 
of exposing a donor to a research protocol for the benefit of the recipient, and give 
advice according to the international standards on human research103, also to prevent 
extensive delay, caused by an additional independent protocol review performed on 
behalf of a donor registry. The role of the unrelated donor might become less explicit 
in the future, but donation of stem cells by family donors will probably continue. It 
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is in the interest of all parties involved to find the best balance between patients’ 
needs and donors’ interests104 and to accomplish long-term safety for future donors.
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In dit proefschrift worden de ervaringen van stamceldonatie door onverwante 
en verwante donoren (minderjarigen en volwassenen) beschreven, alsmede de 
verschillende aspecten van de zorg voor de donor en het proces van het zoeken naar 
een (onverwante) donor. De veiligheid van de donor staat hierbij steeds centraal. In 
dit hoofdstuk worden de verschillende onderwerpen samengevat en in een breder 
perspectief besproken in het licht van huidige en toekomstige ontwikkelingen.
Samenvatting
De eerste succesvolle allogene transplantatie, dat wil zeggen met bloedvormende 
stamcellen afkomstig van een donor, werd in Europa uitgevoerd in 1968 in Leiden. 
sinds 1980 is het aantal indicaties voor hematopoietische stamceltransplantatie 
(HsCT) exponentieel toegenomen. Behalve voor de behandeling van hematologische 
maligniteiten, wordt de therapie met donorstamcellen ook toegepast bij erfelijke 
aangeboren afwijkingen, zoals afweerstoornissen (immuundeficiënties), niet 
kwaadaardige afwijkingen van het bloed (ernstige aplastische anemie, 
sikkelcelanemie, thalassaemie) en stofwisselingsziekten. Aanvankelijk werden de 
stamcellen (onder algehele anesthesie) geoogst uit beenmerg door middel van 
puncties in de bekkenrand of het borstbeen. Met de ontwikkeling van recombinante 
humane groeifactoren in de jaren ’90, werd het mogelijk om grote aantallen 
stamcellen te mobiliseren: na subcutane toediening van Granulocyte Colony 
stimulating Factor (G-CsF) verplaatsen de bloedstamcellen zich vanuit het beenmerg 
naar de bloedsomloop en kunnen als perifere bloedstamcellen (PBsC) met behulp 
van aferese worden geoogst. Een transplantaat met PBsC bevat meer stamcellen 
en bloedvormende voorlopercellen met als gevolg een sneller herstel van vooral 
granulocyten en trombocyten bij de patiënt. Hierdoor is er minder risico op infecties 
en ernstige bloedingen in eerste periode na transplantatie. Een transplantaat met 
PBsC heeft daarom vaak de voorkeur van de behandelend arts boven beenmerg. 
Navelstrengbloed is in de afgelopen jaren een belangrijke nieuwe bron geworden.
In de afgelopen decennia is HsCT voor veel aandoeningen de standaard 
behandeling geworden. De praktijk is echter dynamisch en continu onderhevig 
aan veranderingen. Wetenschappelijk onderzoek is gericht op methodes om de 
toxiciteit van de voorbehandeling voor de transplantatie (de zgn. conditionering) te 
minimaliseren en de kans op ernstige afstotingsreacties door de donorcellen (Graft 
versus Host Disease, GvHD) te beperken. Daarnaast wordt onderzocht op welke wijze 
gebruik kan worden gemaakt van het afweermechanisme van de donor. Toediening 
van immuuncellen van de donor kan een belangrijke rol spelen bij de behandeling 
van terugkeer van de oorspronkelijke ziekte of oncontroleerbare virale infecties na 
de transplantatie. De ontwikkelingen van deze nieuwe behandelmethodes kunnen 
gevolgen hebben voor wijze waarop het donatieproces verloopt en dus ook voor de 
donor.
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De zorg voor de anonieme stamceldonor wordt uitgevoerd door de 
stamceldonorbanken (Registries), en is vastgelegd in de standaarden van de World 
Marrow Donor Association (WMDA). Voor familiedonoren worden deze standaarden 
niet toegepast. Donatie is een vrije keuze, maar een familieband tussen de donor en de 
ontvanger kan de keuzevrijheid in gevaar brengen en zelfs leiden tot een gedwongen 
keuze. Professionals, betrokken bij de zorg voor familiedonoren, moeten gedurende 
het gehele proces streven naar een optimale balans tussen de belangen van zowel 
patiënt als donor. Gedurende de eerste Donor Outcome Workshop in 2009, een initiatief 
van de Late Effecten Working Party van de EBMT, was de zorg voor de familiedonor 
het belangrijkste onderwerp. Doel van de bijeenkomst was om overeenstemming 
te bereiken voor een wereldwijd gestandaardiseerd protocol voor het vastleggen 
van algemene donor data, ernstige bijwerkingen en incidenten van het proces van 
donatie en langetermijneffecten (hoofdstuk 3) De Ethics en Clinical Working Groups 
van de WMDA, die de belangen van de onverwante donoren behartigen zijn in 2010 
in overleg getreden met de European Group for Blood and Marrow Transplantation 
(EBMT), met als doel om de uitgangspunten en aanbevelingen voor de zorg van de 
familiedonor (werven, informeren, begeleiden en melden van ernstige bijwerkingen 
of incidenten) meer te harmoniseren (hoofdstuk 2). Dit was de eerste poging om 
internationaal aandacht te vragen voor de zorg voor familiedonoren. Een groot 
internationaal cohort van familiedonoren biedt mogelijkheden om specifiek voor 
deze groep de risico’s van stamceldonatie te inventariseren. Literatuur op dit gebied 
is schaars en bestaat uit observaties, gevalsbeschrijvingen of retrospectieve analyses. 
Prospectief en gerandomiseerd onderzoek is niet verricht. Causale verbanden in de 
gerapporteerde incidenten zijn hierdoor onmogelijk te bevestigen of ontkennen. De 
kosten voor meerjarige follow-up voor de familiedonor worden niet gedekt door de 
verzekering. Gebrek aan financiële middelen maakt het daarnaast onmogelijk om 
de effecten van het toedienen van G-CsF aan gezonde personen of de invloed van 
multipele donaties op lange termijn wetenschappelijk te onderzoeken. Wij hebben 
een retrospectieve studie verricht* in een cohort van 268 donoren die tussen 1996-
2006 PBsC hebben gedoneerd aan een familielid in het Leids Universitair Medisch 
Centrum. De studie concentreerde zich op de medische geschiktheid van de donor en 
op cardiovasculaire incidenten en maligniteiten gedurende de follow-up (hoofdstuk 
4). Bij gebrek aan criteria voor goed- of afkeuring van de familiedonor, werden de 
bevindingen van de medische keuring van de donoren vergeleken met de criteria 
voor onverwante donoren van de Nederlandse stamceldonorbank Europdonor en 
de Amerikaanse National Marrow Donor Program (NMDP). Op deze manier werd 
getracht achteraf vast te stellen of een familiedonor terecht of onterecht goedgekeurd 
was voor stamceldonatie. Ongeveer 15% van de donoren zou zijn afgekeurd als zij 
onverwante donor waren geweest. Kortetermijnbijwerkingen waren vergelijkbaar 
met die van in de literatuur bekende cohorten van onverwante stamceldonoren. 
* sanquin Blood supply study grant  PPOC 08-008
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In de langetermijnfollow-up werden negen maligniteiten en 14 cardiovasculaire 
incidenten gerapporteerd. In vergelijking met de Nederlandse populatie vielen deze 
aantallen binnen de normale grenzen voor leeftijd en geslacht.
De noodzaak voor registratie van ernstige bijwerkingen en incidenten (serious 
Events and Adverse Reactions - sEAR) werd voor het eerst duidelijk bij de introductie 
van toediening van G-CsF aan gezonde personen (hoofdstuk 5). Daarnaast werd 
door de WMDA ook al snel de patiëntveiligheid betrokken in dit systeem door het 
vastleggen van incidenten met producten (serious Product Events and Adverse 
Reactions - sPEAR). Bij de registratie van sPEAR wordt naast het directe risico 
voor de patiënt ook melding gemaakt van schade aan een product ten gevolge 
van (incorrect of onveilig) transport. Indien een gemelde s(P)EAR dermate ernstig 
is dat onmiddellijke rapportage gewenst is kan door middel van een ‘Rapid Alert’ 
een bericht verspreid worden naar stamceldonorbanken en transplantatiecentra 
wereldwijd. Anonieme melding van s(P)EAR’s is verplicht voor stamceldonorbanken 
die WMDA geaccrediteerd zijn, maar ook niet geaccrediteerde stamceldonorbanken 
worden aangemoedigd om incidenten te melden.
Voor kinderen met beenmergziekten is het niet ongebruikelijk om, als geen 
acceptabele donor of navelstrengbloed eenheid kan worden gevonden, een van de 
ouders stamcellen te laten doneren (hoofdstuk 6). De ervaringen van ouders die 
stamcellen doneerden aan hun kind waren nog niet eerder gerapporteerd. Uit diepte 
interviews met 13 ouders kwamen belangrijke thema’s naar voren: ‘Hoop en Vrees’, 
‘Behoefte aan Informatie’, ‘Alles doen voor je Kind’. Deze thema’s werden gedurende 
het gehele proces (besluitvorming – donatie – reflectie) herkend. De donorrol was 
voor de meeste ouders van ondergeschikt belang; het feit dat zij voelden geen 
andere keus te hebben dan stamcellen te doneren werd in veel interviews verwoord. 
Een voorstel voor een Europese studie naar langetermijneffecten bij ouders die 
stamcellen aan hun kind hebben gedoneerd is goedgekeurd door de EBMT. Naast 
ouders en volwassen familieleden kunnen kinderen als donor optreden voor een 
zieke broer of zus. Wij hebben een retrospectieve studie gedaan naar 210 donoren 
die tussen 1968 en 2002 beenmerg hebben gedoneerd in het Leids Universitair 
Medisch Centrum (hoofdstuk 7). De leeftijd van de donoren varieerde van 0,5 – 12 
jaar op het moment van donatie. Gemiddeld 16 jaar na donatie werden de donoren 
uitgenodigd om deel te nemen aan een langetermijnfollow-up studie. Gezien het 
observationele karakter van de studie kon geen causaal verband worden vastgesteld 
tussen gemelde medische problemen en de donatieprocedure. Twee donoren 
hebben ernstige psychosociale problemen gemeld. Er kon worden geconcludeerd 
dat beenmergdonatie op jonge leeftijd niet leidt tot significante lichamelijke of 
psychische problemen op de lange termijn. Ook in deze studie viel het ontbreken van 
vastomlijnde criteria voor medisch goed- of afkeuren van de donor op. Inmiddels is 
aanbevolen (JACIE standards 5th Edition) om de medische keuring van een donor 
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door een onafhankelijke arts te laten verrichten. Bij twijfel over de geschiktheid 
van de potentiele donor of bij een (historisch) onderliggend lijden zou aanvullend 
advies moeten worden gevraagd van een specialist. Op deze wijze kan worden 
vastgesteld of het risico van algehele anesthesie en beenmergdonatie acceptabel 
zijn. In bovengenoemde studie echter, werd geen van de kinderen afgekeurd als 
donor, hoewel een aantal van hen een ernstige medische voorgeschiedenis had, wat 
in een aantal gevallen leidde tot complicaties tijdens het proces van donatie. Follow-
up van de kinddonoren was beperkt gedocumenteerd. Van 107 donoren werden 
de beenmerguitstrijkjes opnieuw beoordeeld en vergeleken met het rapport. Bijna 
de helft van de donoren (46%) had lage ijzerreserves en bij 15% was ijzerreserve 
afwezig; documentatie over suppletie van ijzer na de beenmergdonatie ontbrak. Bij 
62% van de donoren werd meer beenmerg geoogst dan 15 ml/kg lichaamsgewicht, 
en meer dan de helft van deze kinderen ontving een transfusie met donorbloed. 
Posttransfusie screening voor allo-antilichamen werd niet verricht. De resultaten van 
de studie onderstrepen de noodzaak voor (inter)nationale richtlijnen voor de zorg en 
begeleiding van kinddonoren. 
Het zoeken (de search) naar een onverwante donor vereist naast expertise op 
het gebied van weefseltypering (humaan leukocyten antigeen – HLA), ook kennis 
van internationale wetten en regelgeving rondom stamceldonatie en transport. 
Vertraging gedurende het proces, vooral wanneer een donor is gekozen en gevraagd 
om stamcellen te doneren, is ongewenst (hoofdstuk 8). In een retrospectieve studie 
werd onderzocht wat de toegevoegde waarde van een back-up donor was. Ongeveer 
10% van de geselecteerde donoren werd afgekeurd of was niet beschikbaar op het 
moment dat hij/zij werd gevraagd stamcellen te doneren. Het simultaan zoeken 
naar een back-up donor gedurende de initiële donorsearch is een effectieve manier 
gebleken om vertraging te voorkomen voor alle partijen die betrokken zijn bij de 
transplantatie. Het is van belang dat artsen, wanneer zij hun patiënten informeren 
dat er een donor is gevonden, er ook op wijzen dat een donor medisch kan worden 
afgekeurd. Met betrekking tot de oorzaken voor het afkeuren van donoren werden 
stamceldonorbanken geadviseerd om al vroeg in het stadium van de procedure tot 
de donatie vast te stellen of een donor mogelijk ongeschikt is en kans heeft om 
afgekeurd te worden. Indien er sprake is van bijvoorbeeld ernstig overgewicht, een 
medische voorgeschiedenis of zwangerschapswens kan aanvullend onderzoek soms 
noodzakelijk zijn om de geschiktheid of beschikbaarheid van de donor vast te stellen.
In de afgelopen jaren is het zoeken naar een onverwante donor of 
navelstrengbloedeenheid steeds ingewikkelder geworden (hoofdstuk 9). De 
ontdekking van nieuwe allelen van het HLA-systeem leidt tot nieuwe potentiele 
combinaties voor fenotypes en vereist voortdurende scholing van search 
coördinatoren. Klinische ontwikkelingen, zoals het selecteren en toedienen van 
twee navelstrengbloedeenheden aan één patiënt, vereisen specifieke kennis en 
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vaardigheden met betrekking tot matchalgoritmes. Een langere tijd tussen diagnose 
en transplantatie kan de uitkomst van transplantatie negatief beïnvloeden. Efficiëntie 
om de lengte van het zoekproces naar een onverwante donor of navelstrengbloed 
eenheid tot een minimum beperken is van belang. Voor patiënten met een noordwest 
Europese (NWE) achtergrond is het aantal potentiele donoren in het wereldwijde 
bestand Bone Marrow Donoren Worldwide (BMDW) in het laatste decennium 
bijna verdubbeld. Voor patiënten met een niet-noordwest Europese (non-NWE) 
achtergrond is het aantal potentiele donoren sinds het begin van deze eeuw stabiel 
laag gebleven. Daar komt bij dat non-NWE donoren vaker niet beschikbaar zijn. 
Uit een analyse van alle Nederlandse onverwante donor searches van de afgelopen 
12 jaar blijkt dat toch een aanzienlijk aantal non-NWE patiënten transplantatie 
bereikt. Dit is te danken aan het feit dat zij vaker met navelstrengbloed kunnen 
worden getransplanteerd (waarvoor minder stringente matchcriteria kunnen worden 
toegepast).
Ethische aspecten, de ontwikkeling van lokale, nationale en internationale 
richtlijnen en regelgeving op het gebied van gezondheidszorg en stamceldonatie zijn 
in de afgelopen jaren een steeds voornamere rol gaan spelen, en trekken onverwacht 
soms ook de publieke aandacht (hoofdstuk 10). Het toestaan van een financiële 
vergoeding voor stamceldonatie was in 2009 de reden voor een kort geding, dat 
in de Verenigde staten van Amerika werd aangespannen tegen de National Organ 
Transplantation Act. De aanklager betoogde dat de bij wet verboden betaling op 
stamceldonatie nieuwe potentiele donoren zou weerhouden zich te registreren, ten 
gevolge waarvan patiënten minder kans zouden hebben om een passende donor te 
vinden. De Wereld Gezondheidsorganisatie (WHO) heeft zich op het standpunt gesteld 
dat cellen en weefsels van het menselijk lichaam geen economische waarde hebben 
en derhalve niet kunnen en mogen worden beschouwd als een handelsproduct. Ook 
in de grondbeginselen van de standaarden van de WMDA is vastgelegd dat voor een 
altruïstische stamceldonatie niet betaald mag worden. Een WMDA Taskforce heeft in 
een reactie op deze rechtszaak uitvoerig gemotiveerd waarom stamceldonatie ook in 
de toekomst vrijwillig en onbetaald moet blijven. stamceldonatie is een humanitaire 
daad, die niet in geld is uit te drukken en die voor een patiënt letterlijk een ‘Gift 
of Life’ kan betekenen. Met het bieden van geld voor donatie van stamcellen of 
andere weefsels of organen om een donor te verleiden tot donatie worden situaties 
gecreëerd, waarbij beslissingen soms niet geheel onafhankelijk en vrijwillig kunnen 
worden genomen. Intensieve internationale samenwerking heeft het mogelijk 
gemaakt om patiënten wereldwijd te voorzien van stamcelproducten. De introductie 
van een financiële vergoeding voor stamceldonatie zou een ernstige bedreiging 
kunnen vormen voor de continuïteit van deze internationale uitwisseling en daarmee 
de kans op genezing van patiënten.
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Discussie en toekomstperspectieven
Allogene hematopoietische stamceltransplantatie is de standaard behandeling 
voor een groeiend aantal aandoeningen van het bloed- of de bloedvormende 
organen1. De ontwikkeling van minder toxische voorbereidingsschema’s (ook wel 
non-myeloablatieve conditionering of Reduced Intensity Conditionering genoemd), 
heeft ertoe geleid dat de therapie ook veilig kan worden toegepast bij oudere 
patiënten, die zo een kans op genezing kan worden geboden. Met het stijgen van 
de gemiddelde leeftijd van de patiënt, neemt ook de gemiddelde leeftijd van de 
familiedonor toe. strikter hanteren van keuringscriteria heeft tot direct gevolg dat 
meer familiedonoren worden afgekeurd voor stamceldonatie, waardoor er meer 
vraag is naar stamcellen van onverwante donoren en navelstrengbloedeenheden. Op 
dit moment wordt in meer dan de helft van alle allogene stamceltransplantaties een 
transplantaat van een onverwante donor of navelstrengbloed gebruikt2. Dagelijks 
passeren ongeveer 33 stamcelproducten een internationale grens3. In de afgelopen 
10 jaar (2004-2013) is het aantal geregistreerde onverwante donoren jaarlijks met 
gemiddeld 10% toegenomen (tussen 2011-2013 is dit percentage zelfs iets hoger 
door de toetreding van de Braziliaanse en Chinese stamceldonorbanken tot het 
wereldwijde bestand). Het wereldwijde bestand van navelstrengbloedeenheden is 
gemiddeld met 14,6% per jaar gegroeid4,5. Hoewel ook de toename van het aantal 
hematopoietische stamceltransplantaties (HsCT) wereldwijd aanzienlijk is6, wordt 
aangenomen dat de therapie door verschillende oorzaken nog onvoldoende vaak 
wordt toegepast7. Het is daarom belangrijk om te onderzoeken wat er nodig is om 
deze potentieel curatieve therapie globaal en maximaal te kunnen benutten.
Kenmerken van het optimale donorbestand: jong, man, divers en 
beschikbaar
De eisen die transplantatie centra (TC) stellen aan de ‘ideale donor’ zijn aan 
veranderingen onderhevig. Er is vaak voorkeur voor de jongere donor; stamcellen 
van oudere donoren leiden tot een minder goede ziektevrije overleving van patiënten 
met een hematologische maligniteit8,9. Er is zelfs gesuggereerd om de voorkeur te 
geven aan een jongere onverwante donor boven een oudere familiedonor10. Door de 
tijd heen is er wisselend voorkeur geweest voor een donor met hetzelfde geslacht 
als de patiënt, in het bijzonder voor een mannelijke patiënt. In een recente studie 
bij volwassen mannen met acute leukemie werd gekeken naar het verschil tussen 
transplantatie met een zus of met een mannelijke onverwante donor. Er kon geen 
verschil in ziektevrije overleving worden aangetoond11,12. Het risico op acute Graft 
versus Host Disease (GvHD, omgekeerde afstoting) was echter significant hoger in 
de groep die met de mannelijke onverwante donor was getransplanteerd, waaruit 
de voorkeur voor stamcellen van de vrouwelijke familie donor werd geconcludeerd13. 
Het aantal toegediende stamcellen in een transplantaat is steeds als een belangrijke 
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factor aangemerkt voor transplantatieuitkomst14,15. Dit kan een verklaring zijn 
voor de voorkeur voor mannelijke donoren, van wie door een relatief groter 
lichaamsoppervlak gemiddeld meer stamcellen kunnen worden geoogst16. Echter, 
ook bij mannen heeft een hogere leeftijd een negatief effect op stamcel mobilisatie17. 
In het jaarverslag 2012/2013 van de Canadese stamceldonorbank OneMatch wordt 
de voorkeur van TC voor jonge mannelijke donoren als opvallend gemeld: 75% van 
de geleverde stamcelproducten was afkomstig van mannelijke donoren jonger dan 
36 jaar18. Ook in Nederland wordt deze trend gezien: ruim 70% van de aanvragen 
voor een bloedmonster voor verificatie van de HLA typering ter voorbereiding 
voor transplantatie is voor een mannelijke donor. Het wereldwijde donorbestand 
is weliswaar aanzienlijk toegenomen in de afgelopen jaren, ook de leeftijd van de 
geregistreerde donoren is gemiddeld hoger geworden. Een gevolg hiervan is dat 
donoren vaker op medische grond niet beschikbaar zijn voor stamceldonatie en dus 
eigenlijk onbruikbaar19. Wereldwijd is 19% van de geregistreerde donoren man en 
jonger dan 36 jaar en slechts 10% van alle donoren (ongeacht geslacht) is jonger dan 
26 jaar3. Uitgaande van leeftijd en geslacht voldoet het wereldwijde bestand op dit 
moment niet aan de criteria voor het optimale donorbestand. stamceldonorbanken 
staan voor de uitdaging om te zoeken naar kosteneffectieve oplossingen. Het 
verlagen van de leeftijd voor registratie zou een oplossing kunnen zijn. In Groot 
Brittannië (registratie vanaf 16 jaar) en Canada (registratie vanaf 17 jaar) is dit 
in 2013 geïntroduceerd. De Canadese stamceldonorbank richt zich vooral op het 
werven van mannelijke donoren jonger dan 35 jaar20. Het rekruteren van jongere 
donoren heeft echter ook een keerzijde: stamceldonorbanken zien zich gedwongen 
om hun voorschriften en werkwijzen aan te passen. Tijdens de WMDA Fall Meeting 
in 2013 werd gerapporteerd dat onvoldoende ‘levenservaring’ en de onbekendheid 
met bijvoorbeeld procedures voor geïnformeerde toestemming (informed consent) 
bij jonge donoren, aanpak op maat bij (medische) begeleiding en dus extra training 
van de staf die hiermee is belast vereisen21,22. Het toedienen van G-CsF aan donoren 
jonger dan 18 jaar is niet in alle landen toegestaan; in Nederland is bijvoorbeeld 
geen consensus over de toediening van G-CsF aan gezonde personen jonger dan 18 
jaar. 
Hoewel het wereldwijde bestand Bone Marrow Donoren Worldwide (BMDW) 
gestaag groeit, is het merendeel van de donoren en navelstrengbloedeenheden 
geregistreerd in noordwest Europa (NWE) en noord-Amerika23,24. Dit vormt een 
beperkende factor voor patiënten met een niet-noordwest Europese (niet-NWE) 
achtergrond, voor wie een donor moet worden gevonden. Naast het werven van 
donoren met een niet-NWE achtergrond zijn meer strategieën nodig om de HLA-
diversiteit van de donorpool met succes te kunnen vergroten25. Naast het verwerven 
van nieuwe donoren is het minstens zo belangrijk om actief te streven naar het 
behoud van beschikbare donoren. In de Verenigde staten wordt al sinds eind jaren 
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’90 onderzoek gedaan naar de redenen waarom donoren niet langer beschikbaar 
zijn26. sinds die tijd is in de Verenigde staten het aantal donoren dat tijdens een eerste 
contact niet beschikbaar is toegenomen tot bijna de helft van het totale bestand27,28 
en dit aantal loopt nog steeds op29. Ambivalentie ten aanzien van donatie wordt 
daarbij genoemd als een belangrijke oorzaak voor het verminderd of niet langer 
beschikbaar willen zijn30. Uit onderzoek blijkt dat kort na de registratie meer dan een 
derde van nieuwe donoren aangeeft twijfels te hebben over stamceldonatie en niet 
weet of hij zal doneren indien gevraagd31. specifieke kenmerken zoals (vrouwelijk) 
geslacht, lengte van de periode dat een donor geregistreerd staat en etnische 
achtergrond zijn cumulatieve ‘risico factoren’ voor verminderde beschikbaarheid32. 
Het optimaliseren van het wereldwijde donorbestand kan bijdragen aan de wens 
om een groter aantal patiënten te kunnen transplanteren. Rekruteren onder 
bloeddonoren geeft bijvoorbeeld meer zekerheid over beschikbaarheid op termijn 
en (medische) geschiktheid van de donor. Voor nieuwe niet-bloeddonoren zouden 
wervingsmethoden kunnen worden aangepast, waarbij gebruik wordt gemaakt van 
deze wetenschap en andere parameters31.
Nederlandse patiënten met een niet-NWE achtergrond hebben nu een kans van 
70% om getransplanteerd te worden. Hun kansen om een acceptabele onverwante 
donor te vinden onder de bijna 25 miljoen geregistreerde donoren is echter aanzienlijk 
minder, zowel in kwaliteit als in kwantiteit, dan voor patiënten met een NWE 
achtergrond en is eigenlijk in de afgelopen 10 jaren niet verbeterd (dit proefschrift). 
Daar komt nog bij dat de beschikbaarheid van niet-NWE donoren in beginsel al lager 
is dan van NWE donoren, wat de kans op het vinden van een optimale donor eens 
te meer verkleint25,27,31-36. 
Gragert en collega’s hebben recent een theoretisch model gepresenteerd waarmee 
zij de kans op het vinden van een goed passende donor of navelstrengbloedeenheid 
voor blanke Europeanen en andere bevolkingsgroepen in de Verenigde staten 
hebben berekend37. In dit op populatiegenetica gebaseerde model, wordt gebruik 
gemaakt van de beschikbare donors en navelstrengbloedeenheden van de National 
Marrow Donor Program (ongeveer 50% van het wereldwijde bestand), rekening 
houdend met de beschikbaarheid van donoren. Geconcludeerd wordt dat voor meer 
dan 95% van de patiënten met een (blanke) Europese of Afrikaanse achtergrond 
een onverwante donor of navelstrengbloedeenheid kan worden gevonden. In 
onze retrospectieve analyse werd echter voor 81% van de niet-NWE patiënten 
een acceptabele donor gevonden, waarbij vaker een mismatch moest worden 
geaccepteerd. De aanname van Gragert cs. dat de donorpopulatie een reflectie is 
van de patiëntenpopulatie37 heeft mogelijk tot een overschatting van de kansen 
op een acceptabele donor of navelstrengbloedeenheid geleid. Daarbij is niet in 
ieder transplantatieprotocol een mismatched donor of navelstrengbloedeenheid 
een acceptabele stamcelbron. Patiënten in onze studie waarvoor geen acceptabele 
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donor kon worden gevonden hadden vaak een gemengde etnische achtergrond. 
Donoren met een gemengde etnische achtergrond zijn waarschijnlijk het minst 
vertegenwoordigd in het wereldwijde bestand. Het is daarom van groot belang dat 
beschikbaarheid van donoren, vooral van jonge mannelijke donoren (aangezien zij 
de grootste kans hebben om gevraagd te worden), en donoren uit de niet-NWE 
groep als aandachtspunt wordt benadrukt tijdens donorwervingscampagnes31,32. Dit 
betekent dat de stamceldonorbanken niet alleen moeten kijken naar de omvang van 
hun bestand, maar ook bestaande strategieën voor donorwerving moeten herzien 
om een betere beschikbaarheid van (nieuwe) donoren te bewerkstelligen. Het niet-
beschikbaar zijn van vooral de nieuwe donoren na kostbare wervingsacties kan niet 
langer worden gerechtvaardigd29,38. Via social media, folders en nieuwsbrieven kan 
onder de aandacht worden gebracht dat 10% van de donoren onvindbaar is op het 
moment dat er een verzoek is een bloedmonster af te staan, met mogelijke negatieve 
gevolgen voor patiënten voor wie een donor wordt gezocht. Een oproep om bij 
wijziging van adres ook altijd de stamceldonorbank te informeren kan voorkomen 
dat het zoeken naar een donor voor de patiënt geen ongewenste en onnodige 
vertraging oploopt.
S, M, L, XL - donor registries
Op dit moment zijn er enkele zeer grote stamceldonorbanken (met meer dan 1 
miljoen geregistreerde donoren) en een meerderheid van kleine (<20.000 donoren), 
middelgrote (20.000-100.000 donoren) en grote stamceldonorbanken (>100.000 
donoren)39. Het overgrote deel (>80%) van de onverwante stamcelproducten wordt 
jaarlijks geleverd door vijf van de grotere stamceldonorbanken, waarvan twee zeer 
grote (samen 67% van alle producten). Dit maakt duidelijk hoe kwetsbaar de landen 
met de kleine en middelgrote stamceldonorbanken zijn. zij zijn voor hun patiënten 
afhankelijk geworden van stamcelproducten die door buitenlandse donoren worden 
gedoneerd. Het is onduidelijk waarom ook de meerderheid van de aanvragen aan 
de zeer grote stamceldonorbanken zijn/worden gericht, aangezien het aannemelijk 
is dat donoren met een ‘gangbare/frequente HLA typering’ ook in de nationale 
stamceldonorbank te vinden moeten zijn. Men kan zich afvragen of nationale 
stamceldonorbanken niet in staat zouden moeten zijn om een bepaald percentage 
van de eigen patiënten van nationale stamcelproducten te voorzien. Mede door de 
moeilijke economische tijden en de toenemende kwaliteitseisen in de afgelopen 
jaren hebben de kleine en middelgrote stamceldonorbanken het zwaar en is het 
voor nieuwe stamceldonorbanken nagenoeg onmogelijk om zonder financiële steun 
te starten. Bij het vaststellen van de optimale omvang en samenstelling van het 
wereldwijde donorbestand, moet de balans worden gevonden tussen concurrerende 
belangen27. Nieuwe stamceldonorbanken, in het bijzonder in ontwikkelende landen, 
zijn van belang als het gaat om het toevoegen van nieuwe unieke HLA-fenotypes 
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aan het wereldwijde bestand. In de afgelopen jaren had gemiddeld één op de 15 
nieuwe donoren een nieuw uniek HLA-fenotype. De bijdrage van bijvoorbeeld de 
Braziliaanse stamceldonorbank die in 2011 ging participeren in BMDW maakt 
duidelijk wat de toegevoegde waarde van een nieuwe stamceldonorbank is: in dat 
jaar had één op de 10 nieuwe donoren een uniek HLA-fenotype40. Opvallend is dat 
navelstrengbloedbanken een relatief groter aandeel in de nieuwe HLA fenotypes 
hebben in vergelijking tot donoren in datzelfde land. Navelstrengbloedbanken 
hebben kennelijk meer succes bij het rekruteren onder niet-NWE groepen40. Een 
deel van de nieuwe fenotypes in navelstrengbloedeenheden is ontstaan door een 
gemengde etnische achtergrond. Dit is van groot belang voor de groep patiënten 
waarvoor anders geen acceptabele donor of navelstrengbloedeenheid zou kunnen 
worden gevonden.
Jaarlijks worden stamcellen gedoneerd door 0,1% van alle geregistreerde 
donoren en worden ongeveer 0,8% van de navelstrengbloedeenheden gebruikt voor 
transplantatie3,41. Volledigheid en uitgebreidheid van HLA typering van de donor is 
rechtstreeks van invloed op de kans om voor donatie te worden gevraagd42. Een 
verklaring voor het relatief intensievere gebruik van navelstrengbloedeenheden (er 
wordt naar verhouding 10x zo veel van gebruikt) is mogelijk de grotere diversiteit 
en potentieel snellere beschikbaarheid. Daarbij komt de minder stringente noodzaak 
tot gelijkheid voor de HLA groepen van navelstrengbloed en patiënt als mogelijke 
verklaring voor dit verschil. De verwachte voordelen van navelstrengbloed als 
stamcelbron voor niet-NWE patiënten onderschrijft het belang van het opslaan 
van navelstrengbloedeenheden van hoge kwaliteit, waardoor het tekort aan 
donoren met een niet-NWE achtergrond in het wereldwijde bestand kan worden 
gecompenseerd43. Het is van belang om dit gegeven en het feit dat minder dan 1% 
van de geregistreerde donoren jaarlijks daadwerkelijk stamcellen doneert, kritisch te 
beschouwen voordat ‘meer donors met dezelfde HLA’ worden toegevoegd aan het 
internationale donorbestand43.
Met nieuwe laboratoriumtechnieken zoals ‘Next Generation sequencing (NGs) 
zullen de kosten van hoge resolutie HLA-typering aanzienlijk worden verminderd 
en kunnen ook andere gegevens (bloedgroep, CMV, KIR, etc.) eenvoudig worden 
bepaald, waarmee kwalitatief hoogwaardige donoren kunnen worden toegevoegd 
aan het donorbestand. De Group of European Medium sized Registries is opgericht, 
met als doel om gezamenlijk oplossingen te zoeken voor deze uitdagingen44.
Bereiken van transplantatie – klinische en niet-klinische factoren
In 2001 werd slechts een-derde van alle patiënten, die waren aangemeld voor 
stamceltransplantatie, ook daadwerkelijk getransplanteerd45. Ruim 10 jaar 
later meldt het WMDA jaarverslag dat 45% van alle patiënten voor wie een 
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onverwante donorsearch is gestart wordt getransplanteerd2. Dit is waarschijnlijk 
een onderschatting van het totaal aantal patiënten dat in aanmerking komt voor 
transplantatie. Een recente prospectieve studie rapporteerde dat een onverwante 
donorsearch werd gestart voor 51% van alle patiënten zonder familie donor, zonder 
een duidelijke verklaring wat er met de overige 49% gebeurde46. Ondanks een 
geslaagde donorsearch, gaan transplantaties niet altijd door. De meest voorkomende 
oorzaak om een transplantatie te annuleren is klinische verslechtering (recidief), 
vooral bij patiënten met hoog risico leukemie7,46,47. Tijd is een cruciale factor: bij 
diagnose verrichten van HLA typering en de patiënt op tijd aanmelden voor het 
zoeken naar een donor zijn belangrijk46. Maar ook de tijd die nodig is om een donor 
te zoeken: die kan (en moet in sommige gevallen) teruggedrongen worden48. De 
belangrijkste niet-klinische factor voor niet-NWE patiënten voor het niet bereiken van 
transplantatie is zonder twijfel het gebrek aan donoren. Wij hebben voor Nederlandse 
patiënten aangetoond dat een efficiënt uitgevoerde onverwante donorsearch leidt 
tot een hoger percentage getransplanteerde patiënten en het terugdringen van 
het aantal annuleringen ten gevolge van klinische achteruitgang van de patiënt 
tot ongeveer 10% (dit proefschrift). Om een onverwante donor search zo efficiënt 
mogelijk uit te voeren zijn inspanningen van alle partijen die hierbij betrokken zijn 
en optimale samenwerking met TCs vereist. stamceldonorbanken hebben methodes 
en hulpmiddelen ontwikkeld om de search te verkorten49-53. Het delen van informatie 
en inzichten tussen stamceldonorbanken en TCs kan een belangrijke rol spelen in het 
verbeteren van transplantatiecijfers.
Veiligheid van donoren: de wereldwijde aanpak
Veiligheid van stamceldonoren betreft vooral de medische geschiktheid van de 
donor voor de donatieprocedure. Of de donor een kind of volwassene is, verwant of 
onverwant, er mag niet worden voorbijgegaan aan de belangen van de donor – dat 
is de (ethische) plicht van de zorgverlener. De behandeling met een medicament of 
het onder algehele anesthesie brengen zijn niet in het fysieke belang van de donor 
en vereisen verantwoordelijkheid van de zorgverlener en een attitude waarbij de 
veiligheid van de donor op de eerste plaats komt54. Bij de introductie van het gebruik 
van Granulocyte Colony stimulating Factor (G-CsF) in gezonde personen werd het 
belang van de veiligheid onderkend, in het bijzonder op lange termijn. In een recente 
studie zijn de ernstige bijwerkingen (severe Adverse Events, sAE) op korte en langere 
termijn bij de verschillende vormen van donatie (BM en PBsC) geanalyseerd55. 
Opvallend was dat de bevinding dat het risico op een sAE drie maal hoger is in 
beenmergdonoren. Van belang is de conclusie dat voor een onverwante donor op de 
lange termijn geen verhoogd risico op het ontwikkelen van trombose, een maligniteit 
of auto-immuunziekte is gevonden55. Het is onduidelijk of de bevindingen ook gelden 
voor de verwante donorpopulatie; fysieke gezondheid van onverwante donoren is 
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waarschijnlijk beter dan van familiedonoren.
Voor patiënten is leeftijd niet langer een contra-indicatie voor HsCT. zoals eerder 
opgemerkt hebben oudere patiënten ook oudere broers/zussen. En hoewel leeftijd 
niet noodzakelijkerwijs een indicatie is voor lichamelijke conditie47, hebben ouderen 
vaker co-morbiditeit of een onderliggend lijden en dus vaker reden om niet geschikt 
voor stamceldonatie te worden verklaard (dit proefschrift). Echter, co-morbiditeit 
wordt voor familiedonoren vaker geaccepteerd, simpelweg omdat ‘familiedonoren 
bereid zijn om een hoger risico te aanvaarden’56. Lang werd door medische 
beroepsgroep aangenomen dat familieleden van nature gemotiveerd zijn om het 
leven van een dierbare te redden57. Het zou het altruïstische karakter en het principe 
van ‘goed doen’ als aspect van de menselijke aard benadrukken, om te handelen in 
het belang van anderen58. Indien een familiedonor kiest om te doneren vanuit de 
liefde voor een familielid, heeft vanuit het perspectief van Kant zijn daad geen morele 
waarde, omdat er geen sprake is van een verplichting58. Het is echter onduidelijk 
wat het gevolg is van de eerder genoemde aanname van traditioneel altruïstisch 
denken; kan dit betekenen dat een familielid zich ‘verplicht’ voelt om te doneren, 
en hem weerhouden van de mogelijkheid om een vrije keuze te maken59. Betekent 
dit wellicht dat het ethisch principe van autonomie, dat het recht op een vrije keuze 
onderschrijft, met voeten wordt getreden? Indien het principe van autonomie wordt 
genegeerd dan wordt een persoon gebruikt als middel om een doel te bereiken, 
zonder daarbij rekening te houden met de belangen van die persoon58. Vanuit die 
optiek zou de aanname uitdrukking kunnen geven aan het nuttigheidsbeginsel, 
zoals dat is geformuleerd door Bentham: als kan worden aangenomen dat de kans 
op het slagen van een stamceltransplantatie redelijkerwijs groter is dan de kans op 
het ondervinden van enige schade door de familiedonor, dan is het de plicht van de 
donor om te doneren58. De situatie wordt gecompliceerd indien de donor een kind is 
en nog niet kan instemmen of toestemmen met donatie. Toestemming bij volmacht, 
door de ouders of wettelijk vertegenwoordiger kan dan betekenen dat het kind als 
middel wordt gebruikt om het doel, genezing van een broertje of zusje, te bereiken. 
Dit is niet in overeenstemming met het principe van Kant’s tweede formulering van 
de categorische imperatief: de actie wordt beschouwd als onacceptabel omdat de 
integriteit en waardigheid van het individu (de kinddonor) worden aangetast60. 
In het kader van stamceldonatie door kinderen heeft de American Academy of 
Pediatrics (AAP) een aantal ethische aspecten beschreven en criteria gedefinieerd 
om het gebruik van kinderen als stamceldonor te rechtvaardigen61. Hoewel de AAP 
adviseert te streven naar een protocol voor (wettelijke of ethische) goedkeuring 
voorafgaand aan de donatie, blijft het de vraag of de belangen van de kinddonor 
hiermee voldoende worden beschermd62. Er is een voorstel gedaan om het protocol 
aan te passen, waarbij meer aandacht aan de rechten, het besef en de toestemming 
van het kind wordt gegeven62. Het oogsten van stamcellen is een medische ingreep 
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met potentiele risico’s en aantasting van de integriteit van het lichaam van de 
donor. Het argument van ‘het eigen belang’ blijft daarbij omstreden, aangezien de 
uitkomst van de transplantatie en dus de meerwaarde voor de donor niet vooraf kan 
worden voorspeld63. Het debat over kwaliteit van leven en medische emancipatie 
werd ook bij het publiek actueel door de publicatie van ‘My sister’s Keeper’ (‘De 
Tweede Dochter’)64, waarin een 13-jaar oud meisje leeft in de wetenschap dat zij 
is verwekt om het leven van haar zusje, dat leidt aan leukemie, te redden. zij is 
letterlijk de ‘donor bij volmacht’65, en gaat, na meerdere stamceldonaties en voor 
zij besluit een nier te doneren aan haar zusje, op zoek naar het recht op medische 
emancipatie64. Door het verhaal wordt het duidelijk dat het principe van autonomie 
geen waarde heeft als voorbij wordt gegaan aan de beslissingsbevoegdheid van 
de donor, ook als dat een kind is. Op de beleidsnota van de AAP na, bestaan er 
geen strikte regelgeving of richtlijnen voor de medische geschiktheid, behandeling 
en follow-up voor kinderen die stamcellen doneren. Relatief kleine aanpassingen in 
lokale praktijkvoering kunnen al een groot verschil betekenen voor kinddonoren. 
Het terugbrengen van het maximum volume van te oogsten beenmerg bijvoorbeeld, 
kan voorkomen dat een kinddonor een bloedtransfusie nodig heeft (dit proefschrift). 
Daar komt bij dat uitkomst van transplantatie bij kinderen met hoog risico leukemie 
in de afgelopen jaren, aanzienlijk is verbeterd ongeacht de bron van stamcellen66. In 
een gestructureerd proces van besluitvorming zou kunnen worden overwogen om 
gebruik te maken van een alternatieve stamcelbron, zoals een onverwante donor of 
navelstrengbloedeenheid (indien de tijd dat toelaat). 
De mening dat de medische geschiktheid van de (familie) stamceldonor in het 
belang is van alle betrokken partijen, wordt ook internationaal gedragen67. Dit is 
bevestigd door de oprichting van de EBMT Donor Outcome Committee in 2012 
en vanaf de FACT/JACIE standards versie 568 is de zorg voor de donor expliciet 
benoemd. Dientengevolge zijn initiatieven ontplooid om zorg voor de familiedonor 
strikter te reguleren en implementeren69,70. Nut en noodzaak van goede zorg 
voor stamceldonoren inclusief langetermijnfollow-up is ook door de Wereld 
GezondheidsOrganisatie (WHO) erkend71. Opmerkelijk is dat een vergelijkbare 
discussie wordt gevoerd voor het welzijn van levende nierdonoren; financiële 
steun van de overheid wordt daarbij als essentieel beschouwd voor het opzetten 
van nationale systemen voor levenslange follow-up72,73. Het Worldwide Network 
for Blood and Marrow Transplantation (WBMT) is opgericht om de samenwerking 
tussen bestaande organisaties op het gebied van bloed- en stamceldonatie te 
stroomlijnen en stamceltransplantatie en -donatie wereldwijd te bevorderen74. In 
Donor Outcome Workshops is internationale consensus bereikt over criteria voor 
medische geschiktheid, waarbij tijdens de laatste bijeenkomst vooral het opstellen 
van richtlijnen met internationale consensus van stamceldonatie op oudere of jongere 
leeftijd werden besproken (Wenen, 2013). De ontwikkeling van een Europese Master 
220
Focus on the donor
in Donor Health Care, een Nederlands initiatief met steun van de Europese Unie, is 
een ander voorbeeld waaruit duidelijk wordt dat de zorg voor orgaan-, weefsel- en 
stamceldonoren een professie is die ook internationaal serieus wordt genomen. 
Op het gebied van ernstige incidenten en bijwerkingen heeft de WMDA een 
rapportagesysteem. Het eerdergenoemde s(P)EAR waarschuwingssysteem geeft een 
goede indicatie van ernstige complicaties bij onverwante donoren/producten. Om 
de ernstige bijwerkingen bij familiedonoren te registreren bestaat geen systeem. 
Om meer inzicht te krijgen in de familiedonoren is het van belang om ook voor deze 
groep de ernstige bijwerkingen en incidenten te rapporteren75. Het opzetten van 
een wereldwijd systeem waarin ernstige bijwerkingen en incidenten bij alle levende 
donoren van weefsels en/of organen worden gerapporteerd en geregistreerd moet 
nader worden onderzocht omdat dit tot een enorme verbetering in de zorg voor de 
donor zal leiden.
De toekomst – hoe lang zijn onverwante donoren nog nodig?
Het veld van HsCT is dynamisch en voortdurend onderhevig aan veranderingen, 
die directe gevolgen kunnen hebben voor de stamceldonorbanken. Ontwikkeling 
van nieuwe medicamenten en protocollen voor behandeling met stamcellen 
volgen elkaar snel op. Naast het gebruik van familiedonoren, onverwante donoren 
en navelstrengbloedeenheden wordt nu ook de optie van behandeling met 
doelgerichte (autologe) T-cellen onderzocht. Genezing van chronische myeloide 
leukemie (CML) was minder dan 20 jaar geleden alleen te bereiken met een allogene 
stamceltransplantatie. De ontdekking van een nieuwe therapeutische benadering 
met tyrosine-kinase inhibitors reduceerde voor het merendeel van deze patiënten 
de behoefte aan stamceltransplantatie76. Vergelijkbare ontwikkelingen worden 
gezien op het gebied van chronische lymfatische leukemie (CLL)77. De potentie van 
behandeling met autologe T-cellen om doelgericht de tumor aan te vallen, is onlangs 
gerapporteerd78. Indien de resultaten van dit onderzoek kunnen worden bevestigd 
kan dat uiteindelijk leiden tot een afname van het aantal stamceltransplantaties. Een 
andere ontwikkeling is de hernieuwde belangstelling voor beenmergtransplantatie 
met haploidentieke familie donoren, gevolgd door hoge dosis cyclofosfamide kort na 
transplantatie, om de kans op afstoting en GvHD te voorkomen. De uitkomsten van 
dergelijke transplantaties zijn nagenoeg vergelijkbaar met die van transplantaties 
met HLA-identieke familiedonoren of onverwante donoren79. In 2013 werd 40% van 
alle HsCT patiënten in Italië met stamcellen getransplanteerd van een haploidentieke 
donor. Bacigalupo gaf aan dat de kosten van het stamceltransplantatieprogramma 
hiermee met 10% konden worden verlaagd, terwijl het aantal transplantaties met 
20% was toegenomen80. 
Regionale verschillen in het toepassen van stamceltransplantaties met onverwante 
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donoren zijn groot en geassocieerd met het nationaal inkomen, waardoor het verschil 
tussen de rijke en arme landen steeds groter wordt3,81. Een bijkomend gevolg van de 
economische crisis, is de noodzaak voor transplantatiecentra om te onderzoeken 
hoe de kosten van transplantatie kunnen worden verminderd, zonder afbreuk 
aan de kwaliteit van zorg82,83. Het aantal ligdagen in het ziekenhuis is de grootste 
kostenpost, maar de kosten van de onverwante donorsearch, een stamcelproduct en 
in het bijzonder de kosten van navelstrengbloedeenheden zijn ook onderwerp van 
discussie82,84,85. De kosteneffectiviteit van stamceltransplantatie met verschillende 
stamcelbronnen (inclusief haploidentieke stamcellen) wordt op dit moment 
onderzocht86. In sommige landen geven de verzekeringsmaatschappijen een vaste 
vergoedingen, met het gevolg dat transplantatie met navelstrengbloed niet langer 
tot de mogelijkheden behoort. Het is in het van belang van niet-NWE patiënten dat 
er gezocht wordt naar manieren om het gebruik van navelstrengbloed betaalbaar 
en rendabel te laten blijven87 (dit proefschrift). De huidige discussie concentreert 
zich op de prijs van stamcelproducten in het algemeen en van navelstrengbloed 
in het bijzonder. zowel een ‘vast prijsbeleid’, of een prijs die is gebaseerd op het 
aantal cellen in een navelstrengbloedeenheid (kleinere eenheid – lagere prijs) zou 
ten goede komen aan de patiënt: geld is niet langer een argument om niet de beste 
match te kiezen. Er zijn aanwijzingen dat de toename van etnische diversiteit in 
het wereldwijde navelstrengbloedbestand er toe leidt dat meer patiënten kunnen 
worden getransplanteerd (dit proefschrift). Navelstrengbloedbanken zouden hun 
wervingsmethoden nog meer kunnen aanpassen om de HLA-fenotype diversiteit 
nog verder te vergroten87. Bekendheid bij het grote publiek stimuleren is daarbij 
van groot belang om het doel te bereiken, ook binnen de mogelijkheden van een 
individueel land88. De waarschijnlijkheid dat een navelstrengbloedeenheid wordt 
gebruik is, naast de HLA-typering, direct gerelateerd aan het aantal cellen (TNC) 
die de eenheid bevat89. Eenheden met een hoger aantal TNC hebben meer kans om 
geselecteerd te worden voor transplantatie89. Het is bekend dat niet-NWE eenheden 
vaker minder TNC bevatten, mogelijk houdt dit verband met de relatief kortere 
tijdsduur van de bevalling, maar de toegevoegde waarde van de diversiteit moet niet 
worden onderschat87. Een andere mogelijkheid om een navelstrengbloedeenheid 
breder toepasbaar te maken is het beschikbaar stellen van de moederlijke HLA 
typering. Navelstrengbloedeenheden die de niet-geërfde maternale antigenen 
(NIMA) of geërfde paternale antigenen (IPA) gemeen hebben met de patiënt, hebben 
een positief effect op transplantatie uitkomst: de kans op recidief is kleiner en ook de 
mate van GvHD is minder90,91. Een recente studie heeft aangetoond dat het matchen 
van navelstrengbloed op hoge resolutie voor HLA-A, -B, -C en -DRB1 geassocieerd 
is met de laagste mortaliteit na transplantatie bij patiënten met acute leukemie en 
myelodysplastisch syndroom92. Navelstrengbloedbanken zouden kunnen overwegen 
hun (nieuwe) eenheden op hoge resolutie te laten typeren.
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Donoren en (toekomstig) onderzoek
In de afgelopen decennia zijn motivatie, ervaringen en opvattingen van stamceldonoren 
en stamceldonatie onderzocht en beschreven93. Introductie van nieuwe middelen 
voor mobilisatie van stamcellen en het gebruik van zogenaamde biosimilars heeft 
geleid tot discussie en de vraag naar mogelijkheden van prospectieve studies waarbij 
ook gezonde niet-donoren worden geincludeerd94,95. Beschikbaarheid van donoren, 
wervingsstrategieën en veiligheid van vooral de familiedonor blijven belangrijke 
onderwerpen voor toekomstig onderzoek. Langetermijneffecten van stamceldonatie 
zijn echter niet louter voorbehouden aan fysieke uitkomst, maar ook cognitieve, 
emotionele en psychosociale factoren moeten worden onderzocht. De analyse van 
de Levensloopvragenlijst die is afgenomen bij ons cohort kinddonoren zal worden 
afgerond, waarbij wij meer inzicht hopen te krijgen in de ontwikkeling van jong 
volwassenen die hebben gedoneerd op jonge leeftijd. Daarnaast zal een analyse op 
het gebied van ‘omgaan met pijn’ worden verricht, in een prospectief cohort van 
onverwante en familiedonoren. Ook de relatie tussen stress en stamceldonatie en 
Levensoriëntatie zullen worden geanalyseerd. Alle donoren die hebben deelgenomen 
in onze studies hebben schriftelijke toestemming gegeven en deze studies in 
donorbelang zijn goedgekeurd door de Commissie Medische Ethiek van het Leids 
Universitair Medisch Centrum. Er kunnen situaties ontstaan waarbij donoren indirect 
worden betrokken in een klinische studie (bijvoorbeeld wanneer de donatie deel 
uitmaakt van een experimenteel behandelprotocol). De aanname dat donoren door 
stamcellen af te staan aantonen dat zij in belang van de patiënt handelen, en dus 
ook instemmen met deelname aan wetenschappelijk onderzoek96 gaat voorbij aan 
de autonomie van de donor. De WMDA heeft gesteld dat in dat geval goedkeuring 
van het protocol door de stamceldonorbank en aanvullende toestemming van de 
donor nodig zijn97, hoewel dat mogelijk kan leiden tot vertraging in het proces 
ten nadele van de patiënt. De opstelling van de WMDA heeft geleid tot inzicht bij 
behandelaren van patiënten, dat donoren, net als patiënten, rechten hebben98,99. 
Het blijft een uitdaging om de belangen van alle partijen te harmoniseren100, in het 
bijzonder omdat dit een onbevooroordeelde benadering vereist van degenen die een 
studieprotocol, waarin ook een rol is gereserveerd voor stamceldonoren, moeten 
beoordelen en goedkeuren. Hier is zeker een mogelijkheid voor verbetering: medisch 
ethische commissies of wetenschapscommissies moeten de rol en veiligheid van ieder 
individu (patiënt en donor) dat betrokken is in de studie overwegen, in het bijzonder 
wanneer er meerdere of verlengde donaties zijn opgenomen in het protocol. Het is 
belangrijk om bij de goedkeuring van een studieprotocol ook expliciet de gevolgen 
en aanvaardbaarheid voor de donor te benoemen en te adviseren conform de 
internationale WHO standaarden voor menselijk onderzoek101, zodat vertraging, 
veroorzaakt door aanvullend onafhankelijke beoordeling van een studieprotocol 
door een stamceldonorbank wordt voorkomen. Het is onzeker hoe nadrukkelijk de 
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rol van de onverwante donor in de toekomst zal zijn, maar familiedonoren blijven 
een belangrijke rol spelen. Het zoeken naar de beste balans tussen de noodzaak 
voor de patiënt en het belang van de donor102 blijft daarom actueel voor alle 
betrokken partijen zodat ook op lange termijn de veiligheid van donoren kan worden 
gewaarborgd.
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De weg naar het doctoraat is een lange weg, en zelden zonder oneffenheden. Voor 
mij zijn het welzijn en de veiligheid van de donor van hematopoietische stamcellen 
steeds de onvoorwaardelijke drijfveren geweest om door te gaan. Het is allemaal 
begonnen in 1991 toen ik op de polikliniek kindergeneeskunde geconfronteerd 
werd met kinderen die beenmerg doneerden aan een broertje of zusje met (veelal) 
leukemie. Dat intrigeerde me onmiddellijk: hoe leg je dat uit aan een kind, dat hij een 
medische ingreep moet ondergaan terwijl hij niet ziek is? Het was het begin van een 
lange zoektocht naar antwoorden op steeds nieuwe vragen, die allemaal draaiden 
om die ene persoon: de donor van stamcellen.
Het is daarom niet meer dan correct om in de allereerste plaats een woord van dank 
te richten tot de honderden donoren die bereid zijn geweest om te participeren in de 
verschillende onderzoeken: de ouders die stamcellen doneerden aan hun kinderen, 
de mannen en vrouwen die aan een broer of zus of een onbekende ontvanger 
doneerden, de ‘kinderen’ die zelfs tot 40 jaar na donatie bereid bleken te zijn om 
hun veelal indrukwekkende ervaringen met mij te delen, en de bloedplaatjesdonoren 
die als controlepersonen de vragenlijsten invulden. zonder hun hulp was dit boek er 
niet gekomen, ik ben ze heel veel dank verschuldigd.
De promotor en co-promotoren hebben in de afgelopen jaren ieder op hun eigen 
manier een belangrijke rol gespeeld in mijn leven, en mij steeds geinspireerd om 
steeds weer nieuwe paden van onderzoek in te slaan. Anneke Brand, rots in de 
branding, steun en toeverlaat bij nacht en ontij. steeds als ik bij jou was geweest 
(vaak aan het eind van de dag), was vermoeidheid niet meer belangrijk en had ik 
hernieuwde energie om weer op een andere manier tegen een dataset aan te kijken, 
wat soms verrassende resultaten opleverde. Machteld Oudshoorn, steeds kritisch 
en nauwkeurig - iedere tabel werd door jou nagerekend tot achter de komma, ieder 
percentage gecheckt tot het klopte. Onze gezamenlijke interesse in de HLA-aspecten 
van de onverwante donorsearch leverde vaak stof voor studie en discussie op. 
Daarnaast ben je natuurlijk de beste bron als het gaat om een snoei-, plant-, of ander 
advies voor de tuin! Lynne Ball, collega maar vooral dierbare vriendin; ik bewaar 
dankbare herinneringen aan de avonden achter de computer tijdens het onderzoek 
naar de ervaringen van ouders en kinderen die doneerden, en onze reizen naar de 
EBMT en WMDA bijeenkomsten. 
De medewerkers van het Centrum voor stamceltherapie van het LUMC 
verdienen een pluim: zij informeerden de donoren over de studie en verzamelden de 
vragenlijsten en bloedmonsters, en waren behulpzaam bij het opzoeken van oude 
transfusiegegevens. Peter, Ingrid, Anja, Lona, Dominique, Ineke, Ed, Edwin, Paulien, 
Joost, Yolanda en Jacqueline: heel veel dank voor jullie zeer gewaardeerde inzet! 
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Yvonne, Hanneke en Ouassima van het LTI lab: veel dank voor het afdraaien en 
invriezen van alle ‘bloedjes’ tijdens de studie.
De vele (inter)nationale collega’s wil ik danken voor hun inzet en betrokkenheid 
en als coauteur. Mede dank zij uw inspanningen is er consensus voor de ontwikkeling 
van optimale zorg voor de donor.
A big Thank You to my international colleagues Bronwen shaw and Galen 
switzer, who became true friends over the years. Your support and advice have been 
so valuable.
Tony, collega, vriendin en nu ook paranimf. Dank je wel voor je vriendschap 
in goede en minder goede dagen. Ik hoop dat we nog heel veel samen zullen 
ondernemen.
Lieve sanne en Leonore, grote dochters, ik ben trots op de wijze waarop jullie je 
hebben ontwikkeld tot onafhankelijke vrouwen die elk op eigen wijze een steentje 
bijdragen in de maatschappij. Jullie onvoorwaardelijke liefde is voor mij het beste 
pepmiddel!
Lieve Pap en Mam, dank voor jullie steun en vertrouwen door de jaren heen. Ik 
besef dat ik vaak een eigenwijze dochter ben geweest. Mede dank zij jullie ben ik 
zo ver gekomen.
Lieve Jack, door de jaren heen heb je me steeds weer moed gegeven als ik 
dacht dat het nooit zou lukken, of stikte in een statistische berekening! Jij bleef erin 
geloven, en kreeg gelijk. Dank ook voor al je digitale inspanningen: mede dank zij 
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Cover illustration: “Crossing Borders” - this quilt 
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stem cells migrating from marrow to periphery 
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(machine patchwork, hand application and hand 
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